

T CELL RECEPTORS AND METHODS OF USE THEREOF

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This PCT application claims the priority benefit of U.S. Provisional Application No. 62/880,508, filed July 30, 2019, which is incorporated herein by reference in its entirety.

REFERENCE TO SEQUENCE LISTING SUBMITTED
ELECTRONICALLY VIA EFS-WEB

[0002] The content of the electronically submitted sequence listing (Name: 4285_015PC01_Seqlisting_ST25.txt, Size: 23,008 bytes; and Date of Creation: July 28, 2020) is incorporated herein by reference in its entirety.

FIELD OF THE DISCLOSURE

[0003] The present disclosure provides recombinant T cell receptors ("TCRs") that specifically bind human melanoma-associated antigen 2 (MAGE-A2) and uses thereof.

BACKGROUND OF THE DISCLOSURE

[0004] Immunotherapy has emerged as a critical tool in the battle against a variety of diseases, including cancer. T cell therapies are at the forefront of immunotherapeutic development, and adoptive transfer of antitumor T cells has been shown to induce clinical responses in cancer patients. Though many T cell therapies target mutated tumor antigens, the vast majority of neoantigens are not shared and are unique to each patient.

[0005] Potential non-mutated antigens outnumber mutated antigens by multiple orders of magnitude. The elucidation of T cell epitopes derived from shared antigens may facilitate the robust development of efficacious and safe adoptive T cell therapies that are readily available to a larger cohort of cancer patients. However, the sheer number of non-mutated antigens and the high polymorphism of HLA genes may have hampered comprehensive analyses of the specificity of antitumor T cell responses toward non-mutated antigens.

SUMMARY OF THE DISCLOSURE

[0006] Certain aspects of the present disclosure are directed to a nucleic acid molecule comprising (i) a first nucleotide sequence encoding a recombinant T cell receptor (TCR) or

an antigen binding portion thereof that specifically binds human melanoma-associated antigen 2 (MAGE-A2) ("anti-MAGE-A2 TCR"); and (ii) a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR, wherein the anti-MAGE-A2 TCR cross competes for binding to human MAGE-A2 with a reference TCR, which comprises an alpha chain and a beta chain, and wherein the alpha chain comprises an amino acid sequence as set forth in SEQ ID NO: 1 and the beta chain comprises an amino acid sequence as set forth in SEQ ID NO: 2.

[0007] Certain aspects of the present disclosure are directed to a nucleic acid molecule comprising (i) a first nucleotide sequence encoding a recombinant T cell receptor (TCR) or an antigen binding portion thereof that specifically binds human MAGE-A2 ("anti-MAGE-A2 TCR"); and (ii) a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR, wherein the anti-MAGE-A2 TCR binds the same epitope or an overlapping epitope of human MAGE-A2 as a reference TCR, which comprises an alpha chain and a beta chain, wherein the alpha chain comprises an amino acid sequence as set forth in SEQ ID NO: 1 and the beta chain comprises an amino acid sequence as set forth in SEQ ID NO: 2.

[0008] In some aspects, the anti-MAGE-A2 TCR binds to an epitope of MAGE-A2 consisting of an amino acid sequence as set forth in SEQ ID NO: 13. In some aspects, the epitope is complexed with an HLA class II molecule. In some aspects, the HLA class II molecule is an HLA-DP, HLA-DQ, or HLA-DR allele, or any combination thereof. In some aspects, the HLA class II molecule is an HLA-DP allele. In some aspects, the HLA class II molecule is an HLA-DP4 allele.

[0009] In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises a variable region comprising an alpha chain CDR1, an alpha chain CDR2, and an alpha chain CDR3; and wherein the beta chain comprises variable domain comprising a beta chain CDR1, a beta chain CDR2, and a beta chain CDR3; wherein the alpha chain CDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 7.

[0010] In some aspects, the beta chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 10.

- [0011] In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises a variable region comprising an alpha chain CDR1, an alpha chain CDR2, and an alpha chain CDR3; and wherein the beta chain comprises variable domain comprising a beta chain CDR1, a beta chain CDR2, and a beta chain CDR3; wherein the beta chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 10.
- [0012] In some aspects, the alpha chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the alpha chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 5. In some aspects, the beta chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 8. In some aspects, the alpha chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 6. In some aspects, the beta chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 9.
- [0013] In some aspects, the alpha chain variable domain of the anti-MAGE-A2 TCR comprises an amino acid sequence of a variable domain present in the amino acid sequence set forth SEQ ID NO: 1. In some aspects, the beta chain variable domain of the anti-MAGE-A2 TCR comprises an amino acid sequence of a variable domain present in the amino acid sequence set forth SEQ ID NO: 2.
- [0014] In some aspects, the alpha chain of the anti-MAGE-A2 TCR further comprises a constant region, wherein the constant region is different from endogenous constant region of the alpha chain.
- [0015] In some aspects, the alpha chain of the anti-MAGE-A2 TCR further comprises a constant region, wherein the alpha chain constant region comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to a constant region present in the amino acid sequence set forth SEQ ID NO: 1.
- [0016] In some aspects, the alpha chain constant region comprises an amino acid sequence comprising at least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence set forth SEQ ID NO: 1.

- [0017] In some aspects, the beta chain of the anti-MAGE-A2 TCR further comprises a constant region, wherein the constant region is different from endogenous constant regions of the beta chain.
- [0018] In some aspects, the beta chain of the anti-MAGE-A2 TCR further comprises a constant region, wherein the beta chain constant region comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to a constant region present in the amino acid sequence set forth SEQ ID NO: 2.
- [0019] In some aspects, the beta chain constant region comprises an amino acid sequence comprising at least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence set forth SEQ ID NO: 2.
- [0020] In some aspects, the alpha chain of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 1. In some aspects, the beta chain of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 2.
- [0021] In some aspects, the second nucleotide sequence is one or more siRNAs that reduce the expression of endogenous TCRs. In some aspects, the one or more siRNAs are complementary to a target sequence within a nucleotide sequence encoding a constant region of the endogenous TCRs. In some aspects, the one or more siRNAs comprise one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 25-28.
- [0022] In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain constant region, a beta chain constant region, or both; and wherein the alpha chain constant region, the beta chain constant region, or both comprises an amino acid sequence having at least 1, at least 2, at least 3, at least 4, or at least 5 substitutions within the target sequence relative to the corresponding amino acid sequence of an endogenous TCR.
- [0023] In some aspects, the alpha chain comprises a signal peptide, the beta chain comprises a signal peptide, or both the alpha chain and the beta chain comprise a single peptide. In some aspects, the signal peptide comprises an amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs: 20-22 and any combination thereof.
- [0024] Certain aspects of the present disclosure are directed to a vector comprising a nucleic acid molecule disclosed herein. In some aspects, the vector is a viral vector, a mammalian vector, or bacterial vector. In some aspects, the vector is a retroviral vector. In some aspects, the vector is selected from the group consisting of an adenoviral vector, a

lentivirus, a Sendai virus vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, a hybrid vector, and an adeno associated virus (AAV) vector. In some aspects, the vector is a lentivirus.

[0025] Certain aspects of the present disclosure are directed to a T cell receptor (TCR) or an antigen binding portion thereof comprising the alpha chain variable domain of an anti-MAGE-A2 TCR disclosed herein and the beta chain variable domain of an anti-MAGE-A2 TCR disclosed herein.

[0026] Certain aspects of the present disclosure are directed to a recombinant T cell receptor (TCR) or an antigen binding portion thereof that specifically binds human MAGE-A2 ("an anti-MAGE-A2 TCR"), which cross competes for binding to human MAGE-A2 with a reference TCR; wherein the reference TCR comprises an alpha chain and a beta chain, and wherein the alpha chain comprises an amino acid sequence as set forth in SEQ ID NO: 1 and the beta chain comprises an amino acid sequence as set forth in SEQ ID NO: 2; and wherein the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises a constant region, and wherein the beta chain comprises a constant region; wherein the alpha chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence set forth in SEQ ID NO: 1 or the beta chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence of SEQ ID NO: 2.

[0027] Certain aspects of the present disclosure are directed to a recombinant T cell receptor (TCR) or an antigen binding portion thereof that specifically binds human MAGE-A2 ("an anti-MAGE-A2 TCR"), which binds the same epitope or an overlapping epitope of human MAGE-A2 as a reference TCR; wherein the reference TCR comprises an alpha chain and a beta chain, and wherein the alpha chain comprises an amino acid sequence as set forth in SEQ ID NO: 1 and the beta chain comprises an amino acid sequence as set forth in SEQ ID NO: 2; and wherein the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises a constant region, and wherein the beta chain comprises a constant region; wherein the alpha chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence set forth in SEQ ID NO: 1 or the beta

chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence set forth in SEQ ID NO: 2.

[0028] In some aspects, the anti-MAGE-A2 TCR binds to an epitope of MAGE-A2 consisting of an amino acid sequence as set forth in SEQ ID NO: 13. In some aspects, the epitope is complexed with an HLA class II molecule. In some aspects, the HLA class II molecule is an HLA-DP, HLA-DQ, or HLA-DR allele, or any combination thereof. In some aspects, the HLA class II molecule is an HLA-DP allele. In some aspects, the HLA class II molecule is selected from an HLA-DP4 allele.

[0029] In some aspects, the alpha chain of the anti-MAGE-A2 TCR comprises a variable domain comprising an alpha chain CDR1, an alpha chain CDR2, and an alpha chain CDR3; and wherein the beta chain of the anti-MAGE-A2 TCR comprises variable domain comprising a beta chain CDR1, a beta chain CDR2, and a beta chain CDR3; wherein the alpha chain CDR3 of the anti-MAGE-A2 comprises an amino acid sequence as set forth in SEQ ID NO: 7.

[0030] In some aspects, the beta chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 10.

[0031] In some aspects, the alpha chain of the anti-MAGE-A2 TCR comprises a variable domain comprising an alpha chain CDR1, an alpha chain CDR2, and an alpha chain CDR3; wherein the beta chain of the anti-MAGE-A2 TCR comprises a variable domain comprising a beta chain CDR1, a beta chain CDR2, and a beta chain CDR3; and wherein the beta chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 10.

[0032] In some aspects, the alpha chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the alpha chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 5. In some aspects, the beta chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 8. In some aspects, the alpha chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 6. In some aspects, the beta chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 9.

- [0033] In some aspects, the alpha chain variable domain of the anti-MAGE-A2 TCR comprises an amino acid sequence of a variable domain present in the amino acid sequence set forth in SEQ ID NO: 1. In some aspects, the beta chain variable domain of the anti-MAGE-A2 TCR comprises an amino acid sequence of a variable domain present in the amino acid sequence set forth in SEQ ID NO: 2.
- [0034] In some aspects, the alpha chain constant region comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence of a constant region present in the amino acid sequence set forth in SEQ ID NO: 1.
- [0035] In some aspects, the beta chain constant region comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence of a constant region present in the amino acid sequence set forth in SEQ ID NO: 2.
- [0036] In some aspects, the alpha chain of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 1. In some aspects, the beta chain of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 2.
- [0037] In some aspects, the alpha chain comprises a signal peptide, the beta chain comprises a signal peptide, or both the alpha chain and the beta chain comprise a single peptide. In some aspects, the signal peptide comprises an amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs: 20-22 and any combination thereof.
- [0038] Certain aspects of the present disclosure are directed to a bispecific TCR comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain comprises a TCR or an antigen-binding portion thereof disclosed herein.
- [0039] In some aspects, the first antigen-binding domain comprises a single chain variable fragment ("scFv"). In some aspects, the second antigen-binding domain binds specifically to a protein expressed on the surface of a T cell. In some aspects, the second antigen-binding domain binds specifically to CD3. In some aspects, the second antigen-binding domain comprises an scFv. In some aspects, the first antigen-binding domain and the second antigen-binding domain are linked or associated by a covalent bond. In some aspects,

the first antigen-binding domain and the second antigen-binding domain are linked by a peptide bond.

[0040] Certain aspects of the present disclosure are directed to a cell comprising a nucleic acid molecule disclosed herein, a vector disclosed herein, a TCR disclosed herein, a recombinant TCR disclosed herein, or a bispecific TCR disclosed herein. In some aspects, the cell further expresses CD3. In some aspects, the cell is selected from the group consisting of a T cell, a natural killer (NK) cell, an natural killer T (NKT) cell, or an ILC cell.

[0041] Certain aspects of the present disclosure are directed to a method of treating a cancer in a subject in need thereof, comprising administering to the subject a cell disclosed herein. In some aspects, the cancer is selected from the group consisting of melanoma, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia (ALL) (including non T cell ALL), chronic lymphocytic leukemia (CLL), solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, other B cell malignancies, and combinations of said cancers.

[0042] In some aspects, the cancer is relapsed or refractory. In some aspects, the cancer is locally advanced. In some aspects, the cancer is advanced. In some aspects, the cancer is metastatic.

[0043] In some aspects, the cells are obtained from the subject. In some aspects, the cells are obtained from a donor other than the subject.

- [0044] In some aspects, the subject is preconditioned prior to the administering of the cells. In some aspects, the preconditioning comprises administering to the subject a chemotherapy, a cytokine, a protein, a small molecule, or any combination thereof. In some aspects the preconditioning comprises administering an interleukin. In some aspects, the preconditioning comprises administering IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, or any combination thereof. In some aspects, the preconditioning comprises administering a preconditioning agent selected from the group consisting of cyclophosphamide, fludarabine, vitamin C, an AKT inhibitor, ATRA, Rapamycin, or any combination thereof. In some aspects, the preconditioning comprises administering cyclophosphamide, fludarabine, or both.
- [0045] Certain aspects of the present disclosure are directed to a method of engineering an antigen-targeting cell, comprising transducing a cell collected from a subject in need of a T cell therapy with a nucleic acid molecule disclosed herein or a vector disclosed herein. In some aspects, the antigen-targeting cell further expresses CD4. In some aspects, the cell is a T cell or a natural killer (NK) cell.
- [0046] Certain aspects of the present disclosure are directed to an HLA class II molecule complexed to a peptide, wherein the HLA class II molecule comprises an alpha chain and a beta chain; and wherein the peptide consists of an amino acid sequence as set forth in SEQ ID NO: 13.
- [0047] In some aspects, the HLA class II molecule is an HLA-DP, HLA-DQ, or HLA-DR allele, or any combination thereof. In some aspects, the HLA class II molecule is an HLA-DP allele. In some aspects, the HLA class II molecule is an HLA-DQ allele. In some aspects, the HLA class II molecule is an HLA-DR allele. In some aspects, the HLA class II molecule is a monomer. In some aspects, the HLA class II molecule is a dimer. In some aspects, the HLA class II molecule is a trimer. In some aspects, the HLA class II molecule is a tetramer. In some aspects, the HLA class II molecule is a pentamer.
- [0048] Certain aspects of the present disclosure are directed to an antigen presenting cell (APC), comprising an HLA class II molecule disclosed herein. In some aspects, the HLA class II molecule is expressed on the surface of the APC.
- [0049] Certain aspects of the present disclosure are directed to a method of enriching a target population of T cells obtained from a human subject, comprising contacting the T cells with an HLA class II molecule disclosed herein or a APC disclosed herein, wherein following

the contacting, the enriched population of T cells comprises a higher number of T cells capable of binding the HLA class II molecule relative to the number of T cells capable of binding the HLA class II molecule prior to the contacting.

[0050] Certain aspects of the present disclosure are directed to a method of enriching a target population of T cells obtained from a human subject, comprising contacting the T cells *in vitro* with a peptide, wherein the peptide consists of an amino acid sequence as set forth in SEQ ID NO: 13, wherein following the contacting, the enriched population of T cells comprises a higher number of T cells capable of targeting a tumor cell relative to the number of T cells capable of targeting a tumor cell prior to the contacting. In some aspects, the T cells obtained from the human subject are tumor infiltrating lymphocytes (TIL).

[0051] Certain aspects of the present disclosure are directed to a method of treating a tumor in a subject in need thereof, comprising administering to the subject one or more enriched T cells disclosed herein.

[0052] Certain aspects of the present disclosure are directed to a method of enhancing cytotoxic T cell-mediated targeting of cancer cells in a subject afflicted with a cancer, comprising administering to the subject a peptide having an amino acid sequence as set forth in SEQ ID NO: 13.

[0053] Certain aspects of the present disclosure are directed to a cancer vaccine comprising a peptide having an amino acid sequence as set forth in SEQ ID NO: 13.

[0054] Certain aspects of the present disclosure are directed to a method of selecting a T cell capable of targeting a tumor cell, comprising contacting a population of isolated T cells *in vitro* with a peptide, wherein the peptide consists of an amino acid sequence as set forth in SEQ ID NO: 13. In some aspects, the T cell is a tumor infiltrating lymphocytes (TIL).

BRIEF DESCRIPTION OF THE DRAWINGS

[0055] FIGs. 1A-1B are graphical representations of DP4^{L112W/V141M} dimer staining of peptide-specific CD4⁺ T cells from melanoma patients. Primary CD4⁺ T cells were purified from six DP4⁺ melanoma patients and stimulated with DP4-expressing aAPCs individually pulsed with MAGE-A2₁₀₈₋₁₂₇ peptides and stained with cognate DP4^{L112W/V141M} dimers. Examples of DP4^{L112W/V141M} dimer staining are shown.

[0056] FIGs. 2A-2D are graphical representations of data illustrating that DP4-restricted (06-MAGE-A2₁₀₈₋₁₂₇) TCRs isolated from DP4^{L112W/V141M} dimer-positive cells and

reconstituted in human TCR-defective CD4⁺ T cells were functional in a DP4-restricted and antigen-specific manner. 05-MAGE-A2₁₀₈₋₁₂₇ were cloned from DP4^{L112W/V141M} dimer-positive cells, reconstituted in TCR-defective Jurkat 76/CD4 cells, and stained by the respective DP4^{L112W/V141M} dimers.

[0057] FIG. 3 is a bar graph illustrating the results of IL-2 EPISPOT assays of 06-MAGE-A2₁₀₈₋₁₂₇ stimulated by aAPCs pulsed with MAGE-A2₁₀₈₋₁₂₇ peptides in IL-2 ELISPOT assays. DP4/WT1 (clone 9) TCR was used as a negative control. At least 2 independent experiments were performed. Bars and error bars represent the mean $\pm$ SD of results in triplicate experiments.

[0058] FIGs. 4A-4E are graphical representations of data showing that DP4-restricted MAGE-A2₁₀₈₋₁₂₇ TCRs isolated from DP4^{L112W/V141M} dimer-positive cells and reconstituted in human primary CD4⁺ T cells were functional in a DP4-restricted and antigen-specific manner. 06-MAGE-A2₁₀₈₋₁₂₇ were retrovirally transduced into human primary CD4⁺ T cells and stained with the respective DP4^{L112W/V141M} dimers. *P<0.05 by Student's t-test. Bars and error bars represent the mean $\pm$ SD of results in triplicate experiments (FIG. 4E).

[0059] FIG. 5 is a bar graph showing the results of IFN- γ ELISPOT assays of human primary T cells retrovirally transduced with 06-MAGE-A2₁₀₈₋₁₂₇ and stimulated with peptide-unpulsed HLA-null or DP4-aAPCs. *, P<0.05 by Student's t-test. Bars and error bars represent the mean $\pm$ SD of results in triplicate experiments.

[0060] FIGs. 6A-6E are data illustrating that 06-MAGE-A2₁₀₈₋₁₂₇ TCR recognizes melanoma cell lines in a DP4- and MAGE-A2-dependent manner. FIG. 6A is an image of a Western blot of detection of endogenous MAGE-A2 expression in K562 cells and the melanoma cell lines SK-MEL-21, SK-MEL-28, SK-MEL-37, and Me275, as indicated. FIGs. 6B-6E are graphical representations showing the results of IFN- γ ELISPOT assays of human primary T cells transduced with 06-MAGE-A2₁₀₈₋₁₂₇ TCR and stimulated with SK-MEL-21 (DP4⁺ MAGE-A2⁻; FIG. 6B) or SK-MEL-37 (DP4⁺ MAGE-A2⁺; FIG. 6C) and SK-MEL-28 (FIG. 6D) and Me275 (DP4⁺ MAGE-A2⁺; FIG. 6E) transduced with DP4. *, P<0.05 by Student's t-test. Bars and error bars represent the mean $\pm$ SD of results in triplicate experiments. At least 2 independent experiments were performed.

DETAILED DESCRIPTION OF THE DISCLOSURE

[0061] The present disclosure is directed to TCRs or antigen binding portions thereof that specifically bind to an epitope on MAGE-A2, nucleic acid molecules that encode the same, and cells that comprise the TCR or the nucleic acid molecule. Some aspects of the present disclosure are directed to methods of treating a cancer in a subject in need thereof. Other aspects of the present disclosure are directed to HLA class II molecules complexed to a peptide comprising the epitope of MAGE-A2.

I. Terms

[0062] In order that the present disclosure can be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application.

[0063] It is to be noted that the term "a" or "an" entity refers to one or more of that entity; for example, "a nucleotide sequence," is understood to represent one or more nucleotide sequences. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.

[0064] Furthermore, "and/or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and/or" as used in a phrase such as "A and/or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term "and/or" as used in a phrase such as "A, B, and/or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0065] The term "about" is used herein to mean approximately, roughly, around, or in the regions of. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 10 percent, up or down (higher or lower).

- [0066] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of" and/or "consisting essentially of" are also provided.
- [0067] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.
- [0068] Units, prefixes, and symbols are denoted in their Système International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleotide sequences are written left to right in 5' to 3' orientation. Amino acid sequences are written left to right in amino to carboxy orientation. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.
- [0069] "Administering" refers to the physical introduction of an agent to a subject, using any of the various methods and delivery systems known to those skilled in the art. Exemplary routes of administration for the formulations disclosed herein include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase "parenteral administration" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, as well as *in vivo* electroporation. In some aspects, the formulation is administered via a non-parenteral route, *e.g.*, orally. Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically. Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.

[0070] The term "T cell receptor" (TCR), as used herein, refers to a heteromeric cell-surface receptor capable of specifically interacting with a target antigen. As used herein, "TCR" includes but is not limited to naturally occurring and non-naturally occurring TCRs; full-length TCRs and antigen binding portions thereof; chimeric TCRs; TCR fusion constructs; and synthetic TCRs. In human, TCRs are expressed on the surface of T cells, and they are responsible for T cell recognition and targeting of antigen presenting cells. Antigen presenting cells (APCs) display fragments of foreign proteins (antigens) complexed with the major histocompatibility complex (MHC; also referred to herein as complexed with an HLA molecule, *e.g.*, an HLA class II molecule). A TCR recognizes and binds to the peptide:HLA complex and recruits CD8 (for MHC Class I molecules) or CD4 (for MHC class II molecules), activating the TCR. The activated TCR initiates downstream signaling and an immune response, including the destruction of the EPC.

[0071] In general, a TCR can comprise two chains, an alpha chain and a beta chain (or less commonly a gamma chain and a delta chain), interconnected by disulfide bonds. Each chain comprises a variable domain (alpha chain variable domain and beta chain variable domain) and a constant region (alpha chain constant region and beta chain constant region). The variable domain is located distal to the cell membrane, and the variable domain interacts with an antigen. The constant region is located proximal to the cell membrane. A TCR can further comprise a transmembrane region and a short cytoplasmic tail. As used herein, the term "constant region" encompasses the transmembrane region and the cytoplasmic tail, when present, as well as the traditional "constant region."

[0072] The variable domains can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each alpha chain variable domain and beta chain variable domain comprises three CDRs and four FRs: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Each variable domain contains a binding domain that interacts with an antigen. Though all three CDRs on each chain are involved in antigen binding, CDR3 is believed to be the primary antigen binding region, while CDR1 and CDR2 are believed to primarily recognize the HLA molecule.

[0073] Where not expressly stated, and unless the context indicates otherwise, the term "TCR" also includes an antigen-binding fragment or an antigen-binding portion of any TCR disclosed herein, and includes a monovalent and a divalent fragment or portion, and a single

chain TCR. The term "TCR" is not limited to naturally occurring TCRs bound to the surface of a T cell. As used herein, the term "TCR" further refers to a TCR described herein that is expressed on the surface of a cell other than a T cell (*e.g.*, a cell that naturally expresses or that is modified to express CD4, as described herein), or a TCR described herein that is free from a cell membrane (*e.g.*, an isolated TCR or a soluble TCR).

[0074] An "antigen binding molecule," "portion of a TCR," or "TCR fragment" refers to any portion of an TCR less than the whole. An antigen binding molecule can include the antigenic CDRs.

[0075] An "antigen" refers to any molecule, *e.g.*, a peptide, that provokes an immune response or is capable of being bound by a TCR. An "epitope," as used herein, refers to a portion of a polypeptide that provokes an immune response or is capable of being bound by a TCR. The immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both. A person of skill in the art would readily understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. An antigen and/or an epitope can be endogenously expressed, *i.e.* expressed by genomic DNA, or can be recombinantly expressed. An antigen and/or an epitope can be specific to a certain tissue, such as a cancer cell, or it can be broadly expressed. In addition, fragments of larger molecules can act as antigens. In one aspect, antigens are tumor antigens. An epitope can be present in a longer polypeptide (*e.g.*, in a protein), or an epitope can be present as a fragment of a longer polypeptide. In some aspects, an epitope is complexed with a major histocompatibility complex (MHC; also referred to herein as complexed with an HLA molecule, *e.g.*, an HLA class 1 molecule).

[0076] "MAGE-A2," "melanoma-associated antigen 2," or "cancer/testis antigen 1.2," as used herein, refers to a human protein primarily expressed by tumor cells. MAGE-A2 reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. MAGE-A2 represses p73/TP73 activity. In vitro, MAGE-A2 promotes cell viability in melanoma cell lines. MAGE-A2 is expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma, and breast carcinoma. However, in healthy tissue, MAGE-A2 is only expressed in the testes.

[0077] As used herein, MAGE-A2 refers to not only the full-length sequence, but also variants and fragments thereof. The amino acid sequence of MAGE-A2 (SEQ ID NO: 16) is provided in Table 1 (UniProtKB – P43356).

Table 1. MAGE-A2 Amino Acid Sequence

MAGE-A2 Amino Acid Sequence
MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQQTASSSSTLVEVTLGEVPAADSPSPPHSPQGASSFSTTINY TLWRQSDGESSNQEEGPRMFPDLESEFQAAISRKMVELVHFLLKYPAREPVTKAEMLESVLRNCQDFFPVI FSKA SEYLQLVFGIEVVEVPI SHLYILVTCLGLSYDGLLDNQVMPKTGLLIIVLAI I AIEGDCAPEEKIWEELSMLEVF EGREDSVFAHPRKLLMQDLVQENYLEYRQVPGSDPACYEFLWGPRALIETSYVKVLHHTLKGIGGEPHISYPPLHERA LREGEE (SEQ ID NO: 16)

[0078] The term "HLA," as used herein, refers to the human leukocyte antigen. HLA genes encode the major histocompatibility complex (MHC) proteins in humans. MHC proteins are expressed on the surface of cells, and are involved in activation of the immune response. HLA class II genes encode MHC class II proteins which are expressed on the surface of professional antigen presenting cells (APCs). Non-limiting examples of professional APCs include monocytes, macrophages, dendritic cells (DCs), and B lymphocytes. Some endothelial and epithelial cells can also express MHC class II molecules after inflammatory signals are activated. Humans lacking functional MHC class II molecules are extremely susceptible to an array of infectious diseases and typically die at a young age.

[0079] As used herein, an "HLA class II molecule" or "MHC class II molecule" refers to a protein product of a wild-type or variant HLA class II gene encoding an MHC class II molecule. Accordingly, "HLA class II molecule" and "MHC class II molecule" are used interchangeably herein. A typical MHC Class II molecule comprises two protein chains: an alpha chain and a beta chain. In general, naturally occurring alpha chains and beta chains each comprise a transmembrane domain, which anchors the alpha/beta chain to the cell surface, and an extracellular domain, which carries the antigen and interacts with a TCR and/or CD4 expressed on a T cell.

[0080] Both the MHC Class II alpha and beta chains are encoded by the HLA gene complex. The HLA complex is located within the 6p21.3 region on the short arm of human chromosome 6 and contains more than 220 genes of diverse function. The HLA gene complex is highly variant, with over 20,000 HLA alleles and related alleles, including over 250 MHC class II alpha chain alleles and 5,000 MHC class II beta chain alleles, known in the art, encoding thousands of MHC class II proteins (*see, e.g.,* hla.alleles.org, last visited May 20, 2019, which is incorporated by reference herein in its entirety). For example one such HLA-DP allele, DP4 is the most frequently found allele in many ethnic groups.

[0081] Three loci in the HLA complex encode MHC Class II proteins: HLA-DP, HLA-DQ, and HLA-DR. HLA-DO and HLA-DM encode proteins that associate with the MHC class II molecule and support its configuration and function.

[0082] When the MHC class II molecule is complexed with an antigen peptide, the 10-30 amino acid long antigen peptide binds the peptide-binding groove and is presented extracellularly to CD4⁺ cells. Both the alpha- and beta-chains fold into two separate domains; alpha-1 and alpha-2 for the alpha polypeptide, and beta-1 and beta-2 for the beta polypeptide. The open-ended peptide-binding groove which holds the presented antigen is found between the alpha-1 and beta-1 domains. Upon interaction with a CD4⁺ T cell, the MHC class II complex interacts with a T cell receptor (TCR) expressed on the surface of the T cell. In addition, the beta chain of the MHC class II molecule weakly interacts ($K_D > 2$ mM) with CD4 expressed on the surface of the T cell. The canonical CD4 amino acid sequence (UniProt - P01730) is provided in Table 2 (SEQ ID NO: 17).

Table 2. Human CD4 Amino Acid Sequence

MNRGVFPRHLLLVQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTGP SKLNDRADSRRLWDQGNFPLIIKLNKIEDSDTYICEVEDQKEEVQLLVFGLTANS DTHLLQGQSLTLTLESP PGSSPSVQCRSPRGKNIQGGKTLVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQV EFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVSVKRVTDQPKLQMGKKLPLHLTLPLQALPQYA GSGNLTALALEAKTGKLGHEVNLVVMRATQLQKNLTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVVVLNPEA GMWQCLLSDSGQVLLSNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQAERMSQIKRL LSEKKTCCPHRFQKTCSPI (SEQ ID NO: 17)
--

[0083] The term "autologous" refers to any material derived from the same individual to which it is later to be re-introduced. For example, an autologous T cell therapy comprises administering to a subject a T cell that was isolated from the same subject. The term "allogeneic" refers to any material derived from one individual which is then introduced to another individual of the same species. For example, an allogeneic T cell transplantation comprises administering to a subject a T cell that was obtained from a donor other than the subject.

[0084] A "cancer" refers to a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth results in the formation of malignant tumors that invade neighboring tissues and may also metastasize to distant parts of the body through the lymphatic system or bloodstream. A "cancer" or "cancer tissue" can include a tumor. Examples of cancers that can be treated by the methods of the present invention include, but are not limited to, cancers of the immune system including lymphoma, leukemia, and other leukocyte malignancies. In some aspects,

the methods of the present invention can be used to reduce the tumor size of a tumor derived from, for example, bone cancer, renal cancer, prostate cancer, breast cancer, colon cancer, lung cancer, cutaneous or intraocular malignant melanoma, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL) (including non T cell ALL), chronic lymphocytic leukemia (CLL), solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, other B cell malignancies, and combinations of said cancers. The particular cancer can be responsive to chemo- or radiation therapy or the cancer can be refractory.

[0085] A refractory cancer refers to a cancer that is not amendable to surgical intervention, and the cancer is either initially unresponsive to chemo- or radiation therapy or the cancer becomes unresponsive over time.

[0086] An "anti-tumor effect" as used herein, refers to a biological effect that can present as a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in tumor cell proliferation, a decrease in the number of metastases, an increase in overall or progression-free survival, an increase in life expectancy, or amelioration of various physiological symptoms associated with the tumor. An anti-tumor effect can also refer to the prevention of the occurrence of a tumor, *e.g.*, a vaccine.

- [0087] The term "progression-free survival," which can be abbreviated as PFS, as used herein refers to the time from the treatment date to the date of disease progression per the revised IWG Response Criteria for Malignant Lymphoma or death from any cause.
- [0088] "Disease progression" or "progressive disease," which can be abbreviated as PD, as used herein, refers to a worsening of one or more symptom associated with a particular disease. For example, disease progression for a subject afflicted with a cancer can include an increase in the number or size of one or more malignant lesions, tumor metastasis, and death.
- [0089] The "duration of response," which can be abbreviated as DOR, as used herein refers to the period of time between a subject's first objective response to the date of confirmed disease progression, per the revised IWG Response Criteria for Malignant Lymphoma, or death.
- [0090] The term "overall survival," which can be abbreviated as OS, is defined as the time from the date of treatment to the date of death.
- [0091] A "cytokine," as used herein, refers to a non-antibody protein that is released by one cell in response to contact with a specific antigen, wherein the cytokine interacts with a second cell to mediate a response in the second cell. A cytokine can be endogenously expressed by a cell or administered to a subject. Cytokines may be released by immune cells, including macrophages, B cells, T cells, and mast cells to propagate an immune response. Cytokines can induce various responses in the recipient cell. Cytokines can include homeostatic cytokines, chemokines, pro-inflammatory cytokines, effectors, and acute-phase proteins. For example, homeostatic cytokines, including interleukin (IL) 7 and IL-15, promote immune cell survival and proliferation, and pro-inflammatory cytokines can promote an inflammatory response. Examples of homeostatic cytokines include, but are not limited to, IL-2, IL-4, IL-5, IL-7, IL-10, IL-12p40, IL-12p70, IL-15, and interferon (IFN) gamma. Examples of pro-inflammatory cytokines include, but are not limited to, IL-1a, IL-1b, IL-6, IL-13, IL-17a, tumor necrosis factor (TNF)-alpha, TNF-beta, fibroblast growth factor (FGF) 2, granulocyte macrophage colony-stimulating factor (GM-CSF), soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular adhesion molecule 1 (sVCAM-1), vascular endothelial growth factor (VEGF), VEGF-C, VEGF-D, and placental growth factor (PLGF). Examples of effectors include, but are not limited to, granzyme A, granzyme B, soluble Fas ligand (sFasL), and perforin. Examples of acute phase-proteins include, but are not limited to, C-reactive protein (CRP) and serum amyloid A (SAA).

[0092] "Chemokines" are a type of cytokine that mediates cell chemotaxis, or directional movement. Examples of chemokines include, but are not limited to, IL-8, IL-16, eotaxin, eotaxin-3, macrophage-derived chemokine (MDC or CCL22), monocyte chemotactic protein 1 (MCP-1 or CCL2), MCP-4, macrophage inflammatory protein 1 α (MIP-1 α , MIP-1a), MIP-1 β (MIP-1b), gamma-induced protein 10 (IP-10), and thymus and activation regulated chemokine (TARC or CCL17).

[0093] Other examples of analytes and cytokines of the present invention include, but are not limited to chemokine (C-C motif) ligand (CCL) 1, CCL5, monocyte-specific chemokine 3 (MCP3 or CCL7), monocyte chemoattractant protein 2 (MCP-2 or CCL8), CCL13, IL-1, IL-3, IL-9, IL-11, IL-12, IL-14, IL-17, IL-20, IL-21, granulocyte colony-stimulating factor (G-CSF), leukemia inhibitory factor (LIF), oncostatin M (OSM), CD154, lymphotoxin (LT) beta, 4-1BB ligand (4-1BBL), a proliferation-inducing ligand (APRIL), CD70, CD153, CD178, glucocorticoid-induced TNFR-related ligand (GITRL), tumor necrosis factor superfamily member 14 (TNFSF14), OX40L, TNF- and ApoL-related leukocyte-expressed ligand 1 (TALL-1), or TNF-related apoptosis-inducing ligand (TRAIL).

[0094] A "therapeutically effective amount," "effective dose," "effective amount," or "therapeutically effective dosage" of a drug or therapeutic agent is any amount of the drug that, when used alone or in combination with another therapeutic agent, protects a subject against the onset of a disease or promotes disease regression evidenced by a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in *in vitro* assays.

[0095] The term "lymphocyte" as used herein includes natural killer (NK) cells, T cells, or B cells. NK cells are a type of cytotoxic (cell toxic) lymphocyte that represent a major component of the inherent immune system. NK cells reject tumors and cells infected by viruses. It works through the process of apoptosis or programmed cell death. They were termed "natural killers" because they do not require activation in order to kill cells. T-cells play a major role in cell-mediated-immunity (no antibody involvement). T-cell receptors (TCR) differentiate T cells from other lymphocyte types. The thymus, a specialized organ of

the immune system, is primarily responsible for the T cell's maturation. There are six types of T-cells, namely: Helper T-cells (*e.g.*, CD4⁺ cells), Cytotoxic T-cells (also known as TC, cytotoxic T lymphocyte, CTL, T-killer cell, cytolytic T cell, CD8⁺ T-cells or killer T cell), Memory T-cells ((i) stem memory T_{SCM} cells, like naive cells, are CD45RO⁻, CCR7⁺, CD45RA⁺, CD62L⁺ (L-selectin), CD27⁺, CD28⁺ and IL-7Rα⁺, but they also express large amounts of CD95, IL-2Rβ, CXCR3, and LFA-1, and show numerous functional attributes distinctive of memory cells); (ii) central memory T_{CM} cells express L-selectin and the CCR7, they secrete IL-2, but not IFNγ or IL-4, and (iii) effector memory T_{EM} cells, however, do not express L-selectin or CCR7 but produce effector cytokines like IFNγ and IL-4), Regulatory T-cells (Tregs, suppressor T cells, or CD4⁺CD25⁺ regulatory T cells), Natural Killer T-cells (NKT) and Gamma Delta T-cells. B-cells, on the other hand, play a principal role in humoral immunity (with antibody involvement). A B cell makes antibodies and antigens and performs the role of antigen-presenting cells (APCs) and turns into memory B-cells after activation by antigen interaction. In mammals, immature B-cells are formed in the bone marrow, where its name is derived from.

[0096] The term "genetically engineered" or "engineered" refers to a method of modifying the genome of a cell, including, but not limited to, deleting a coding or non-coding region or a portion thereof or inserting a coding region or a portion thereof. In some aspects, the cell that is modified is a lymphocyte, *e.g.*, a T cell or a modified cell that expresses CD4, which can either be obtained from a patient or a donor. The cell can be modified to express an exogenous construct, such as, *e.g.*, a T cell receptor (TCR) disclosed herein, which is incorporated into the cell's genome. In some aspects, the cell is modified to express CD4.

[0097] An "immune response" refers to the action of a cell of the immune system (for example, T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells and neutrophils) and soluble macromolecules produced by any of these cells or the liver (including Abs, cytokines, and complement) that results in selective targeting, binding to, damage to, destruction of, and/or elimination from a vertebrate's body of invading pathogens, cells or tissues infected with pathogens, cancerous or other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues.

[0098] The term "immunotherapy" refers to the treatment of a subject afflicted with, or at risk of contracting or suffering a recurrence of, a disease by a method comprising inducing,

enhancing, suppressing or otherwise modifying an immune response. Examples of immunotherapy include, but are not limited to, T cell therapies. T cell therapy can include adoptive T cell therapy, tumor-infiltrating lymphocyte (TIL) immunotherapy, autologous cell therapy, engineered autologous cell therapy (eACT), and allogeneic T cell transplantation.

[0099] Cells used in an immunotherapy described herein can come from any source known in the art. For example, T cells can be differentiated *in vitro* from a hematopoietic stem cell population, or T cells can be obtained from a subject. T cells can be obtained from, *e.g.*, peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In addition, the T cells can be derived from one or more T cell lines available in the art. T cells can also be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as FICOLL™ separation and/or apheresis. Additional methods of isolating T cells for a T cell therapy are disclosed in U.S. Patent Publication No. 2013/0287748, which is herein incorporated by references in its entirety. An immunotherapy can also comprise administering a modified cell to a subject, wherein the modified cell expresses CD4 and a TCR disclosed herein. In some aspects, the modified cell is not a T cell.

[0100] A "patient" as used herein includes any human who is afflicted with a cancer (*e.g.*, a lymphoma or a leukemia). The terms "subject" and "patient" are used interchangeably herein.

[0101] The terms "peptide," "polypeptide," and "protein" are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein's or peptide's sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. "Polypeptides" include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The

polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.

[0102] "Stimulation," as used herein, refers to a primary response induced by binding of a stimulatory molecule with its cognate ligand, wherein the binding mediates a signal transduction event. A "stimulatory molecule" is a molecule on a T cell, *e.g.*, the T cell receptor (TCR)/CD4 complex, that specifically binds with a cognate stimulatory ligand present on an antigen present cell. A "stimulatory ligand" is a ligand that when present on an antigen presenting cell (*e.g.*, an aAPC, a dendritic cell, a B-cell, and the like) can specifically bind with a stimulatory molecule on a T cell, thereby mediating a primary response by the T cell, including, but not limited to, activation, initiation of an immune response, proliferation, and the like. Stimulatory ligands include, but are not limited to, an MHC Class II molecule loaded with a peptide, an anti-CD4 antibody, a superagonist anti-CD2 antibody, a superagonist anti-CD28 antibody, and a superagonist anti-CD3 antibody.

[0103] The terms "conditioning" and "pre-conditioning" are used interchangeably herein and indicate preparing a patient in need of a T cell therapy for a suitable condition. Conditioning as used herein includes, but is not limited to, reducing the number of endogenous lymphocytes, removing a cytokine sink, increasing a serum level of one or more homeostatic cytokines or pro-inflammatory factors, enhancing an effector function of T cells administered after the conditioning, enhancing antigen presenting cell activation and/or availability, or any combination thereof prior to a T cell therapy. In one aspect, "conditioning" comprises increasing a serum level of one or more cytokines, *e.g.*, interleukin 7 (IL-7), interleukin 15 (IL-15), interleukin 10 (IL-10), interleukin 5 (IL-5), gamma-induced protein 10 (IP-10), interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-1), placental growth factor (PLGF), C-reactive protein (CRP), soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular adhesion molecule 1 (sVCAM-1), or any combination thereof. In another aspect, "conditioning" comprises increasing a serum level of IL-7, IL-15, IP-10, MCP-1, PLGF, CRP, or any combination thereof.

[0104] "Treatment" or "treating" of a subject refers to any type of intervention or process performed on, or the administration of an active agent to, the subject with the objective of reversing, alleviating, ameliorating, inhibiting, slowing down or preventing the onset, progression, development, severity or recurrence of a symptom, complication or condition, or biochemical indicia associated with a disease. In one aspect, "treatment" or "treating"

includes a partial remission. In another aspect, "treatment" or "treating" includes a complete remission.

[0105] The use of the alternative (*e.g.*, "or") should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the indefinite articles "a" or "an" should be understood to refer to "one or more" of any recited or enumerated component.

[0106] The terms "about" or "comprising essentially of" refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, *i.e.*, the limitations of the measurement system. For example, "about" or "comprising essentially of" can mean within 1 or more than 1 standard deviation per the practice in the art. Alternatively, "about" or "comprising essentially of" can mean a range of up to 10% (*i.e.*, $\pm 10\%$). For example, about 3mg can include any number between 2.7 mg and 3.3 mg (for 10%). Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of "about" or "comprising essentially of" should be assumed to be within an acceptable error range for that particular value or composition.

[0107] As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.

[0108] Various aspects of the invention are described in further detail in the following subsections.

II. Compositions of the Disclosure

[0109] The present disclosure is directed to T Cell Receptors (TCRs) or antigen binding portions thereof that specifically bind to an epitope on MAGE-A2, nucleic acid molecules that encode the same, and cells that comprise the TCR or the nucleic acid molecule. Some aspects of the present disclosure are directed to methods of treating a cancer in a subject in need thereof, comprising administering to the subject a cell comprising the TCRs described herein. Other aspects of the present disclosure are directed to an epitope of MAGE-A2 that

the TCRs bind to and HLA class II molecules complexed to a peptide comprising the epitope of MAGE-A2.

[0110] The T-cell receptor, or TCR, is a molecule found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate: that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR.

[0111] The TCR is composed of two different protein chains (that is, it is a heterodimer). In 95% of human T cells, the TCR consists of an alpha (α) chain and a beta (β) chain (encoded by TRA and TRB, respectively), whereas in 5% of human T cells, the TCR consists of gamma and delta (γ/δ) chains (encoded by TRG and TRD, respectively). This ratio changes during ontogeny and in diseased states (such as leukemia). It also differs between species. Orthologues of the 4 loci have been mapped in various species. Each locus can produce a variety of polypeptides with constant and variable regions.

[0112] When the TCR engages with antigenic peptide and MHC (peptide/MHC), the T lymphocyte is activated through signal transduction, that is, a series of biochemical events mediated by associated enzymes, co-receptors, specialized adaptor molecules, and activated or released transcription factors.

II.A. Nucleic Acid Molecules

[0113] Certain aspects of the present disclosure are directed to nucleic acid molecules comprising (i) a first nucleotide sequence encoding a recombinant TCR or an antigen binding portion thereof that specifically binds human MAGE-A2 ("anti-MAGE-A2 TCR"); and (ii) a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. In some aspects, the second nucleotide sequence is a non-naturally occurring sequence. In other aspects, the second nucleotide sequence is synthetic. In yet other aspects, the second nucleotide sequence comprises a sequence that targets a nucleotide sequence encoding the endogenous TCR. In some aspects, the anti-MAGE-A2 TCR cross competes for binding to human MAGE-A2 with a reference TCR. In some aspects, the anti-MAGE-A2 TCR binds the same epitope or an overlapping epitope of human MAGE-A2 as a reference TCR.

[0114] In some aspects, the reference TCR comprises an alpha chain and a beta chain; wherein the alpha chain comprises a complementarity determining region 1 (CDR1), a CDR2, and a CDR3; wherein the beta chain comprises a CDR1, a CDR2, and a CDR3; and wherein the reference TCR comprises the alpha chain CDR3 set forth in SEQ ID NO: 7 and the beta chain CDR3 set forth in SEQ ID NO: 10. In some aspects, the alpha chain CDR1, CDR2, and CDR3 sequences present in the amino acid sequence set forth in SEQ ID NO: 1, and reference TCR comprises the beta chain CDR1, CDR2, and CDR3 sequences present in the amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the reference TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises an amino acid sequence as set forth in SEQ ID NO: 1 and the beta chain comprises an amino acid sequence as set forth in SEQ ID NO: 2.

Table 3. Alpha Chain and Beta Chain TCR Sequences

SEQ ID NO:	TCR Chain	Sequence
1	Alpha Chain (amino acid)	QKVTQAQTEISVVEKEDVTLDCVYETRDTTYLFWYKQPPSGELVFLIRRNSEFDEQNEI SGRYSWNFQKSTSSFNFTITASQVVDASVYFCALSVGTYKYIFGTGTRLKVLANIQNPD PAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKSDSVYITDKTVLDMRSMDFKSN SAVAW SNKSDFACANAFNNSIIPEDTFFPSPFESSCDVKLVEKSFETDTNLFQNL SVIGFRILL LKVAGFNLLMTLRLWSS
18	Alpha Chain (nucleotide)	CAGAAGGTAACCAAGCGCAGACTGAAATTTCTGTGGTGGAGAAGGAGGATGTGACCTT GGACTGTGTGTATGAAACCCGTGATACTACTTATTACTTATTCTGGTACAAGCAACCAC CAAGTGGAGAATTGGTTTTCCTTATTCGTTCGGAACCTCTTTGATGAGCAAAATGAAATA AGTGGTCGGTATTCTTGGAACTCCAGAAATCCACCACTTCCTTCAACTTCACCATCAC AGCCTCACAAGTCGTGGACTCAGCAGTATACTTCTGTGCTCTGAGTGTAGGAACCTACA AATACATCTTTGGAACAGGCACCAAGGCTGAAGGTTTATAGCAAATATCCAGAACCCTGAC CCTGCCGTGTACCAGCTGAGAGACTCTAAATCCAGTGACAAGTCTGTCTGCCTATTAC CGATTTTGATTCTCAAACAAATGTGTCAAAAGTAAGGATTCTGATGTGTATATCACAG ACAAACTGTGCTAGACATGAGGTCTATGGACTTCAAGAGCAACAGTGTGTGGCCTGG AGCAACAAATCTGACTTTGCATGTGCAACGCCTTCAACAACAGCATTATTCAGAAGA CACCTTCTTCCCAGCCAGAAAGTTCTGTGATGTCAAGCTGGTCGAGAAAAGCTTTG AAACAGATACGAACCTAACTTTCAAACCTGTCAAGTATTGGGTTCCGAATCCTCCTC CTGAAAGTGGCCGGGTTTAATCTGCTCATGACGCTGCGGCTGTGGTCCAGC
21	Alpha Chain Signal Peptide (amino acid)	MLTASLLRAVIASICVVSSMA
23	Alpha Chain Signal Peptide (nucleotide)	ATGCTGACTGCCAGCCTGTTGAGGGCAGTCATAGCCTCCATCTGTGTTGTATCCAGCAT GGCT
2	Beta Chain (amino acid)	DTGVSQNPRHKITKRQNVTFRCDFISEHNRLYWYRQTLGQGPEFLTYFQNEAQLEKSR LLSDRFSAERP KGSFSTLEIQRTREQDSAMYLCASSPGTGGRETQYFGPGTRLLVLEDL KNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWVNGKEVHSGVSTDPQP LKEQPALNDSRYCLSSRLRVSAFWQNP RNHFRCQVQFYGLSENDEWTQDRAKPVQTIV SAEAWGRADCGFTSES YQQGVLSATILYEILLGKATLYAVLV SALVLMAMVKRKDSRG
19	Beta Chain (nucleotide)	GATACTGGAGTCTCCAGAACCCAGACACAAGATCACAAAGAGGGGACAGAATGTAAC TTTCAGGTGTGATCCAATTTCTGAACACAACCGCCTTTATTGGTACCGACAGACCCTGG GGCAGGGCCAGAGTTTCTGACTTACTTCCAGAATGAAGCTCAACTAGAAAAATCAAGG

		CTGCTCAGTGATCGGTTCTCTGCAGAGAGGCCCTAAGGGATCTTTCTCCACCTGGAGAT CCAGCGCACAGAGCAGGGGGACTCGGCCATGTATCTCTGTGCCAGCAGCCCCGGGACAG GGGGGAGGGAGACCAGTACTTCGGGCCAGGCACGCGGCTCCTGGTGCTCGAGGACCTG AAAAACGTGTTCCACCCGAGGTCGCTGTGTTTGAGCCATCAGAAGCAGAGATCTCCCA CACCCAAAAGGCCACACTGGTATGCCTGGCCACAGGCTTCTACCCGACCACGTGGAGC TGAGCTGGTGGGTGAATGGGAAGGAGGTGCACAGTGGGGTCAGCACAGACCCGACGCC CTCAAGGAGCAGCCCCGCCCTCAATGACTCCAGATACTGCCTGAGCAGCCGCCTGAGGGT CTCGGCCACCTTCTGGCAGAACCCCGCAACCACTTCCGCTGTCAAGTCCAGTTCTACG GGCTCTCGGAGAATGACGAGTGGACCCAGGATAGGGCCAAACCCGTACCCAGATCGTC AGCGCCGAGGCCTGGGGTAGAGCAGACTGTGGCTTCACCTCCGAGTCTTACCAGCAAGG GGTCCTGTCTGCCACCATCCTCTATGAGATCTTGCTAGGGAAGGCCACCTTGTATGCCG TGCTGGTCAGTGCCCTCGTGCTGATGGCCATGGTCAAGAGAAAGGATTCCAGAGGC
22	Beta Chain Signal Peptide (amino acid)	MGTSLLCWMALCLLGADHA
24	Beta Chain Signal Peptide (nucleotide)	ATGGGCACCAGCCTCCTCTGCTGGATGGCCCTGTGTCTCCTGGGGGCAGATCACGCA
20	Signal Peptide (Fibroin-L derived)	MMRPVLVLLFATSALA

II.A.1. TCR Encoded by the First Nucleotide Sequence

[0115] The present disclosure is directed to a TCR encoded by the first nucleotide sequence described herein. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain and a beta chain, wherein the alpha chain comprises a variable domain comprising an alpha chain CDR1, an alpha chain CDR2, and an alpha chain CDR3; and wherein the beta chain comprises variable domain comprising a beta chain CDR1, a beta chain CDR2, and a beta chain CDR3. In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 7 (CALSVGTYKYIF). In some aspects, the anti-MAGE-A2 TCR comprises a beta chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 10 (CASSPGTGGRETQYF). In some aspects, the non-CDR regions in the alpha chain and/or the beta chain are further modified, *e.g.*, substitution or mutation of one amino acid, two amino acids, three amino acids, four amino acids, five amino acids, or six amino acids, thereby the alpha chain and/or the beta chain are not naturally occurring. In some aspects, the substitutions or mutations can improve the TCRs described herein in various ways, *e.g.*, binding affinity, binding specificity, stability, viscosity, or any combination thereof.

[0116] In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain CDR1, wherein the alpha chain CDR1 of the anti-MAGE-

A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 5 (TRDTTTY). In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain CDR1, wherein the beta chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 8 (SEHNR).

[0117] In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain CDR2, wherein the alpha chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 6 (RNSFDEQN). In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain CDR2, wherein the beta chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 9 (FQNEAQ).

[0118] In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain variable domain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with a variable domain of the alpha chain amino acid sequence set forth in SEQ ID NO: 1. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain variable domain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, or at least about 99% sequence identity with a variable domain of the alpha chain amino acid sequence set forth in SEQ ID NO: 1, wherein the anti-MAGE-A2 TCR comprises an alpha chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain variable domain present in the alpha chain amino acid sequence set forth in SEQ ID NO: 1.

[0119] In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain variable domain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with a variable domain of the beta chain amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain variable domain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, or at least about 99% sequence identity with a variable domain of the beta chain amino acid sequence set forth in SEQ ID

NO: 2, wherein the anti-MAGE-A2 TCR comprises a beta chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 10. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain variable domain present in the amino acid sequence set forth in SEQ ID NO: 2.

[0120] In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide further comprises an alpha chain constant region, a beta chain constant region, or both an alpha chain constant region and a beta chain constant region. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain constant region having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with a constant region of the alpha chain amino acid sequence set forth in SEQ ID NO: 1. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain constant region having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, or at least about 99% sequence identity with a constant region of the alpha chain amino acid sequence set forth in SEQ ID NO: 1, wherein the anti-MAGE-A2 TCR comprises an alpha chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain constant region present in the alpha chain amino acid sequence set forth in SEQ ID NO: 1. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide further comprises an alpha constant region that is different from endogenous, *e.g.*, naturally occurring, constant regions of the alpha chain. In some aspects, the alpha chain constant region comprises an amino acid sequence comprising at least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to the amino acid sequence of the constant region of the alpha chain amino acid sequence set forth in SEQ ID NO: 1.

[0121] In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain constant region having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with a constant region of the beta chain amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain constant region having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least

about 96%, at least about 97% at least about 98%, or at least about 99% sequence identity with a constant region of the beta chain amino acid sequence set forth in SEQ ID NO: 2, wherein the anti-MAGE-A2 TCR comprises a beta chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 10. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain constant region present in the amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide further comprises a beta constant region that is different from endogenous, *e.g.*, naturally occurring, constant regions of the beta chain. In some aspects, the beta chain constant region comprises an amino acid sequence comprising at least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to the amino acid sequence of the constant region of the beta chain amino acid sequence set forth in SEQ ID NO: 2.

[0122] In certain aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the alpha chain amino acid sequence set forth in SEQ ID NO: 1. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the alpha chain amino acid sequence set forth in SEQ ID NO: 1, wherein the anti-MAGE-A2 TCR comprises an alpha chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain comprising the amino acid sequence set forth in SEQ ID NO: 1.

[0123] In certain aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the beta chain amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the beta chain amino acid sequence set forth in SEQ ID NO: 2, wherein the anti-MAGE-A2 TCR comprises a beta

chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 10. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises a beta chain comprising the amino acid sequence set forth in SEQ ID NO: 2.

[0124] In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence comprises an alpha chain constant region, a beta chain constant region, or both; and wherein the alpha chain constant region, the beta chain constant region, or both comprises an amino acid sequence having at least 1, at least 2, at least 3, at least 4, or at least 5 substitutions within the target sequence relative to the corresponding amino acid sequence of an endogenous TCR.

[0125] In some aspects, the alpha chain of the anti-MAGE-A2 TCR encoded by the first nucleotide sequence further comprises a signal peptide. Any signal peptide can be used in the anti-MAGE-A2 TCR alpha chains disclosed herein. In some aspects the signal peptide is a naturally occurring TCR alpha chain signal peptide. In some aspects, the signal peptide comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the amino acid sequence set forth in SEQ ID NO: 21. In some aspects, the signal peptide is a heterologous signal peptide, *e.g.*, a signal peptide derived from a protein other than a TCR alpha chain. In some aspects, the signal peptide is a synthetic signal peptide. In some aspects, the signal peptide comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the amino acid sequence set forth in SEQ ID NO: 20 or 22. In some aspects, the alpha chain of MAGE-A2 TCR encoded by the first nucleotide sequence does not comprise a signal peptide.

[0126] In some aspects, the signal peptide of the alpha chain is encoded by a nucleic acid sequence having at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the nucleic acid sequence set forth in SEQ ID NO: 23 or 24.

[0127] In some aspects, the beta chain of the anti-MAGE-A2 TCR encoded by the first nucleotide sequence further comprises a signal peptide. Any signal peptide can be used in the

anti-MAGE-A2 TCR beta chains disclosed herein. In some aspects the signal peptide is a naturally occurring TCR beta chain signal peptide. In some aspects, the signal peptide comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the amino acid sequence set forth in SEQ ID NO: 22. In some aspects, the signal peptide is a heterologous signal peptide, *e.g.*, a signal peptide derived from a protein other than a TCR beta chain. In some aspects, the signal peptide is a synthetic signal peptide. In some aspects, the signal peptide comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the amino acid sequence set forth in SEQ ID NO: 20 or 21. In some aspects, the beta chain of MAGE-A2 TCR encoded by the first nucleotide sequence does not comprise a signal peptide.

[0128] In some aspects, the signal peptide of the beta chain is encoded by a nucleic acid sequence having at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the nucleic acid sequence set forth in SEQ ID NO: 23 or 24.

[0129] In some aspects, each of the alpha chain and the beta chain of the anti-MAGE-A2 TCR encoded by the first nucleotide sequence further comprises a signal peptide. In some aspects, the signal peptide of the alpha chain is the same as the signal peptide of the beta chain. In some aspects, the signal peptide of the alpha chain is different from the signal peptide of the beta chain.

II.A.2. Epitopes

[0130] In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide sequence binds the same epitope as a reference TCR. In some aspects, the anti-MAGE-A2 TCR binds to an epitope of MAGE-A2 comprising the amino acid sequence set forth in SEQ ID NO: 13 (AISRKMVELVHFLLLKYRAR). In some aspects, the anti-MAGE-A2 TCR binds to an epitope of MAGE-A2 consisting of an amino acid sequence as set forth in SEQ

ID NO: 13. In some aspects, the epitope consists of amino acid residues 108-127 of MAGE-A2 (SEQ ID NO: 16), *e.g.*, "MAGE-A2₁₀₈₋₁₂₇."

[0131] In certain aspects, the epitope is part of a larger polypeptide, *e.g.*, a peptide that comprises the epitope sequence and (i) one or more additional amino acids N-terminal to the epitope sequence and/or (ii) one or more additional amino acids C-terminal to the epitope sequence. In some aspects, the polypeptide comprising the epitope is at least about 10 amino acids, at least about 11 amino acids, at least about 12 amino acids, at least about 13 amino acids, at least about 14 amino acids, at least about 15 amino acids, at least about 16 amino acids, at least about 17 amino acids, at least about 18 amino acids, at least about 19 amino acids, at least about 20 amino acids, at least about 25 amino acids, at least about 30 amino acids, at least about 35 amino acids, at least about 40 amino acids, at least about 45 amino acids, or at least about 50 amino acids in length. In certain aspects, the polypeptide comprising the epitope is at least about 5 to at least about 10, at least about 5 to at least about 15, at least about 5 to at least about 20, at least about 10 to at least about 15, at least about 10 to at least about 20, at least about 10 to at least about 25, at least about 10 to at least about 30, at least about 10 to at least about 35, at least about 10 to at least about 40, at least about 10 to at least about 45, at least about 10 to at least about 50, at least about 15 to at least about 20, at least about 15 to at least about 25, at least about 15 to at least about 30, at least about 15 to at least about 35, at least about 15 to at least about 40, at least about 15 to at least about 45, or at least about 15 to at least about 50 amino acids in length.

[0132] In certain aspects, the polypeptide comprising the epitope comprises the epitope and at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15 additional amino acids N-terminal to the epitope. In certain aspects, the polypeptide comprising the epitope comprises the epitope and at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15 additional amino acids C-terminal to the epitope.

[0133] In certain aspects, the epitope is complexed with an HLA class II molecule. The human leukocyte antigen (HLA) system (the major histocompatibility complex [MHC] in humans) is an important part of the immune system and is controlled by genes located on

chromosome 6. It encodes cell surface molecules specialized to present antigenic peptides to the T-cell receptor (TCR) on T cells. (See also Overview of the Immune System.) MHC molecules that present antigen (Ag) are divided into 2 main classes: Class I MHC molecules and Class II MHC molecules.

[0134] Class II MHC molecules are present as transmembrane glycoproteins on the surface of professional antigen presenting cells (APCs). Intact class II molecules consist of an alpha chain and a beta chain. The gene encoding the alpha chain of MHC II class molecules is composed of 5 exons, and the gene encoding the beta chain is composed of 6 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exons 4 and 5 contribute to the transmembrane domain and cytoplasmic tail for each of the alpha and beta subunits. Three loci in the HLA complex encode MHC class II proteins: HLA-DR, HLA-DQ, and HLA-DP. T cells that express CD4 molecules react with class II MHC molecules. These lymphocytes often have a cytotoxic function and activate a response to eliminate self-cells infected with intracellular pathogens or to destroy extracellular parasites.. Because only professional antigen presenting cells (APCs) express class II MHC molecules, only these cells present antigen for CD4 T cells (CD4 binds to the nonpolymorphic part of the alpha-2 and beta-2 domains of the alpha and beta chains of an MHC class II molecule respectively).

[0135] In some aspects, the HLA class II alpha and beta chains are selected from an HLA-DR, HLA-DP, and HLA-DQ allele. In certain aspects, the HLA class II alpha chain is an HLA-DR alpha chain. In some aspects the HLA class II beta chain is an HLA-DR beta chain. In certain aspects, the HLA class II alpha chain is an HLA-DP alpha chain. In some aspects the HLA class II beta chain is an HLA-DP beta chain. In certain aspects, the HLA class II alpha chain is an HLA-DQ alpha chain. In some aspects the HLA class II beta chain is an HLA-DQ beta chain.

[0136] Many HLA-DR, HLA-DP, and HLA-DQ alleles are known in the art, and any of the known alleles can be used in the present disclosure. An updated list of HLA alleles is available at hla.alleles.org/ (last visited on June 18, 2019), which is incorporated by reference herein in its entirety.

II.A.3 The Second Nucleotide Sequence

[0137] The second nucleotide sequence of the nucleic acid molecule disclosed herein can be any sequence or can encode for any polypeptide that is capable of inhibiting the expression of an endogenous TCR. In some aspects, the second nucleotide sequence is one or more siRNAs. In some aspects, the one or more siRNAs are complementary to a target sequence within a nucleotide sequence encoding a constant region of an endogenous TCR. In certain aspects, the one or more siRNAs are complementary to a target sequence within a nucleotide sequence encoding a constant region of wild-type, human TCR. In some aspects, the one or more siRNAs are complementary to a target sequence within a nucleotide sequence encoding a constant region of the alpha chain of wild-type TCR. In some aspects, the one or more siRNAs are complementary to a target sequence within a nucleotide sequence encoding a constant region of the beta chain of wild-type TCR. In some aspects, the one or more siRNAs comprise (i) one or more siRNA's that are complementary to a target sequence within a nucleotide sequence encoding a constant region of the alpha chain of wild-type TCR and (ii) one or more siRNA's that are complementary to a target sequence within a nucleotide sequence encoding a constant region of the beta chain of wild-type TCR.

[0138] In some aspects, the one or more siRNAs comprise a nucleotide sequence selected from the group consisting of SEQ ID NOs: 25-28 (Table 4). In some aspects, the second nucleotide sequence of the nucleic acid molecule encodes one or more siRNAs, wherein the one or more siRNAs are complementary to a target sequence within a nucleotide sequence encoding a constant region of the alpha chain of wild-type TCR, and wherein the one or more siRNAs comprise the nucleic acid sequences set forth in SEQ ID NOs: 25 and 26.

Table 4. siRNA Sequences

SEQ ID NO:	siRNA	Sequence (Nucleotides 1-19 are ribonucleotides; nucleotides 20-21 are deoxyribonucleotides)
25	siRNA-TCRa-1	GUAAGGAUUCUGAUGUGUATT
26	siRNA-TCRa-2	UACACAUCAGAAUCCUUAUACTT
27	siRNA-TCRb-1	CCACCAUCCUCUAUGAGAUU
28	siRNA-TCRb-2	AUCUCAUAGAGGAUGGUGGTT

[0139] In some aspects, the second nucleotide sequence of the nucleic acid molecule encodes one or more siRNAs, wherein the one or more siRNAs are complementary to a target sequence within a nucleotide sequence encoding a constant region of the beta chain of wild-type TCR, and wherein the one or more siRNAs comprise the nucleic acid sequences set forth in SEQ ID NOs: 27 and 28. In some aspects, the second nucleotide sequence of the nucleic acid molecule encodes one or more siRNAs, wherein the one or more siRNAs comprise (i)

one or more siRNAs that are complementary to a target sequence within a nucleotide sequence encoding a constant region of the alpha chain of wild-type TCR, wherein the one or more siRNAs comprise the nucleic acid sequences set forth in SEQ ID NOs: 29 and 30; and (ii) one or more siRNAs that are complementary to a target sequence within a nucleotide sequence encoding a constant region of the beta chain of wild-type TCR, wherein the one or more siRNAs comprise the nucleic acid sequences set forth in SEQ ID NOs: 27 and 28.

[0140] In some aspects, the second nucleotide sequence of the nucleic acid molecule comprises SEQ ID NOs: 25-28. In some aspects, the second nucleotide sequence comprises SEQ ID NOs: 25-28, wherein one or more of SEQ ID NOs: 25-28 is separated by one or more nucleic acids that do not encode an siRNA. In certain aspects, the one or more siRNAs are selected from the siRNAs disclosed in U.S. Publication No. 2010/0273213 A1, which is incorporated by reference herein in its entirety.

[0141] In some aspects, the second nucleotide sequence of the nucleic acid molecule encodes a protein, wherein the protein is capable of inhibiting the expression of an endogenous, *e.g.*, wild-type, TCR. In some aspects, the second nucleotide sequence encodes Cas9.

II.A.3 Vectors

[0142] Certain aspects of the present disclosure are directed to vectors comprising a nucleic acid molecule disclosed herein. In some aspects, the vector is a viral vector. In some aspects, the vector is a viral particle or a virus. In some aspects, the vector is a mammalian vector. In some aspects, the vector is a bacterial vector.

[0143] In certain aspects, the vector is a retroviral vector. In some aspects, the vector is selected from the group consisting of an adenoviral vector, a lentivirus, a Sendai virus, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, and an adeno associated virus (AAV) vector. In particular aspects, the vector is an AAV vector. In some aspects, the vector is a lentivirus. In particular aspects, the vector is an AAV vector. In some aspects, the vector is a Sendai virus. In some aspects, the vector is a hybrid vector. Examples of hybrid vectors that can be used in the present disclosure can be found in Huang and Kamihira, *Biotechnol. Adv.* 31(2):208-23 (2103), which is incorporated by reference herein in its entirety.

II.B. Recombinant T Cell Receptors (TCRs)

- [0144] Certain aspects of the present disclosure are directed to recombinant T cell receptors (TCRs) or an antigen binding portion thereof that specifically bind human MAGE-A2 ("an anti-MAGE-A2 TCR"). In some aspects, the anti-MAGE-A2 TCR is encoded by the a nucleic acid molecule disclosed herein.
- [0145] In some aspects, the anti-MAGE-A2 TCR cross competes for binding to human MAGE-A2 with a reference TCR. In some aspects, the anti-MAGE-A2 TCR binds the same epitope or an overlapping epitope of human MAGE-A2 as a reference TCR. In some aspects, the reference TCR comprises an alpha chain and a beta chain, and the alpha chain comprises of the reference TCR comprises an amino acid sequence as set forth in SEQ ID NO: 1. In some aspects, the beta chain of the reference TCR comprises an amino acid sequence as set forth in SEQ ID NO: 2.
- [0146] In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises a constant region, and wherein the beta chain comprises a constant region; wherein the alpha chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to the constant region of an alpha chain comprising the amino acid sequence set forth in SEQ ID NO: 1. In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises a constant region, and wherein the beta chain comprises a constant region; wherein the beta chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to the constant region of a beta chain comprising the amino acid sequence set forth in SEQ ID NO: 2.
- [0147] In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises a constant region, and wherein the beta chain comprises a constant region; wherein (i) the alpha chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to the constant region of an alpha chain comprising the amino acid sequence set forth in SEQ ID NO: 1; and (ii) the beta chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to the constant region of a beta chain comprising the amino acid sequence set forth in SEQ ID NO: 2.

- [0148] In some aspects, the alpha chain of the anti-MAGE-A2 TCR comprises a variable domain comprising an alpha chain CDR1, an alpha chain CDR2, and an alpha chain CDR3; and the beta chain of the anti-MAGE-A2 TCR comprises a variable domain comprising a beta chain CDR1, a beta chain CDR2, and a beta chain CDR3. In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the anti-MAGE-A2 TCR comprises a beta chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 10.
- [0149] In some aspects, the alpha chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 5. In some aspects, the beta chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 8.
- [0150] In some aspects, the alpha chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 6. In some aspects, the beta chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 9.
- [0151] In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain variable domain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with a variable domain of the alpha chain amino acid sequence set forth in SEQ ID NO: 1. In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain variable domain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, or at least about 99% sequence identity with a variable domain of the alpha chain amino acid sequence set forth in SEQ ID NO: 1, wherein the anti-MAGE-A2 TCR comprises an alpha chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain variable domain present in the alpha chain amino acid sequence set forth in SEQ ID NO: 1.
- [0152] In some aspects, the anti-MAGE-A2 TCR comprises a beta chain variable domain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with a variable domain of the beta chain amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the anti-MAGE-A2 TCR comprises a beta chain variable domain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, or at least about 99% sequence

identity with a variable domain of the beta chain amino acid sequence set forth in SEQ ID NO: 2, wherein the anti-MAGE-A2 TCR comprises a beta chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 10. In some aspects, the anti-MAGE-A2 TCR comprises a beta chain variable domain present in the beta chain amino acid sequence set forth in SEQ ID NO: 2.

[0153] In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide further comprises an alpha chain constant region, a beta chain constant region, or both an alpha chain constant region and a beta chain constant region. In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain constant region having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with a constant region of the alpha chain amino acid sequence set forth in SEQ ID NO: 1. In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain constant region having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, or at least about 99% sequence identity with a constant region of the alpha chain amino acid sequence set forth in SEQ ID NO: 1, wherein the anti-MAGE-A2 TCR comprises an alpha chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain constant region present in the alpha chain amino acid sequence set forth in SEQ ID NO: 1. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide further comprises an alpha constant region that is different from endogenous, *e.g.*, naturally occurring, constant regions of the alpha chain. In some aspects, the alpha chain constant region comprises an amino acid sequence comprising at least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to the amino acid sequence of the constant region of the alpha chain amino acid sequence set forth in SEQ ID NO: 1.

[0154] In some aspects, the anti-MAGE-A2 TCR comprises a beta chain constant region having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with a constant region of the beta chain amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the anti-MAGE-A2 TCR comprises a beta chain constant region having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, or at least about 99% sequence

identity with a constant region of the beta chain amino acid sequence set forth in SEQ ID NO: 2, wherein the anti-MAGE-A2 TCR comprises a beta chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 10. In some aspects, the anti-MAGE-A2 TCR comprises a beta chain constant region present in the beta chain amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the anti-MAGE-A2 TCR encoded by the first nucleotide further comprises a beta constant region that is different from endogenous, *e.g.*, naturally occurring, constant regions of the beta chain. In some aspects, the beta chain constant region comprises an amino acid sequence comprising at least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to the amino acid sequence of the constant region of the beta chain amino acid sequence set forth in SEQ ID NO: 2.

[0155] In certain aspects, the anti-MAGE-A2 TCR comprises an alpha chain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the alpha chain amino acid sequence set forth in SEQ ID NO: 1. In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the alpha chain amino acid sequence set forth in SEQ ID NO: 1, wherein the anti-MAGE-A2 TCR comprises an alpha chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 7. In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain comprising the amino acid sequence set forth in SEQ ID NO: 1.

[0156] In certain aspects, the anti-MAGE-A2 TCR comprises a beta chain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the beta chain amino acid sequence set forth in SEQ ID NO: 2. In some aspects, the anti-MAGE-A2 TCR comprises a beta chain having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97% at least about 98%, at least about 99%, or about 100% sequence identity with the beta chain amino acid sequence set forth in SEQ ID NO: 2, wherein the anti-MAGE-A2 TCR comprises a beta chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 10. In some aspects, the anti-MAGE-A2 TCR comprises a beta chain comprising the amino acid sequence set forth in SEQ ID NO: 2.

[0157] In some aspects, the anti-MAGE-A2 TCR comprises an alpha chain constant region, a beta chain constant region, or both; and wherein the alpha chain constant region, the beta chain constant region, or both comprises an amino acid sequence having at least 1, at least 2, at least 3, at least 4, or at least 5 substitutions within the target sequence relative to the corresponding amino acid sequence of an endogenous TCR.

II.B.2. Epitopes

[0158] In some aspects, the anti-MAGE-A2 TCR binds the same epitope as a reference TCR. In some aspects, the anti-MAGE-A2 TCR binds to an epitope of MAGE-A2 comprising the amino acid sequence set forth in SEQ ID NO: 13. In some aspects, the anti-MAGE-A2 TCR binds to an epitope of MAGE-A2 consisting of an amino acid sequence as set forth in SEQ ID NO: 13. In some aspects, the epitope consists of amino acid residues 108-127 of MAGE-A2 (SEQ ID NO: 16), *e.g.*, "MAGE-A2₁₀₈₋₁₂₇."

[0159] In certain aspects, the epitope is complexed with an HLA class II molecule. In some aspects, the HLA class II molecule comprises an alpha chain and a beta chain. In some aspects, the alpha chain is selected from an HLA-DR alpha chain, an HLA-DP alpha chain, and an HLA-DQ alpha chain. In some aspects, the beta chain is selected from an HLA-DR beta chain, an HLA-DP beta chain, and an HLA-DQ beta chain. In certain aspects, the HLA class II molecule comprises an HLA-DR alpha chain and an HLA-DR beta chain. In certain aspects, the HLA class II molecule comprises an HLA-DP alpha chain and an HLA-DP beta chain. In certain aspects, the HLA class II molecule comprises an HLA-DQ alpha chain and an HLA-DQ beta chain.

[0160] Many HLA-DR, HLA-DP, and HLA-DQ alleles are known in the art, and any of the known alleles can be used in the present disclosure. An updated list of HLA alleles is available at hla.alleles.org/ (last visited on February 27, 2019), which is incorporated by reference herein in its entirety.

II.B.3. Bispecific T Cell Receptors (TCRs)

[0161] Certain aspects of the present disclosure are directed to a bispecific TCR comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain comprises a TCR or an antigen-binding portion thereof

disclosed herein. In some aspects, the first antigen-binding domain comprises a single chain variable fragment ("scFv").

[0162] In some aspects, the second antigen-binding domain binds specifically to a protein expressed on the surface of a T cell. Any protein expressed on the surface of a T cell can be targeted by the bispecific antibody disclosed herein. In certain aspects, the protein expressed on the surface of a T cell is not expressed by other cells. In some aspects, the protein expressed on the surface of a T cell is expressed on the surface of one or more other human immune cells. In some aspects, the protein expressed on the surface of a T cell is expressed on the surface of one or more other human immune cells, but it is not expressed on the surface of a human non-immune cell. In some aspects, the second antigen-binding domain binds specifically to a protein expressed on the surface of a T cell selected from CD3, CD4, CD2, CD5, CD6, CD8, CD11a (LFA-1 α), CD43, CD45, and CD53. In certain aspects, the second antigen-binding domain binds specifically to CD3. In certain aspects, the second antigen-binding domain binds specifically to CD4. In some aspects, the second antigen-binding domain comprises an scFv.

[0163] In some aspects, the first antigen-binding domain and the second antigen-binding domain are linked or associated by a covalent bond. In some aspects, the first antigen-binding domain and the second antigen-binding domain are linked by a peptide bond.

II.C. Cells Expressing TCRs

[0164] Certain aspects of the present disclosure are directed to cells comprising a nucleic acid molecule disclosed herein, a vector disclosed herein, a recombinant TCR disclosed herein, a bispecific TCR disclosed herein, or any combination thereof. Any cell can be used in the present disclosure.

[0165] In certain aspects, the cell expresses CD4. CD4 expression can be naturally occurring, *e.g.*, the CD4 is expressed from a nucleic acid sequence that is endogenously expressed by the cell. For example, T cells, monocytes, macrophages, dendritic cells, and natural killer (NK) cells naturally express CD4. Thus, in some aspects, the cell is a T cell, a monocyte, a macrophage, a dendritic cell, or a natural killer cell. In certain aspects, the cell is a T cell selected from a natural killer T (NKT) cell and an innate lymphoid cell (ILC). In some aspects, the cell is a monocyte. In some aspects, the cell is a macrophage. In some aspects, the cell is a dendritic cell.

[0166] In some aspects, the T cell is isolated from a human subject. In some aspects, the human subject is the same subject that will ultimately receive the T cell therapy. In other aspects, the subject is a donor subject, wherein the donor subject is not the same subject that will receive the T cell therapy.

[0167] In some aspects, the cell is a cell that does not naturally express CD4, wherein the cell has been modified to express CD4. In some aspects, the cell comprises a transgene encoding CD4, wherein the transgene is expressed by the cell. In some aspects, the cell comprises a transgene encoding a protein that activates expression of endogenous CD4 by the cell. In some aspects, the cell comprises a transgene encoding a protein or siRNA that inhibits an inhibitor of CD4 expression in the cell. In some aspects, the transgene is incorporated into the genome of the cell. In some aspects, the transgene is not incorporated into the genome of the cell.

[0168] In some aspects, the cell that is modified to express CD4 is isolated from a human subject. In some aspects, the human subject is the same subject that will ultimately receive the cell therapy. In other aspects, the subject is a donor subject, wherein the donor subject is not the same subject that will receive the cell therapy.

II.D. HLA Class II Molecules

[0169] Certain aspects of the present disclosure are directed to a HLA class II molecule complexed to a peptide, wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 13. In some aspects, the peptide consists of the amino acid sequence set forth in SEQ ID NO: 13.

[0170] In some aspects, the HLA Class II molecule is an HLA-DR, HLA-DP, or an HLA-DQ allele. In some aspects, the HLA class II molecule is any HLA allele disclosed at hla.alleles.org/ (last visited on February 27, 2019)

[0171] In some aspects, the HLA Class II molecule comprises an alpha chain and a beta chain. In some aspects, the sequence of the alpha chain is selected from any of the HLA alpha chain protein sequences available at hla.alleles.org (last visited February 27, 2019).

II.D.1. HLA-DP Class II Molecules

[0172] In some aspects, the alpha chain is an HLA-DP alpha chain. Any HLA-DP alpha chain allele known in the art can be used in the compositions and methods disclosed herein. In some aspects, the alpha chain is selected from an HLA-DPA1*01, HLA-DPA1*02, HLA-

DPA1*03, and HLA-DPA1*04 allele. In certain aspects, the DP alpha chain comprises an HLA-DPA1*01 allele. In certain aspects, the DP alpha chain comprises an HLA-DPA1*02 allele. In certain aspects, the DP alpha chain comprises an HLA-DPA1*03 allele. In certain aspects, the DP alpha chain comprises an HLA-DPA1*04 allele.

[0173] In certain aspects, the DP alpha chain is selected from DPA1*01:03:01:01, DPA1*01:03:01:02, DPA1*01:03:01:03, DPA1*01:03:01:04, DPA1*01:03:01:05, DPA1*01:03:01:06, DPA1*01:03:01:07, DPA1*01:03:01:08, DPA1*01:03:01:09, DPA1*01:03:01:10, DPA1*01:03:01:11, DPA1*01:03:01:12, DPA1*01:03:01:13, DPA1*01:03:01:14, DPA1*01:03:01:15, DPA1*01:03:01:16, DPA1*01:03:01:17, DPA1*01:03:01:18Q, DPA1*01:03:01:19, DPA1*01:03:01:20, DPA1*01:03:01:21, DPA1*01:03:01:22, DPA1*01:03:01:23, DPA1*01:03:02, DPA1*01:03:03, DPA1*01:03:04, DPA1*01:03:05, DPA1*01:03:06, DPA1*01:03:07, DPA1*01:03:08, DPA1*01:03:09, DPA1*01:04, DPA1*01:05, DPA1*01:06:01, DPA1*01:06:02, DPA1*01:07, DPA1*01:08, DPA1*01:09, DPA1*01:10, DPA1*01:11, DPA1*01:12, DPA1*01:13, DPA1*01:14, DPA1*01:15, DPA1*01:16, DPA1*01:17, DPA1*01:18, DPA1*01:19, DPA1*02:01:01:01, DPA1*02:01:01:02, DPA1*02:01:01:03, DPA1*02:01:01:04, DPA1*02:01:01:05, DPA1*02:01:01:06, DPA1*02:01:01:07, DPA1*02:01:01:08, DPA1*02:01:01:09, DPA1*02:01:01:10, DPA1*02:01:01:11, DPA1*02:01:02:01, DPA1*02:01:02:02, DPA1*02:01:03, DPA1*02:01:04, DPA1*02:01:05, DPA1*02:01:06, DPA1*02:01:07, DPA1*02:01:08:01, DPA1*02:01:08:02, DPA1*02:02:02:01, DPA1*02:02:02:02, DPA1*02:02:02:03, DPA1*02:02:02:04, DPA1*02:02:02:05, DPA1*02:02:03, DPA1*02:02:04, DPA1*02:02:05, DPA1*02:02:06, DPA1*02:03, DPA1*02:04, DPA1*02:05, DPA1*02:06, DPA1*02:07:01:01, DPA1*02:07:01:02, DPA1*02:07:01:03, DPA1*02:08, DPA1*02:09, DPA1*02:10, DPA1*02:11, DPA1*02:12, DPA1*02:13N, DPA1*02:14, DPA1*02:15, DPA1*02:16, DPA1*03:01:01:01, DPA1*03:01:01:02, DPA1*03:01:01:03, DPA1*03:01:01:04, DPA1*03:01:01:05, DPA1*03:01:02, DPA1*03:02, DPA1*03:03, DPA1*03:04, DPA1*04:01:01:01, DPA1*04:01:01:02, DPA1*04:01:01:03, DPA1*04:02, or any combination thereof.

[0174] In some aspects, the beta chain is an HLA-DP beta chain. Any HLA-DP beta chain allele known in the art can be used in the compositions and methods disclosed herein. In certain aspects, the DP beta chain comprises an allele selected from an DPB1*01, DPB1*02, DPB1*03, DPB1*04, DPB1*05, DPB1*06, DPB1*08, DPB1*09, DPB1*10,

DPB1*100, DPB1*101, DPB1*102, DPB1*103, DPB1*104, DPB1*105, DPB1*106,
DPB1*107, DPB1*108, DPB1*109, DPB1*11, DPB1*110, DPB1*111, DPB1*112,
DPB1*113, DPB1*114, DPB1*115, DPB1*116, DPB1*117, DPB1*118, DPB1*119,
DPB1*120, DPB1*121, DPB1*122, DPB1*123, DPB1*124, DPB1*125, DPB1*126,
DPB1*127, DPB1*128, DPB1*129, DPB1*13, DPB1*130, DPB1*131, DPB1*132,
DPB1*133, DPB1*134, DPB1*135, DPB1*136, DPB1*137, DPB1*138, DPB1*139,
DPB1*14, DPB1*140, DPB1*141, DPB1*142, DPB1*143, DPB1*144, DPB1*145,
DPB1*146, DPB1*147, DPB1*148, DPB1*149, DPB1*15, DPB1*150, DPB1*151,
DPB1*152, DPB1*153, DPB1*154, DPB1*155, DPB1*156, DPB1*157, DPB1*158,
DPB1*159, DPB1*16, DPB1*160, DPB1*161, DPB1*162, DPB1*163, DPB1*164,
DPB1*165, DPB1*166, DPB1*167, DPB1*168, DPB1*169, DPB1*17, DPB1*170,
DPB1*171, DPB1*172, DPB1*173, DPB1*174, DPB1*175, DPB1*176, DPB1*177,
DPB1*178, DPB1*179, DPB1*18, DPB1*180, DPB1*181, DPB1*182, DPB1*183,
DPB1*184, DPB1*185, DPB1*186, DPB1*187, DPB1*188, DPB1*189, DPB1*19,
DPB1*190, DPB1*191, DPB1*192, DPB1*193, DPB1*194, DPB1*195, DPB1*196,
DPB1*197, DPB1*198, DPB1*199, DPB1*20, DPB1*200, DPB1*201, DPB1*202,
DPB1*203, DPB1*204, DPB1*205, DPB1*206, DPB1*207, DPB1*208, DPB1*209,
DPB1*21, DPB1*210, DPB1*211, DPB1*212, DPB1*213, DPB1*214, DPB1*215,
DPB1*216, DPB1*217, DPB1*218, DPB1*219, DPB1*22, DPB1*220, DPB1*221,
DPB1*222, DPB1*223, DPB1*224, DPB1*225, DPB1*226, DPB1*227, DPB1*228,
DPB1*229, DPB1*23, DPB1*230, DPB1*231, DPB1*232, DPB1*233, DPB1*234,
DPB1*235, DPB1*236, DPB1*237, DPB1*238, DPB1*239, DPB1*24, DPB1*240,
DPB1*241, DPB1*242, DPB1*243, DPB1*244, DPB1*245, DPB1*246, DPB1*247,
DPB1*248, DPB1*249, DPB1*25, DPB1*250, DPB1*251, DPB1*252, DPB1*253,
DPB1*254, DPB1*255, DPB1*256, DPB1*257, DPB1*258, DPB1*259, DPB1*26,
DPB1*260, DPB1*261, DPB1*262, DPB1*263, DPB1*264, DPB1*265, DPB1*266,
DPB1*267, DPB1*268, DPB1*269, DPB1*27, DPB1*270, DPB1*271, DPB1*272,
DPB1*273, DPB1*274, DPB1*275, DPB1*276, DPB1*277, DPB1*278, DPB1*279,
DPB1*28, DPB1*280, DPB1*281, DPB1*282, DPB1*283, DPB1*284, DPB1*285,
DPB1*286, DPB1*287, DPB1*288, DPB1*289, DPB1*29, DPB1*290, DPB1*291,
DPB1*292, DPB1*293, DPB1*294, DPB1*295, DPB1*296, DPB1*297, DPB1*298,
DPB1*299, DPB1*30, DPB1*300, DPB1*301, DPB1*302, DPB1*303, DPB1*304,

DPB1*305, DPB1*306, DPB1*307, DPB1*308, DPB1*309, DPB1*31, DPB1*310,
DPB1*311, DPB1*312, DPB1*313, DPB1*314, DPB1*315, DPB1*316, DPB1*317,
DPB1*318, DPB1*319, DPB1*32, DPB1*320, DPB1*321, DPB1*322, DPB1*323,
DPB1*324, DPB1*325, DPB1*326, DPB1*327, DPB1*328, DPB1*329, DPB1*33,
DPB1*330, DPB1*331, DPB1*332, DPB1*333, DPB1*334, DPB1*335, DPB1*336,
DPB1*337, DPB1*338, DPB1*339, DPB1*34, DPB1*340, DPB1*341, DPB1*342,
DPB1*343, DPB1*344, DPB1*345, DPB1*346, DPB1*347, DPB1*348, DPB1*349,
DPB1*35, DPB1*350, DPB1*351, DPB1*352, DPB1*353, DPB1*354, DPB1*355,
DPB1*356, DPB1*357, DPB1*358, DPB1*359, DPB1*36, DPB1*360, DPB1*361,
DPB1*362, DPB1*363, DPB1*364, DPB1*365, DPB1*366, DPB1*367, DPB1*368,
DPB1*369, DPB1*37, DPB1*370, DPB1*371, DPB1*372, DPB1*373, DPB1*374,
DPB1*375, DPB1*376, DPB1*377, DPB1*378, DPB1*379, DPB1*38, DPB1*380,
DPB1*381, DPB1*382, DPB1*383, DPB1*384, DPB1*385, DPB1*386, DPB1*387,
DPB1*388, DPB1*389, DPB1*39, DPB1*390, DPB1*391, DPB1*392, DPB1*393,
DPB1*394, DPB1*395, DPB1*396, DPB1*397, DPB1*398, DPB1*399, DPB1*40,
DPB1*400, DPB1*401, DPB1*402, DPB1*403, DPB1*404, DPB1*405, DPB1*406,
DPB1*407, DPB1*408, DPB1*409, DPB1*41, DPB1*410, DPB1*411, DPB1*412,
DPB1*413, DPB1*414, DPB1*415, DPB1*416, DPB1*417, DPB1*418, DPB1*419,
DPB1*420, DPB1*421, DPB1*422, DPB1*423, DPB1*424, DPB1*425, DPB1*426,
DPB1*427, DPB1*428, DPB1*429, DPB1*430, DPB1*431, DPB1*432, DPB1*433,
DPB1*434, DPB1*435, DPB1*436, DPB1*437, DPB1*438, DPB1*439, DPB1*44,
DPB1*440, DPB1*441, DPB1*442, DPB1*443, DPB1*444, DPB1*445, DPB1*446,
DPB1*447, DPB1*448, DPB1*449, DPB1*45, DPB1*450, DPB1*451, DPB1*452,
DPB1*453, DPB1*454, DPB1*455, DPB1*456, DPB1*457, DPB1*458, DPB1*459,
DPB1*46, DPB1*460, DPB1*461, DPB1*462, DPB1*463, DPB1*464, DPB1*465,
DPB1*466, DPB1*467, DPB1*468, DPB1*469, DPB1*47, DPB1*470, DPB1*471,
DPB1*472, DPB1*473, DPB1*474, DPB1*475, DPB1*476, DPB1*477, DPB1*478,
DPB1*479, DPB1*48, DPB1*480, DPB1*481, DPB1*482, DPB1*483, DPB1*484,
DPB1*485, DPB1*486, DPB1*487, DPB1*488, DPB1*489, DPB1*49, DPB1*490,
DPB1*491, DPB1*492, DPB1*493, DPB1*494, DPB1*495, DPB1*496, DPB1*497,
DPB1*498, DPB1*499, DPB1*50, DPB1*500, DPB1*501, DPB1*502, DPB1*503,
DPB1*504, DPB1*505, DPB1*506, DPB1*507, DPB1*508, DPB1*509, DPB1*51,

DPB1*510, DPB1*511, DPB1*512, DPB1*513, DPB1*514, DPB1*515, DPB1*516,
DPB1*517, DPB1*518, DPB1*519, DPB1*52, DPB1*520, DPB1*521, DPB1*522,
DPB1*523, DPB1*524, DPB1*525, DPB1*526, DPB1*527, DPB1*528, DPB1*529,
DPB1*53, DPB1*530, DPB1*531, DPB1*532, DPB1*533, DPB1*534, DPB1*535,
DPB1*536, DPB1*537, DPB1*538, DPB1*539, DPB1*54, DPB1*540, DPB1*541,
DPB1*542, DPB1*543, DPB1*544, DPB1*545, DPB1*546, DPB1*547, DPB1*548,
DPB1*549, DPB1*55, DPB1*550, DPB1*551, DPB1*552, DPB1*553, DPB1*554,
DPB1*555, DPB1*556, DPB1*557, DPB1*558, DPB1*559, DPB1*56, DPB1*560,
DPB1*561, DPB1*562, DPB1*563, DPB1*564, DPB1*565, DPB1*566, DPB1*567,
DPB1*568, DPB1*569, DPB1*57, DPB1*570, DPB1*571, DPB1*572, DPB1*573,
DPB1*574, DPB1*575, DPB1*576, DPB1*577, DPB1*578, DPB1*579, DPB1*58,
DPB1*580, DPB1*581, DPB1*582, DPB1*583, DPB1*584, DPB1*585, DPB1*586,
DPB1*587, DPB1*588, DPB1*589, DPB1*59, DPB1*590, DPB1*591, DPB1*592,
DPB1*593, DPB1*594, DPB1*595, DPB1*596, DPB1*597, DPB1*598, DPB1*599,
DPB1*60, DPB1*600, DPB1*601, DPB1*602, DPB1*603, DPB1*604, DPB1*605,
DPB1*606, DPB1*607, DPB1*608, DPB1*609, DPB1*61, DPB1*610, DPB1*611,
DPB1*612, DPB1*613, DPB1*614, DPB1*615, DPB1*616, DPB1*617, DPB1*618,
DPB1*619, DPB1*62, DPB1*620, DPB1*621, DPB1*622, DPB1*623, DPB1*624,
DPB1*625, DPB1*626, DPB1*627, DPB1*628, DPB1*629, DPB1*63, DPB1*630,
DPB1*631, DPB1*632, DPB1*633, DPB1*634, DPB1*635, DPB1*636, DPB1*637,
DPB1*638, DPB1*639, DPB1*64, DPB1*640, DPB1*641, DPB1*642, DPB1*643,
DPB1*644, DPB1*645, DPB1*646, DPB1*647, DPB1*648, DPB1*649, DPB1*65,
DPB1*650, DPB1*651, DPB1*652, DPB1*653, DPB1*654, DPB1*655, DPB1*656,
DPB1*657, DPB1*658, DPB1*659, DPB1*66, DPB1*660, DPB1*661, DPB1*662,
DPB1*663, DPB1*664, DPB1*665, DPB1*666, DPB1*667, DPB1*668, DPB1*669,
DPB1*67, DPB1*670, DPB1*671, DPB1*672, DPB1*673, DPB1*674, DPB1*675,
DPB1*676, DPB1*677, DPB1*678, DPB1*679, DPB1*68, DPB1*680, DPB1*681,
DPB1*682, DPB1*683, DPB1*684, DPB1*685, DPB1*686, DPB1*687, DPB1*688,
DPB1*689, DPB1*69, DPB1*690, DPB1*691, DPB1*692, DPB1*693, DPB1*694,
DPB1*695, DPB1*696, DPB1*697, DPB1*698, DPB1*699, DPB1*70, DPB1*700,
DPB1*701, DPB1*702, DPB1*703, DPB1*704, DPB1*705, DPB1*706, DPB1*707,
DPB1*708, DPB1*709, DPB1*71, DPB1*710, DPB1*711, DPB1*712, DPB1*713,

DPB1*714, DPB1*715, DPB1*716, DPB1*717, DPB1*718, DPB1*719, DPB1*72,
DPB1*720, DPB1*721, DPB1*722, DPB1*723, DPB1*724, DPB1*725, DPB1*726,
DPB1*727, DPB1*728, DPB1*729, DPB1*73, DPB1*730, DPB1*731, DPB1*732,
DPB1*733, DPB1*734, DPB1*735, DPB1*736, DPB1*737, DPB1*738, DPB1*739,
DPB1*74, DPB1*740, DPB1*741, DPB1*742, DPB1*743, DPB1*744, DPB1*745,
DPB1*746, DPB1*747, DPB1*748, DPB1*749, DPB1*75, DPB1*750, DPB1*751,
DPB1*752, DPB1*753, DPB1*754, DPB1*755, DPB1*756, DPB1*757, DPB1*758,
DPB1*759, DPB1*76, DPB1*760, DPB1*761, DPB1*762, DPB1*763, DPB1*764,
DPB1*765, DPB1*766, DPB1*767, DPB1*768, DPB1*769, DPB1*77, DPB1*770,
DPB1*771, DPB1*772, DPB1*773, DPB1*774, DPB1*775, DPB1*776, DPB1*777,
DPB1*778, DPB1*779, DPB1*78, DPB1*780, DPB1*781, DPB1*782, DPB1*783,
DPB1*784, DPB1*785, DPB1*786, DPB1*787, DPB1*788, DPB1*789, DPB1*79,
DPB1*790, DPB1*791, DPB1*792, DPB1*794, DPB1*795, DPB1*796, DPB1*797,
DPB1*798, DPB1*799, DPB1*80, DPB1*800, DPB1*801, DPB1*802, DPB1*803,
DPB1*804, DPB1*805, DPB1*806, DPB1*807, DPB1*808, DPB1*809, DPB1*81,
DPB1*810, DPB1*811, DPB1*812, DPB1*813, DPB1*814, DPB1*815, DPB1*816,
DPB1*817, DPB1*818, DPB1*819, DPB1*82, DPB1*820, DPB1*821, DPB1*822,
DPB1*823, DPB1*824, DPB1*825, DPB1*826, DPB1*827, DPB1*828, DPB1*829,
DPB1*83, DPB1*830, DPB1*831, DPB1*832, DPB1*833, DPB1*834, DPB1*835,
DPB1*836, DPB1*837, DPB1*838, DPB1*839, DPB1*84, DPB1*840, DPB1*841,
DPB1*842, DPB1*843, DPB1*844, DPB1*845, DPB1*846, DPB1*847, DPB1*848,
DPB1*849, DPB1*85, DPB1*850, DPB1*851, DPB1*852, DPB1*853, DPB1*854,
DPB1*855, DPB1*856, DPB1*857, DPB1*858, DPB1*859, DPB1*86, DPB1*860,
DPB1*861, DPB1*862, DPB1*863, DPB1*864, DPB1*865, DPB1*866, DPB1*867,
DPB1*868, DPB1*869, DPB1*87, DPB1*870, DPB1*871, DPB1*872, DPB1*873,
DPB1*874, DPB1*875, DPB1*876, DPB1*877, DPB1*878, DPB1*879, DPB1*88,
DPB1*880, DPB1*881, DPB1*882, DPB1*883, DPB1*884, DPB1*885, DPB1*886,
DPB1*887, DPB1*888, DPB1*889, DPB1*89, DPB1*890, DPB1*891, DPB1*892,
DPB1*893, DPB1*894, DPB1*895, DPB1*896, DPB1*897, DPB1*898, DPB1*899,
DPB1*90, DPB1*900, DPB1*901, DPB1*902, DPB1*903, DPB1*904, DPB1*905,
DPB1*906, DPB1*907, DPB1*908, DPB1*909, DPB1*91, DPB1*910, DPB1*911,
DPB1*912, DPB1*913, DPB1*914, DPB1*915, DPB1*916, DPB1*917, DPB1*918,

DPB1*919, DPB1*92, DPB1*920, DPB1*921, DPB1*922, DPB1*923, DPB1*924, DPB1*925, DPB1*926, DPB1*927, DPB1*928, DPB1*929, DPB1*93, DPB1*930, DPB1*931, DPB1*932, DPB1*933, DPB1*934, DPB1*935, DPB1*936, DPB1*937, DPB1*938, DPB1*939, DPB1*94, DPB1*940, DPB1*941, DPB1*942, DPB1*943, DPB1*944, DPB1*945, DPB1*946, DPB1*947, DPB1*948, DPB1*949, DPB1*95, DPB1*950, DPB1*951, DPB1*952, DPB1*953, DPB1*954, DPB1*955, DPB1*956, DPB1*957, DPB1*958, DPB1*959, DPB1*96, DPB1*960, DPB1*961, DPB1*962, DPB1*963, DPB1*964, DPB1*965, DPB1*97, DPB1*98, and DPB1*99. In some aspects, the DP beta chain comprises an HLA-DPB1*01, HLA-DPB1*02, HLA-DPB1*01, HLA-DPB1*03, HLA-DPB1*04, HLA-DPB1*05, HLA-DPB1*06, HLA-DPB1*08, HLA-DPB1*09 allele, and any combination thereof. In certain aspects, the DP beta chain comprises an HLA-DPB1*04 allele. In particular aspects, the DP beta chain comprises an HLA-DPB1*04:01 allele.

[0175] In some aspects, the DP beta chain comprises an allele selected from DPB1*01:01:01:01, DPB1*01:01:01:02, DPB1*01:01:01:03, DPB1*01:01:01:04, DPB1*01:01:01:05, DPB1*01:01:01:06, DPB1*01:01:01:07, DPB1*01:01:01:08, DPB1*01:01:01:09, DPB1*01:01:01:10, DPB1*01:01:02:01, DPB1*01:01:02:02, DPB1*01:01:03, DPB1*01:01:04, DPB1*01:01:05, DPB1*01:01:06, DPB1*02:01:02:01, DPB1*02:01:02:02, DPB1*02:01:02:03, DPB1*02:01:02:04, DPB1*02:01:02:05, DPB1*02:01:02:06, DPB1*02:01:02:07, DPB1*02:01:02:08, DPB1*02:01:02:09, DPB1*02:01:02:10, DPB1*02:01:02:11, DPB1*02:01:02:12, DPB1*02:01:02:13, DPB1*02:01:02:14, DPB1*02:01:02:15, DPB1*02:01:02:16, DPB1*02:01:02:17, DPB1*02:01:02:18, DPB1*02:01:02:19, DPB1*02:01:02:20, DPB1*02:01:02:21, DPB1*02:01:02:22, DPB1*02:01:02:23, DPB1*02:01:02:24, DPB1*02:01:02:25, DPB1*02:01:02:26, DPB1*02:01:02:27, DPB1*02:01:02:28, DPB1*02:01:02:29, DPB1*02:01:02:30, DPB1*02:01:02:31, DPB1*02:01:02:32, DPB1*02:01:02:33, DPB1*02:01:02:34, DPB1*02:01:02:35, DPB1*02:01:02:36, DPB1*02:01:02:37, DPB1*02:01:02:38, DPB1*02:01:02:39, DPB1*02:01:02:40, DPB1*02:01:02:41, DPB1*02:01:02:42, DPB1*02:01:02:43, DPB1*02:01:03, DPB1*02:01:04, DPB1*02:01:05, DPB1*02:01:06, DPB1*02:01:07, DPB1*02:01:08, DPB1*02:01:09, DPB1*02:01:10, DPB1*02:01:11, DPB1*02:01:12, DPB1*02:01:13, DPB1*02:01:14, DPB1*02:01:15, DPB1*02:01:16, DPB1*02:01:17, DPB1*02:01:18, DPB1*02:01:19, DPB1*02:01:20,

DPB1*02:01:21, DPB1*02:01:22, DPB1*02:01:23, DPB1*02:01:24, DPB1*02:01:25,
DPB1*02:01:26, DPB1*02:01:27, DPB1*02:01:28, DPB1*02:01:29, DPB1*02:01:30,
DPB1*02:01:31, DPB1*02:01:32, DPB1*02:01:33, DPB1*02:01:34, DPB1*02:01:35,
DPB1*02:01:36, DPB1*02:01:37, DPB1*02:01:38, DPB1*02:01:39, DPB1*02:01:40,
DPB1*02:01:41, DPB1*02:01:42, DPB1*02:01:43, DPB1*02:02:01:01, DPB1*02:02:01:02,
DPB1*02:02:01:03, DPB1*02:02:01:04, DPB1*02:02:01:05, DPB1*02:02:01:06,
DPB1*02:02:01:07, DPB1*02:02:02, DPB1*02:02:03, DPB1*03:01:01:01,
DPB1*03:01:01:02, DPB1*03:01:01:03, DPB1*03:01:01:04, DPB1*03:01:01:05,
DPB1*03:01:01:06, DPB1*03:01:01:07, DPB1*03:01:01:08, DPB1*03:01:01:09,
DPB1*03:01:01:10, DPB1*03:01:01:11, DPB1*03:01:02, DPB1*03:01:03, DPB1*03:01:04,
DPB1*03:01:05, DPB1*03:01:06, DPB1*03:01:07, DPB1*03:01:08, DPB1*03:01:09,
DPB1*03:01:10, DPB1*03:01:11, DPB1*03:01:12, DPB1*04:01:01:01, DPB1*04:01:01:02,
DPB1*04:01:01:03, DPB1*04:01:01:04, DPB1*04:01:01:05, DPB1*04:01:01:06,
DPB1*04:01:01:07, DPB1*04:01:01:08, DPB1*04:01:01:09, DPB1*04:01:01:10,
DPB1*04:01:01:11, DPB1*04:01:01:12, DPB1*04:01:01:13, DPB1*04:01:01:14,
DPB1*04:01:01:15, DPB1*04:01:01:16, DPB1*04:01:01:17, DPB1*04:01:01:18,
DPB1*04:01:01:19, DPB1*04:01:01:20, DPB1*04:01:01:21, DPB1*04:01:01:22,
DPB1*04:01:01:23, DPB1*04:01:01:24N, DPB1*04:01:01:25, DPB1*04:01:01:26,
DPB1*04:01:01:27, DPB1*04:01:01:28, DPB1*04:01:01:29, DPB1*04:01:01:30,
DPB1*04:01:01:31, DPB1*04:01:01:32, DPB1*04:01:01:33, DPB1*04:01:01:34,
DPB1*04:01:02, DPB1*04:01:03, DPB1*04:01:04:01, DPB1*04:01:04:02, DPB1*04:01:05,
DPB1*04:01:06, DPB1*04:01:07, DPB1*04:01:08, DPB1*04:01:09, DPB1*04:01:10,
DPB1*04:01:11, DPB1*04:01:12, DPB1*04:01:13, DPB1*04:01:14, DPB1*04:01:15,
DPB1*04:01:16, DPB1*04:01:17, DPB1*04:01:18, DPB1*04:01:19, DPB1*04:01:20,
DPB1*04:01:21, DPB1*04:01:22, DPB1*04:01:23, DPB1*04:01:24, DPB1*04:01:25,
DPB1*04:01:26, DPB1*04:01:27, DPB1*04:01:28, DPB1*04:01:29, DPB1*04:01:30,
DPB1*04:01:31, DPB1*04:01:32, DPB1*04:01:33, DPB1*04:01:34, DPB1*04:01:35,
DPB1*04:01:36, DPB1*04:01:37, DPB1*04:01:38, DPB1*04:01:39, DPB1*04:01:40,
DPB1*04:02:01:01, DPB1*04:02:01:02, DPB1*04:02:01:03, DPB1*04:02:01:04,
DPB1*04:02:01:05, DPB1*04:02:01:06, DPB1*04:02:01:07, DPB1*04:02:01:08,
DPB1*04:02:01:09, DPB1*04:02:01:10, DPB1*04:02:01:11, DPB1*04:02:01:12,
DPB1*04:02:01:13, DPB1*04:02:01:14, DPB1*04:02:02, DPB1*04:02:03, DPB1*04:02:04,

DPB1*04:02:05, DPB1*04:02:06, DPB1*04:02:07, DPB1*04:02:08, DPB1*04:02:09,
DPB1*04:02:10, DPB1*04:02:11, DPB1*04:02:12, DPB1*04:02:13, DPB1*04:02:14,
DPB1*05:01:01:01, DPB1*05:01:01:02, DPB1*05:01:01:03, DPB1*05:01:01:04,
DPB1*05:01:01:05, DPB1*05:01:01:06, DPB1*05:01:01:07, DPB1*05:01:01:08,
DPB1*05:01:01:09, DPB1*05:01:01:10, DPB1*05:01:02, DPB1*05:01:03, DPB1*05:01:04,
DPB1*05:01:05, DPB1*05:01:06, DPB1*05:01:07, DPB1*05:01:08, DPB1*05:01:09,
DPB1*06:01:01:01, DPB1*06:01:01:02, DPB1*06:01:01:03, DPB1*06:01:02,
DPB1*06:01:03, DPB1*06:01:04, DPB1*06:01:05, DPB1*08:01, DPB1*09:01:01,
DPB1*09:01:02, DPB1*09:01:03, DPB1*09:01:04, DPB1*100:01, DPB1*101:01,
DPB1*102:01, DPB1*103:01, DPB1*104:01:01:01, DPB1*104:01:01:02,
DPB1*104:01:01:03, DPB1*104:01:01:04, DPB1*104:01:01:05, DPB1*104:01:01:06,
DPB1*104:01:02, DPB1*105:01:01:01, DPB1*105:01:01:02, DPB1*105:01:01:03,
DPB1*105:01:01:04, DPB1*105:01:01:05, DPB1*105:01:01:06, DPB1*105:01:01:07,
DPB1*105:01:01:08, DPB1*105:01:01:09, DPB1*105:01:01:10, DPB1*106:01,
DPB1*107:01, DPB1*108:01, DPB1*109:01, DPB1*10:01:01:01, DPB1*10:01:01:02,
DPB1*10:01:02, DPB1*10:01:03, DPB1*10:01:04, DPB1*110:01, DPB1*111:01,
DPB1*112:01, DPB1*113:01, DPB1*114:01, DPB1*115:01, DPB1*116:01, DPB1*117:01,
DPB1*118:01, DPB1*119:01, DPB1*11:01:01:01, DPB1*11:01:01:02, DPB1*11:01:02,
DPB1*11:01:03, DPB1*11:01:04, DPB1*120:01N, DPB1*121:01, DPB1*122:01,
DPB1*123:01, DPB1*124:01:01:01, DPB1*124:01:01:02, DPB1*124:01:02:01,
DPB1*124:01:02:02, DPB1*125:01, DPB1*126:01:01:01, DPB1*126:01:01:02,
DPB1*127:01, DPB1*128:01, DPB1*129:01, DPB1*130:01, DPB1*131:01:01:01,
DPB1*131:01:01:02, DPB1*131:01:02, DPB1*131:01:03, DPB1*132:01, DPB1*133:01,
DPB1*134:01, DPB1*135:01, DPB1*136:01, DPB1*137:01, DPB1*138:01, DPB1*139:01,
DPB1*13:01:01:01, DPB1*13:01:01:02, DPB1*13:01:01:03, DPB1*13:01:01:04,
DPB1*13:01:01:05, DPB1*13:01:01:06, DPB1*13:01:01:07, DPB1*13:01:01:08,
DPB1*13:01:02, DPB1*13:01:03, DPB1*140:01, DPB1*141:01, DPB1*142:01,
DPB1*143:01, DPB1*144:01, DPB1*145:01, DPB1*146:01, DPB1*147:01, DPB1*148:01,
DPB1*149:01, DPB1*14:01:01:01, DPB1*14:01:01:02, DPB1*14:01:01:03,
DPB1*14:01:02, DPB1*14:01:03, DPB1*14:01:04, DPB1*14:01:05, DPB1*14:01:06,
DPB1*14:01:07, DPB1*14:01:08, DPB1*14:01:09, DPB1*150:01, DPB1*151:01,
DPB1*152:01, DPB1*153:01, DPB1*154:01N, DPB1*155:01:01, DPB1*155:01:02,

DPB1*156:01, DPB1*157:01, DPB1*158:01, DPB1*159:01N, DPB1*15:01:01:01, DPB1*15:01:01:02, DPB1*15:01:01:03, DPB1*15:01:01:04, DPB1*15:01:02, DPB1*15:01:03, DPB1*160:01, DPB1*161:01N, DPB1*162:01:01, DPB1*162:01:02, DPB1*163:01, DPB1*164:01, DPB1*165:01, DPB1*166:01, DPB1*167:01, DPB1*168:01, DPB1*169:01, DPB1*16:01:01:01, DPB1*16:01:01:02, DPB1*16:01:02, DPB1*16:01:03, DPB1*170:01, DPB1*171:01, DPB1*172:01, DPB1*173:01, DPB1*174:01, DPB1*175:01, DPB1*176:01, DPB1*177:01, DPB1*178:01, DPB1*179:01, DPB1*17:01:01:01, DPB1*17:01:01:02, DPB1*17:01:02, DPB1*17:01:03, DPB1*180:01, DPB1*181:01, DPB1*182:01, DPB1*183:01, DPB1*184:01, DPB1*185:01, DPB1*186:01, DPB1*187:01, DPB1*188:01, DPB1*189:01, DPB1*18:01:01:01, DPB1*18:01:01:02, DPB1*18:01:01:03, DPB1*18:01:02, DPB1*18:01:03, DPB1*190:01, DPB1*191:01, DPB1*192:01, DPB1*193:01, DPB1*194:01, DPB1*195:01, DPB1*196:01, DPB1*197:01, DPB1*198:01, DPB1*199:01, DPB1*19:01:01:01, DPB1*19:01:01:02, DPB1*19:01:01:03, DPB1*200:01, DPB1*201:01, DPB1*202:01, DPB1*203:01:01, DPB1*203:01:02, DPB1*204:01, DPB1*205:01, DPB1*206:01, DPB1*207:01, DPB1*208:01, DPB1*209:01, DPB1*20:01:01:01, DPB1*20:01:01:02, DPB1*20:01:02, DPB1*20:01:03, DPB1*20:01:04, DPB1*210:01, DPB1*211:01, DPB1*212:01, DPB1*213:01:01, DPB1*213:01:02, DPB1*214:01, DPB1*215:01, DPB1*216:01N, DPB1*217:01, DPB1*218:01N, DPB1*219:01, DPB1*21:01, DPB1*220:01, DPB1*221:01, DPB1*222:01, DPB1*223:01, DPB1*224:01, DPB1*225:01, DPB1*226:01, DPB1*227:01:01, DPB1*227:01:02, DPB1*228:01, DPB1*229:01, DPB1*22:01:01:01, DPB1*22:01:01:02, DPB1*230:01, DPB1*231:01, DPB1*232:01, DPB1*233:01, DPB1*234:01, DPB1*235:01, DPB1*236:01:01, DPB1*236:01:02, DPB1*237:01, DPB1*238:01, DPB1*239:01, DPB1*23:01:01:01, DPB1*23:01:01:02, DPB1*23:01:02, DPB1*240:01, DPB1*241:01, DPB1*242:01, DPB1*243:01, DPB1*244:01, DPB1*245:01, DPB1*246:01, DPB1*247:01, DPB1*248:01, DPB1*249:01, DPB1*24:01, DPB1*250:01, DPB1*251:01, DPB1*252:01, DPB1*253:01, DPB1*254:01, DPB1*255:01, DPB1*256:01, DPB1*257:01, DPB1*258:01, DPB1*259:01, DPB1*25:01, DPB1*260:01, DPB1*261:01, DPB1*262:01, DPB1*263:01, DPB1*264:01, DPB1*265:01, DPB1*266:01, DPB1*267:01, DPB1*268:01, DPB1*269:01, DPB1*26:01:01, DPB1*26:01:02, DPB1*26:01:03, DPB1*270:01, DPB1*271:01, DPB1*272:01, DPB1*273:01, DPB1*274:01, DPB1*275:01, DPB1*276:01, DPB1*277:01, DPB1*278:01, DPB1*279:01:01, DPB1*279:01:02, DPB1*27:01, DPB1*280:01,

DPB1*281:01, DPB1*282:01, DPB1*283:01, DPB1*284:01, DPB1*285:01, DPB1*286:01, DPB1*287:01, DPB1*288:01, DPB1*289:01, DPB1*28:01, DPB1*290:01, DPB1*291:01, DPB1*292:01, DPB1*293:01, DPB1*294:01, DPB1*295:01, DPB1*296:01, DPB1*297:01, DPB1*298:01, DPB1*299:01, DPB1*29:01, DPB1*300:01, DPB1*301:01, DPB1*302:01, DPB1*303:01, DPB1*304:01, DPB1*305:01, DPB1*306:01, DPB1*307:01, DPB1*308:01, DPB1*309:01, DPB1*30:01:01:01, DPB1*30:01:01:02, DPB1*310:01, DPB1*311:01, DPB1*312:01, DPB1*313:01, DPB1*314:01, DPB1*315:01, DPB1*316:01, DPB1*317:01, DPB1*318:01, DPB1*319:01, DPB1*31:01:01:01, DPB1*31:01:01:02, DPB1*320:01, DPB1*321:01, DPB1*322:01, DPB1*323:01, DPB1*324:01, DPB1*325:01, DPB1*326:01, DPB1*327:01, DPB1*328:01N, DPB1*329:01, DPB1*32:01, DPB1*330:01, DPB1*331:01, DPB1*332:01, DPB1*333:01, DPB1*334:01, DPB1*335:01, DPB1*336:01, DPB1*337:01, DPB1*338:01, DPB1*339:01, DPB1*33:01:01:01, DPB1*33:01:01:02, DPB1*33:01:01:03, DPB1*33:01:01:04, DPB1*33:01:01:05, DPB1*340:01, DPB1*341:01, DPB1*342:01, DPB1*343:01, DPB1*344:01, DPB1*345:01, DPB1*346:01, DPB1*347:01, DPB1*348:01:01, DPB1*348:01:02, DPB1*349:01, DPB1*34:01:01:01, DPB1*34:01:01:02, DPB1*34:01:02, DPB1*350:01, DPB1*351:01, DPB1*352:01:01, DPB1*352:01:02, DPB1*353:01, DPB1*354:01:01, DPB1*354:01:02, DPB1*355:01, DPB1*356:01, DPB1*357:01N, DPB1*358:01, DPB1*359:01, DPB1*35:01:01, DPB1*360:01, DPB1*361:01, DPB1*362:01, DPB1*363:01, DPB1*364:01, DPB1*365:01, DPB1*366:01, DPB1*367:01, DPB1*368:01, DPB1*369:01, DPB1*36:01, DPB1*370:01, DPB1*371:01, DPB1*372:01, DPB1*373:01, DPB1*374:01, DPB1*375:01, DPB1*376:01, DPB1*377:01, DPB1*378:01, DPB1*379:01, DPB1*37:01, DPB1*380:01, DPB1*381:01, DPB1*382:01N, DPB1*383:01, DPB1*384:01, DPB1*385:01, DPB1*386:01, DPB1*387:01, DPB1*388:01, DPB1*389:01, DPB1*38:01, DPB1*390:01, DPB1*391:01, DPB1*392:01, DPB1*393:01, DPB1*394:01, DPB1*395:01, DPB1*396:01, DPB1*397:01, DPB1*398:01, DPB1*399:01, DPB1*39:01:01:01, DPB1*39:01:01:02, DPB1*39:01:01:03, DPB1*39:01:01:04, DPB1*39:01:02, DPB1*39:01:03, DPB1*400:01, DPB1*401:01N, DPB1*402:01, DPB1*403:01N, DPB1*404:01, DPB1*405:01, DPB1*406:01, DPB1*407:01, DPB1*408:01, DPB1*409:01, DPB1*40:01:01:01, DPB1*40:01:01:02, DPB1*40:01:01:03, DPB1*40:01:02, DPB1*410:01, DPB1*411:01, DPB1*412:01, DPB1*413:01, DPB1*414:01:01:01, DPB1*414:01:01:02, DPB1*415:01, DPB1*416:01:01:01, DPB1*416:01:01:02, DPB1*416:01:01:03, DPB1*416:01:02, DPB1*417:01:01,

DPB1*417:01:02, DPB1*418:01, DPB1*419:01, DPB1*41:01:01:01, DPB1*41:01:01:02, DPB1*41:01:02, DPB1*420:01, DPB1*421:01, DPB1*422:01, DPB1*423:01:01, DPB1*423:01:02, DPB1*424:01, DPB1*425:01, DPB1*426:01, DPB1*427:01, DPB1*428:01, DPB1*429:01, DPB1*430:01, DPB1*431:01, DPB1*432:01, DPB1*433:01, DPB1*434:01, DPB1*435:01, DPB1*436:01, DPB1*437:01, DPB1*438:01, DPB1*439:01, DPB1*440:01, DPB1*441:01, DPB1*442:01, DPB1*443:01, DPB1*444:01, DPB1*445:01, DPB1*446:01, DPB1*447:01, DPB1*448:01, DPB1*449:01, DPB1*44:01, DPB1*450:01N, DPB1*451:01, DPB1*452:01, DPB1*453:01, DPB1*454:01, DPB1*455:01N, DPB1*456:01, DPB1*457:01, DPB1*458:01, DPB1*459:01, DPB1*45:01, DPB1*460:01, DPB1*461:01, DPB1*462:01, DPB1*463:01:01:01, DPB1*463:01:01:02, DPB1*463:01:01:03, DPB1*464:01, DPB1*465:01, DPB1*466:01, DPB1*467:01, DPB1*468:01, DPB1*469:01, DPB1*46:01:01, DPB1*46:01:02, DPB1*470:01, DPB1*471:01, DPB1*472:01, DPB1*473:01, DPB1*474:01, DPB1*475:01, DPB1*476:01, DPB1*477:01, DPB1*478:01, DPB1*479:01, DPB1*47:01:01:01, DPB1*47:01:01:02, DPB1*47:01:01:03, DPB1*480:01, DPB1*481:01, DPB1*482:01, DPB1*483:01, DPB1*484:01, DPB1*485:01, DPB1*486:01, DPB1*487:01, DPB1*488:01, DPB1*489:01, DPB1*48:01, DPB1*490:01, DPB1*491:01, DPB1*492:01, DPB1*493:01, DPB1*494:01, DPB1*495:01, DPB1*496:01, DPB1*497:01, DPB1*498:01, DPB1*499:01, DPB1*49:01:01:01, DPB1*49:01:01:02, DPB1*49:01:01:03, DPB1*500:01, DPB1*501:01, DPB1*502:01, DPB1*503:01, DPB1*504:01, DPB1*505:01, DPB1*506:01, DPB1*507:01N, DPB1*508:01, DPB1*509:01, DPB1*50:01, DPB1*510:01, DPB1*511:01, DPB1*512:01, DPB1*513:01, DPB1*514:01, DPB1*515:01, DPB1*516:01, DPB1*517:01, DPB1*518:01, DPB1*519:01, DPB1*51:01:01:01, DPB1*51:01:01:02, DPB1*520:01, DPB1*521:01, DPB1*522:01, DPB1*523:01:01, DPB1*523:01:02, DPB1*524:01, DPB1*525:01, DPB1*526:01, DPB1*527:01, DPB1*528:01, DPB1*529:01, DPB1*52:01, DPB1*530:01, DPB1*531:01, DPB1*532:01, DPB1*533:01, DPB1*534:01, DPB1*535:01, DPB1*536:01, DPB1*537:01, DPB1*538:01, DPB1*539:01, DPB1*53:01, DPB1*540:01, DPB1*541:01, DPB1*542:01, DPB1*543:01, DPB1*544:01, DPB1*545:01, DPB1*546:01, DPB1*547:01, DPB1*548:01, DPB1*549:01, DPB1*54:01, DPB1*550:01, DPB1*551:01N, DPB1*552:01, DPB1*553:01, DPB1*554:01, DPB1*555:01, DPB1*556:01, DPB1*557:01, DPB1*558:01, DPB1*559:01, DPB1*55:01:01:01, DPB1*55:01:01:02, DPB1*55:01:01:03, DPB1*55:01:01:04, DPB1*55:01:01:05, DPB1*55:01:02, DPB1*560:01, DPB1*561:01,

DPB1*562:01, DPB1*563:01, DPB1*564:01, DPB1*565:01, DPB1*566:01, DPB1*567:01, DPB1*568:01, DPB1*569:01, DPB1*56:01, DPB1*570:01N, DPB1*571:01, DPB1*572:01, DPB1*573:01, DPB1*574:01, DPB1*575:01, DPB1*576:01, DPB1*577:01, DPB1*578:01, DPB1*579:01, DPB1*57:01, DPB1*580:01, DPB1*581:01, DPB1*582:01, DPB1*583:01, DPB1*584:01:01:01, DPB1*584:01:01:02, DPB1*584:01:01:03, DPB1*584:01:02:01, DPB1*584:01:02:02, DPB1*585:01:01:01, DPB1*585:01:01:02, DPB1*586:01, DPB1*587:01, DPB1*588:01, DPB1*589:01, DPB1*58:01, DPB1*590:01, DPB1*591:01, DPB1*592:01, DPB1*593:01, DPB1*594:01, DPB1*595:01, DPB1*596:01, DPB1*597:01, DPB1*598:01N, DPB1*599:01, DPB1*59:01, DPB1*600:01, DPB1*601:01, DPB1*602:01, DPB1*603:01, DPB1*604:01, DPB1*605:01, DPB1*606:01, DPB1*607:01, DPB1*608:01, DPB1*609:01, DPB1*60:01, DPB1*610:01, DPB1*611:01, DPB1*612:01, DPB1*613:01, DPB1*614:01, DPB1*615:01, DPB1*616:01, DPB1*617:01, DPB1*618:01, DPB1*619:01, DPB1*61:01N, DPB1*620:01, DPB1*621:01, DPB1*622:01, DPB1*623:01, DPB1*624:01, DPB1*625:01, DPB1*626:01, DPB1*627:01, DPB1*628:01, DPB1*629:01, DPB1*62:01, DPB1*630:01, DPB1*631:01, DPB1*632:01, DPB1*633:01, DPB1*634:01, DPB1*635:01, DPB1*636:01, DPB1*637:01, DPB1*638:01, DPB1*639:01, DPB1*63:01, DPB1*640:01, DPB1*641:01, DPB1*642:01, DPB1*643:01, DPB1*644:01, DPB1*645:01, DPB1*646:01, DPB1*647:01, DPB1*648:01:01:01, DPB1*648:01:01:02, DPB1*649:01, DPB1*64:01N, DPB1*650:01, DPB1*651:01, DPB1*652:01, DPB1*653:01, DPB1*654:01, DPB1*655:01, DPB1*656:01, DPB1*657:01N, DPB1*658:01, DPB1*659:01, DPB1*65:01:01, DPB1*65:01:02, DPB1*660:01, DPB1*661:01N, DPB1*662:01, DPB1*663:01, DPB1*664:01, DPB1*665:01, DPB1*666:01, DPB1*667:01, DPB1*668:01:01:01, DPB1*668:01:01:02, DPB1*669:01, DPB1*66:01, DPB1*670:01, DPB1*671:01, DPB1*672:01, DPB1*673:01, DPB1*674:01, DPB1*675:01, DPB1*676:01, DPB1*677:01, DPB1*678:01, DPB1*679:01, DPB1*67:01, DPB1*680:01, DPB1*681:01, DPB1*682:01, DPB1*683:01, DPB1*684:01, DPB1*685:01, DPB1*686:01, DPB1*687:01, DPB1*688:01, DPB1*689:01, DPB1*68:01, DPB1*690:01, DPB1*691:01N, DPB1*692:01, DPB1*693:01N, DPB1*694:01, DPB1*695:01, DPB1*696:01N, DPB1*697:01Q, DPB1*698:01, DPB1*699:01, DPB1*69:01:01:01, DPB1*69:01:01:02, DPB1*700:01N, DPB1*701:01, DPB1*702:01, DPB1*703:01, DPB1*704:01, DPB1*705:01, DPB1*706:01, DPB1*707:01, DPB1*708:01, DPB1*709:01, DPB1*70:01, DPB1*710:01, DPB1*711:01, DPB1*712:01N, DPB1*713:01, DPB1*714:01, DPB1*715:01, DPB1*716:01,

DPB1*717:01, DPB1*718:01, DPB1*719:01, DPB1*71:01:01, DPB1*71:01:02,
DPB1*720:01, DPB1*721:01, DPB1*722:01, DPB1*723:01, DPB1*724:01N,
DPB1*725:01, DPB1*726:01, DPB1*727:01, DPB1*728:01, DPB1*729:01,
DPB1*72:01:01:01, DPB1*72:01:01:02, DPB1*72:01:01:03, DPB1*730:01, DPB1*731:01,
DPB1*732:01N, DPB1*733:01, DPB1*734:01, DPB1*735:01, DPB1*736:01,
DPB1*737:01, DPB1*738:01N, DPB1*739:01, DPB1*73:01, DPB1*740:01, DPB1*741:01,
DPB1*742:01, DPB1*743:01N, DPB1*744:01, DPB1*745:01, DPB1*746:01,
DPB1*747:01, DPB1*748:01N, DPB1*749:01, DPB1*74:01, DPB1*750:01, DPB1*751:01,
DPB1*752:01, DPB1*753:01, DPB1*754:01N, DPB1*755:01, DPB1*756:01N,
DPB1*757:01, DPB1*758:01, DPB1*759:01, DPB1*75:01, DPB1*760:01, DPB1*761:01,
DPB1*762:01, DPB1*763:01, DPB1*764:01, DPB1*765:01, DPB1*766:01, DPB1*767:01,
DPB1*768:01, DPB1*769:01, DPB1*76:01, DPB1*770:01, DPB1*771:01, DPB1*772:01,
DPB1*773:01, DPB1*774:01, DPB1*775:01, DPB1*776:01, DPB1*777:01N,
DPB1*778:01, DPB1*779:01, DPB1*77:01, DPB1*780:01, DPB1*781:01, DPB1*782:01,
DPB1*783:01, DPB1*784:01, DPB1*785:01, DPB1*786:01:01N, DPB1*786:01:02N,
DPB1*787:01, DPB1*788:01, DPB1*789:01, DPB1*78:01, DPB1*790:01, DPB1*791:01,
DPB1*792:01N, DPB1*794:01N, DPB1*795:01, DPB1*796:01, DPB1*797:01,
DPB1*798:01, DPB1*799:01, DPB1*79:01, DPB1*800:01N, DPB1*801:01, DPB1*802:01,
DPB1*803:01, DPB1*804:01, DPB1*805:01, DPB1*806:01:01:01, DPB1*806:01:01:02,
DPB1*807:01, DPB1*808:01, DPB1*809:01, DPB1*80:01, DPB1*810:01, DPB1*811:01,
DPB1*812:01, DPB1*813:01, DPB1*814:01, DPB1*815:01, DPB1*816:01, DPB1*817:01,
DPB1*818:01, DPB1*819:01, DPB1*81:01:01:01, DPB1*81:01:01:02, DPB1*81:01:02,
DPB1*820:01, DPB1*821:01N, DPB1*822:01, DPB1*823:01, DPB1*824:01,
DPB1*825:01, DPB1*826:01, DPB1*827:01, DPB1*828:01, DPB1*829:01, DPB1*82:01,
DPB1*830:01, DPB1*831:01N, DPB1*832:01, DPB1*833:01, DPB1*834:01,
DPB1*835:01, DPB1*836:01, DPB1*837:01, DPB1*838:01N, DPB1*839:01, DPB1*83:01,
DPB1*840:01, DPB1*841:01, DPB1*842:01, DPB1*843:01, DPB1*844:01N,
DPB1*845:01, DPB1*846:01, DPB1*847:01, DPB1*848:01, DPB1*849:01, DPB1*84:01,
DPB1*850:01, DPB1*851:01, DPB1*852:01, DPB1*853:01, DPB1*854:01, DPB1*855:01,
DPB1*856:01, DPB1*857:01, DPB1*858:01, DPB1*859:01, DPB1*85:01:01:01,
DPB1*85:01:01:02, DPB1*85:01:02, DPB1*860:01, DPB1*861:01, DPB1*862:01N,
DPB1*863:01, DPB1*864:01, DPB1*865:01N, DPB1*866:01N, DPB1*867:01N,

DPB1*868:01N, DPB1*869:01N, DPB1*86:01, DPB1*870:01N, DPB1*871:01N, DPB1*872:01N, DPB1*873:01N, DPB1*874:01N, DPB1*875:01N, DPB1*876:01N, DPB1*877:01N, DPB1*878:01N, DPB1*879:01:01:01, DPB1*879:01:01:02, DPB1*879:01:01:03, DPB1*87:01, DPB1*880:01, DPB1*881:01, DPB1*882:01, DPB1*883:01, DPB1*884:01, DPB1*885:01, DPB1*886:01, DPB1*887:01, DPB1*888:01, DPB1*889:01, DPB1*88:01, DPB1*890:01, DPB1*891:01, DPB1*892:01, DPB1*893:01, DPB1*894:01N, DPB1*895:01, DPB1*896:01, DPB1*897:01, DPB1*898:01, DPB1*899:01, DPB1*89:01, DPB1*900:01, DPB1*901:01, DPB1*902:01, DPB1*903:01, DPB1*904:01, DPB1*905:01, DPB1*906:01, DPB1*907:01, DPB1*908:01, DPB1*909:01, DPB1*90:01:01, DPB1*90:01:02, DPB1*910:01, DPB1*911:01N, DPB1*912:01, DPB1*913:01, DPB1*914:01, DPB1*915:01, DPB1*916:01, DPB1*917:01N, DPB1*918:01, DPB1*919:01N, DPB1*91:01:01:01, DPB1*91:01:01:02, DPB1*920:01, DPB1*921:01, DPB1*922:01, DPB1*923:01, DPB1*924:01, DPB1*925:01N, DPB1*926:01, DPB1*927:01, DPB1*928:01, DPB1*929:01, DPB1*92:01, DPB1*930:01, DPB1*931:01, DPB1*932:01, DPB1*933:01, DPB1*934:01Q, DPB1*935:01Q, DPB1*936:01Q, DPB1*937:01, DPB1*938:01, DPB1*939:01N, DPB1*93:01, DPB1*940:01, DPB1*941:01N, DPB1*942:01, DPB1*943:01, DPB1*944:01, DPB1*945:01, DPB1*946:01, DPB1*947:01, DPB1*948:01, DPB1*949:01, DPB1*94:01, DPB1*950:01N, DPB1*951:01, DPB1*952:01, DPB1*953:01, DPB1*954:01, DPB1*955:01, DPB1*956:01, DPB1*957:01, DPB1*958:01, DPB1*959:01N, DPB1*95:01, DPB1*960:01N, DPB1*961:01, DPB1*962:01, DPB1*963:01, DPB1*964:01, DPB1*965:01:01:01, DPB1*965:01:01:02, DPB1*96:01, DPB1*97:01, DPB1*98:01, DPB1*99:01, and any combination thereof.

II.D.2. HLA-DQ Class II Molecules

[0176] In some aspects, the alpha chain is an HLA-DQ alpha chain. Any HLA-DQ alpha chain allele known in the art can be used in the compositions and methods disclosed herein. In some aspects, the alpha chain is selected from an HLA-DQA1*01, HLA-DQA1*02, HLA-DQA1*03, HLA-DQA1*04, HLA-DQA1*05, and HLA-DQA1*06 allele. In some aspects, the alpha chain is an HLA-DQA1 allele selected from *01:01:01:01, *01:01:01:02, *01:01:01:03, *01:01:01:05, *01:01:01:06, *01:01:02, *01:01:03, *01:01:04, *01:01:05, *01:02:01:01, *01:02:01:02, *01:02:01:03, *01:02:01:04, *01:02:01:05, *01:02:01:06,

*01:02:01:07, *01:02:01:08, *01:02:01:09, *01:02:01:10, *01:02:01:11, *01:02:01:12, *01:02:02:01, *01:02:02:02, *01:02:02:03, *01:02:02:04, *01:02:03, *01:02:04, *01:03:01:01, *01:03:01:02, *01:03:01:03, *01:03:01:04, *01:03:01:05, *01:03:01:06, *01:03:01:07, *01:03:01:08, *01:03:01:09, *01:04:01:01, *01:04:01:02, *01:04:01:03, *01:04:01:04, *01:04:02, *01:05:01, *01:05:02, *01:06, *01:07Q, *01:08, *01:09, *01:10, *01:11, *01:12, *01:13, *01:14, *01:15N, *01:16N, *01:17, *01:18, *01:19, *01:20, *01:21, *01:22, *01:23, *01:24, *01:25, *01:26, *02:01:01:01, *02:01:01:02, *02:01:02, *02:02N, *02:03, *03:01:01, *03:01:03, *03:02:01:01, *03:02:01:02, *03:03:01:01, *03:03:01:02, *03:03:01:03, *03:03:01:04, *03:03:01:05, *03:03:01:06, *03:03:01:07, *03:03:02, *03:04, *03:05, *03:06, *03:07, *04:01:01:01, *04:01:01:02, *04:01:01:03, *04:01:01:04, *04:01:01:05, *04:01:01:06, *04:01:01:07, *04:01:01:08, *04:01:02:01, *04:01:02:02, *04:01:03, *04:02, *04:03N, *04:04, *04:05, *05:01:01:01, *05:01:01:02, *05:01:01:03, *05:01:01:04, *05:01:02, *05:01:04, *05:01:05, *05:01:06, *05:02, *05:03:01:01, *05:03:01:02, *05:04, *05:05:01:01, *05:05:01:02, *05:05:01:03, *05:05:01:04, *05:05:01:05, *05:05:01:06, *05:05:01:07, *05:05:01:08, *05:05:01:09, *05:05:01:10, *05:05:01:11, *05:05:01:12, *05:05:01:13, *05:05:01:14, *05:05:01:15, *05:05:01:16, *05:05:01:17, *05:05:01:18, *05:05:01:19, *05:05:01:20, *05:06:01:01, *05:06:01:02, *05:07, *05:08, *05:09, *05:10, *05:11, *05:12, *05:13, *05:14, *05:15N, *06:01:01:01, *06:01:01:02, *06:01:01:03, *06:01:01:04, *06:01:02, *06:02, and any combination thereof.

[0177] In some aspects, the beta chain is an HLA-DQ beta chain. Any HLA-DQ beta chain allele known in the art can be used in the compositions and methods disclosed herein. In some aspects the beta chain is selected from an HLA-DQB1*02, HLA-DQB1*03, HLA-DQB1*04, HLA-DQB1*05, and HLA-DQB1*06 allele.

[0178] In certain aspects, the DQ beta chain comprises an allele selected from DQB1*02:01:01, DQB1*02:01:02, DQB1*02:01:03, DQB1*02:01:04, DQB1*02:01:05, DQB1*02:01:06, DQB1*02:01:07, DQB1*02:01:08, DQB1*02:01:09, DQB1*02:01:10, DQB1*02:01:11, DQB1*02:01:12, DQB1*02:01:13, DQB1*02:01:14, DQB1*02:01:15, DQB1*02:01:16, DQB1*02:01:17, DQB1*02:01:18, DQB1*02:01:19, DQB1*02:01:20, DQB1*02:01:21, DQB1*02:01:22, DQB1*02:01:23, DQB1*02:01:24, DQB1*02:01:25, DQB1*02:01:26, DQB1*02:01:27, DQB1*02:01:28, DQB1*02:01:29, DQB1*02:01:30, DQB1*02:01:31, DQB1*02:02:01:01, DQB1*02:02:01:02, DQB1*02:02:01:03, DQB1*02:02:01:04, DQB1*02:02:02, DQB1*02:02:03, DQB1*02:02:04, DQB1*02:02:05,

DQB1*02:02:06, DQB1*02:02:07, DQB1*02:02:08, DQB1*02:02:09, DQB1*02:03:01,
DQB1*02:03:02, DQB1*02:04, DQB1*02:05, DQB1*02:06, DQB1*02:07:01,
DQB1*02:07:02, DQB1*02:08, DQB1*02:09, DQB1*02:10, DQB1*02:100, DQB1*02:101,
DQB1*02:102, DQB1*02:103, DQB1*02:104, DQB1*02:105, DQB1*02:106,
DQB1*02:107, DQB1*02:108, DQB1*02:109, DQB1*02:11, DQB1*02:110, DQB1*02:111,
DQB1*02:112, DQB1*02:113, DQB1*02:114, DQB1*02:115, DQB1*02:116,
DQB1*02:117, DQB1*02:118, DQB1*02:119, DQB1*02:12, DQB1*02:120, DQB1*02:121,
DQB1*02:122, DQB1*02:123, DQB1*02:124, DQB1*02:125, DQB1*02:126,
DQB1*02:127, DQB1*02:128, DQB1*02:129N, DQB1*02:13, DQB1*02:130,
DQB1*02:131, DQB1*02:132N, DQB1*02:133, DQB1*02:134N, DQB1*02:135,
DQB1*02:136, DQB1*02:137, DQB1*02:138, DQB1*02:139, DQB1*02:140,
DQB1*02:141, DQB1*02:142, DQB1*02:14:01, DQB1*02:14:02, DQB1*02:15,
DQB1*02:16, DQB1*02:17, DQB1*02:18N, DQB1*02:19, DQB1*02:20N, DQB1*02:21,
DQB1*02:22, DQB1*02:23, DQB1*02:24, DQB1*02:25, DQB1*02:26, DQB1*02:27,
DQB1*02:28, DQB1*02:29, DQB1*02:30, DQB1*02:31, DQB1*02:32, DQB1*02:33,
DQB1*02:34, DQB1*02:35, DQB1*02:36, DQB1*02:37, DQB1*02:38, DQB1*02:39,
DQB1*02:40, DQB1*02:41, DQB1*02:42, DQB1*02:43, DQB1*02:44, DQB1*02:45,
DQB1*02:46, DQB1*02:47, DQB1*02:48, DQB1*02:49, DQB1*02:50, DQB1*02:51,
DQB1*02:52, DQB1*02:53Q, DQB1*02:54, DQB1*02:55, DQB1*02:56, DQB1*02:57,
DQB1*02:58N, DQB1*02:59, DQB1*02:60, DQB1*02:61, DQB1*02:62, DQB1*02:63,
DQB1*02:64, DQB1*02:65, DQB1*02:66, DQB1*02:67NX, DQB1*02:68, DQB1*02:69,
DQB1*02:70, DQB1*02:71, DQB1*02:72, DQB1*02:73, DQB1*02:74, DQB1*02:75,
DQB1*02:76, DQB1*02:77, DQB1*02:78, DQB1*02:79, DQB1*02:80, DQB1*02:81,
DQB1*02:82, DQB1*02:83, DQB1*02:84, DQB1*02:85, DQB1*02:86, DQB1*02:87,
DQB1*02:88, DQB1*02:89:01, DQB1*02:89:02, DQB1*02:90, DQB1*02:91,
DQB1*02:92, DQB1*02:93, DQB1*02:94, DQB1*02:95, DQB1*02:96N, DQB1*02:97,
DQB1*02:98, DQB1*02:99, DQB1*03:01:01:01, DQB1*03:01:01:02, DQB1*03:01:01:03,
DQB1*03:01:01:04, DQB1*03:01:01:05, DQB1*03:01:01:06, DQB1*03:01:01:07,
DQB1*03:01:01:08, DQB1*03:01:01:09, DQB1*03:01:01:10, DQB1*03:01:01:11,
DQB1*03:01:01:12, DQB1*03:01:01:14, DQB1*03:01:01:15, DQB1*03:01:01:16,
DQB1*03:01:01:17, DQB1*03:01:01:18, DQB1*03:01:01:19, DQB1*03:01:01:20,
DQB1*03:01:02, DQB1*03:01:03, DQB1*03:01:04, DQB1*03:01:05, DQB1*03:01:06,

DQB1*03:01:07, DQB1*03:01:08, DQB1*03:01:09, DQB1*03:01:10, DQB1*03:01:11,
DQB1*03:01:12, DQB1*03:01:13, DQB1*03:01:14, DQB1*03:01:15, DQB1*03:01:16,
DQB1*03:01:17, DQB1*03:01:18, DQB1*03:01:19, DQB1*03:01:20, DQB1*03:01:21,
DQB1*03:01:22, DQB1*03:01:23, DQB1*03:01:24, DQB1*03:01:25, DQB1*03:01:26,
DQB1*03:01:27, DQB1*03:01:28, DQB1*03:01:29, DQB1*03:01:30, DQB1*03:01:31,
DQB1*03:01:32, DQB1*03:01:33, DQB1*03:01:34, DQB1*03:01:35, DQB1*03:01:36,
DQB1*03:01:37, DQB1*03:01:38, DQB1*03:01:39, DQB1*03:01:40, DQB1*03:01:41,
DQB1*03:01:42, DQB1*03:01:43, DQB1*03:01:44, DQB1*03:01:45, DQB1*03:01:46,
DQB1*03:02:01:01, DQB1*03:02:01:02, DQB1*03:02:01:03, DQB1*03:02:01:04,
DQB1*03:02:01:05, DQB1*03:02:01:06, DQB1*03:02:01:07, DQB1*03:02:01:08,
DQB1*03:02:02, DQB1*03:02:03, DQB1*03:02:04, DQB1*03:02:05, DQB1*03:02:06,
DQB1*03:02:07, DQB1*03:02:08, DQB1*03:02:09, DQB1*03:02:10, DQB1*03:02:11,
DQB1*03:02:12, DQB1*03:02:13, DQB1*03:02:14, DQB1*03:02:15, DQB1*03:02:16,
DQB1*03:02:17, DQB1*03:02:18, DQB1*03:02:19, DQB1*03:02:20, DQB1*03:02:21,
DQB1*03:02:22, DQB1*03:02:23, DQB1*03:02:24, DQB1*03:02:25, DQB1*03:02:26,
DQB1*03:02:27, DQB1*03:02:28, DQB1*03:02:29, DQB1*03:02:30, DQB1*03:03:02:01,
DQB1*03:03:02:02, DQB1*03:03:02:03, DQB1*03:03:02:04, DQB1*03:03:02:05,
DQB1*03:03:03, DQB1*03:03:04, DQB1*03:03:05, DQB1*03:03:06, DQB1*03:03:07,
DQB1*03:03:08, DQB1*03:03:09, DQB1*03:03:10, DQB1*03:03:11, DQB1*03:03:12,
DQB1*03:03:13, DQB1*03:03:14, DQB1*03:03:15, DQB1*03:03:16, DQB1*03:03:17,
DQB1*03:03:18, DQB1*03:03:19, DQB1*03:03:20, DQB1*03:03:21, DQB1*03:04:01,
DQB1*03:04:02, DQB1*03:04:03, DQB1*03:04:04, DQB1*03:05:01, DQB1*03:05:02,
DQB1*03:05:03, DQB1*03:05:04, DQB1*03:06, DQB1*03:07, DQB1*03:08,
DQB1*03:09, DQB1*03:100, DQB1*03:101, DQB1*03:102, DQB1*03:103, DQB1*03:104,
DQB1*03:105, DQB1*03:106, DQB1*03:107, DQB1*03:108, DQB1*03:109,
DQB1*03:10:01, DQB1*03:10:02:01, DQB1*03:10:02:02, DQB1*03:11, DQB1*03:110,
DQB1*03:111, DQB1*03:112, DQB1*03:113, DQB1*03:114, DQB1*03:115,
DQB1*03:116, DQB1*03:117, DQB1*03:118N, DQB1*03:119, DQB1*03:12,
DQB1*03:120, DQB1*03:121, DQB1*03:122, DQB1*03:123, DQB1*03:124,
DQB1*03:125, DQB1*03:126, DQB1*03:127, DQB1*03:128, DQB1*03:129, DQB1*03:13,
DQB1*03:130, DQB1*03:131, DQB1*03:132, DQB1*03:133, DQB1*03:134,
DQB1*03:135, DQB1*03:136, DQB1*03:137, DQB1*03:138, DQB1*03:139,

DQB1*03:140, DQB1*03:141, DQB1*03:142, DQB1*03:143, DQB1*03:144,
DQB1*03:145, DQB1*03:146, DQB1*03:147, DQB1*03:148, DQB1*03:149,
DQB1*03:14:01, DQB1*03:14:02, DQB1*03:15, DQB1*03:150, DQB1*03:151,
DQB1*03:152, DQB1*03:153, DQB1*03:154, DQB1*03:155, DQB1*03:156,
DQB1*03:157, DQB1*03:158, DQB1*03:159, DQB1*03:16, DQB1*03:160, DQB1*03:161,
DQB1*03:162, DQB1*03:163, DQB1*03:164, DQB1*03:165, DQB1*03:166,
DQB1*03:167, DQB1*03:168, DQB1*03:169, DQB1*03:170, DQB1*03:171,
DQB1*03:172, DQB1*03:173, DQB1*03:174, DQB1*03:175, DQB1*03:176,
DQB1*03:177, DQB1*03:178, DQB1*03:179, DQB1*03:17:01, DQB1*03:17:02,
DQB1*03:18, DQB1*03:180, DQB1*03:181, DQB1*03:182, DQB1*03:183, DQB1*03:184,
DQB1*03:185, DQB1*03:186, DQB1*03:187, DQB1*03:188, DQB1*03:189,
DQB1*03:190, DQB1*03:191, DQB1*03:192, DQB1*03:193, DQB1*03:194,
DQB1*03:195, DQB1*03:196, DQB1*03:197Q, DQB1*03:198:01, DQB1*03:198:02,
DQB1*03:199, DQB1*03:19:01, DQB1*03:19:02, DQB1*03:19:03, DQB1*03:19:04,
DQB1*03:20, DQB1*03:200, DQB1*03:201, DQB1*03:202, DQB1*03:203, DQB1*03:204,
DQB1*03:205, DQB1*03:206, DQB1*03:207, DQB1*03:208, DQB1*03:209, DQB1*03:21,
DQB1*03:210, DQB1*03:211, DQB1*03:212, DQB1*03:213NX, DQB1*03:214,
DQB1*03:215, DQB1*03:216, DQB1*03:217, DQB1*03:218, DQB1*03:219,
DQB1*03:220, DQB1*03:221, DQB1*03:222, DQB1*03:223, DQB1*03:224,
DQB1*03:225, DQB1*03:226, DQB1*03:227, DQB1*03:228, DQB1*03:229,
DQB1*03:22:01, DQB1*03:22:02, DQB1*03:230, DQB1*03:231, DQB1*03:232,
DQB1*03:233, DQB1*03:234, DQB1*03:235, DQB1*03:236, DQB1*03:237N,
DQB1*03:238, DQB1*03:239, DQB1*03:23:01, DQB1*03:23:02, DQB1*03:23:03,
DQB1*03:24, DQB1*03:240, DQB1*03:241, DQB1*03:242, DQB1*03:243, DQB1*03:244,
DQB1*03:245, DQB1*03:246, DQB1*03:247, DQB1*03:248, DQB1*03:249,
DQB1*03:250, DQB1*03:251, DQB1*03:252, DQB1*03:253, DQB1*03:254,
DQB1*03:255, DQB1*03:256, DQB1*03:257, DQB1*03:258, DQB1*03:259,
DQB1*03:25:01, DQB1*03:25:02, DQB1*03:26, DQB1*03:260, DQB1*03:261,
DQB1*03:262, DQB1*03:263, DQB1*03:264, DQB1*03:265, DQB1*03:266,
DQB1*03:267, DQB1*03:268, DQB1*03:269N, DQB1*03:27, DQB1*03:270,
DQB1*03:271, DQB1*03:272, DQB1*03:273, DQB1*03:274, DQB1*03:275,
DQB1*03:277, DQB1*03:278, DQB1*03:279, DQB1*03:28, DQB1*03:280, DQB1*03:281,

DQB1*03:282N, DQB1*03:283, DQB1*03:284, DQB1*03:285, DQB1*03:286,
DQB1*03:287, DQB1*03:288, DQB1*03:289, DQB1*03:29, DQB1*03:290, DQB1*03:291,
DQB1*03:292, DQB1*03:293, DQB1*03:294, DQB1*03:295, DQB1*03:296,
DQB1*03:297, DQB1*03:298, DQB1*03:299, DQB1*03:30, DQB1*03:300, DQB1*03:301,
DQB1*03:302, DQB1*03:303N, DQB1*03:304, DQB1*03:305, DQB1*03:306,
DQB1*03:307, DQB1*03:308, DQB1*03:309, DQB1*03:31, DQB1*03:310N,
DQB1*03:311, DQB1*03:312, DQB1*03:313, DQB1*03:314, DQB1*03:315,
DQB1*03:316, DQB1*03:317:01, DQB1*03:317:02, DQB1*03:318, DQB1*03:319,
DQB1*03:32, DQB1*03:320, DQB1*03:321, DQB1*03:322, DQB1*03:323, DQB1*03:324,
DQB1*03:326, DQB1*03:327, DQB1*03:328, DQB1*03:329, DQB1*03:33, DQB1*03:330,
DQB1*03:331, DQB1*03:332, DQB1*03:333, DQB1*03:334N4bp, DQB1*03:335,
DQB1*03:336, DQB1*03:337, DQB1*03:338N, DQB1*03:339N, DQB1*03:34,
DQB1*03:340N, DQB1*03:341, DQB1*03:342, DQB1*03:343, DQB1*03:344,
DQB1*03:345, DQB1*03:346, DQB1*03:347, DQB1*03:348, DQB1*03:349, DQB1*03:35,
DQB1*03:350, DQB1*03:351, DQB1*03:352, DQB1*03:353, DQB1*03:354N,
DQB1*03:355, DQB1*03:356NX, DQB1*03:357N, DQB1*03:358N, DQB1*03:36,
DQB1*03:37, DQB1*03:38:01, DQB1*03:38:02, DQB1*03:39, DQB1*03:40,
DQB1*03:41, DQB1*03:42, DQB1*03:43, DQB1*03:44, DQB1*03:45, DQB1*03:46,
DQB1*03:47, DQB1*03:48, DQB1*03:49, DQB1*03:50, DQB1*03:51, DQB1*03:52,
DQB1*03:53, DQB1*03:54, DQB1*03:55, DQB1*03:56, DQB1*03:57, DQB1*03:58,
DQB1*03:59, DQB1*03:60, DQB1*03:61, DQB1*03:62, DQB1*03:63, DQB1*03:64,
DQB1*03:65, DQB1*03:66N, DQB1*03:67, DQB1*03:68, DQB1*03:69, DQB1*03:70,
DQB1*03:71, DQB1*03:72, DQB1*03:73, DQB1*03:74, DQB1*03:75, DQB1*03:76,
DQB1*03:77, DQB1*03:78, DQB1*03:79, DQB1*03:80, DQB1*03:81, DQB1*03:82,
DQB1*03:83, DQB1*03:84N, DQB1*03:85, DQB1*03:86, DQB1*03:87, DQB1*03:88,
DQB1*03:89, DQB1*03:90N, DQB1*03:91Q, DQB1*03:92, DQB1*03:93, DQB1*03:94,
DQB1*03:95N, DQB1*03:96, DQB1*03:97, DQB1*03:98, DQB1*03:99Q,
DQB1*04:01:01:01, DQB1*04:01:01:02, DQB1*04:01:02, DQB1*04:01:03,
DQB1*04:01:04, DQB1*04:01:05, DQB1*04:02:01:01, DQB1*04:02:01:04,
DQB1*04:02:01:05, DQB1*04:02:01:06, DQB1*04:02:01:07, DQB1*04:02:01:08,
DQB1*04:02:01:09, DQB1*04:02:01:10, DQB1*04:02:02, DQB1*04:02:03,
DQB1*04:02:04, DQB1*04:02:05, DQB1*04:02:06, DQB1*04:02:07, DQB1*04:02:08,

DQB1*04:02:09, DQB1*04:02:10, DQB1*04:02:11, DQB1*04:02:12, DQB1*04:02:13, DQB1*04:02:14, DQB1*04:02:15, DQB1*04:02:16, DQB1*04:02:17, DQB1*04:02:18, DQB1*04:03:01, DQB1*04:03:02, DQB1*04:03:03, DQB1*04:04, DQB1*04:05, DQB1*04:06, DQB1*04:07, DQB1*04:08, DQB1*04:09, DQB1*04:10, DQB1*04:11, DQB1*04:12, DQB1*04:13, DQB1*04:14, DQB1*04:15, DQB1*04:16, DQB1*04:17, DQB1*04:18, DQB1*04:19, DQB1*04:20, DQB1*04:21, DQB1*04:22, DQB1*04:23, DQB1*04:24, DQB1*04:25N, DQB1*04:26, DQB1*04:27, DQB1*04:28, DQB1*04:29, DQB1*04:30, DQB1*04:31, DQB1*04:32, DQB1*04:33, DQB1*04:34, DQB1*04:35, DQB1*04:36N, DQB1*04:37, DQB1*04:38, DQB1*04:39, DQB1*04:40, DQB1*04:41N, DQB1*04:42, DQB1*04:43, DQB1*04:44, DQB1*04:45, DQB1*04:46N, DQB1*04:47, DQB1*04:48, DQB1*04:49, DQB1*04:50, DQB1*04:51, DQB1*04:52, DQB1*04:53, DQB1*04:54, DQB1*04:55, DQB1*04:56, DQB1*04:57, DQB1*04:58, DQB1*04:59N, DQB1*04:60, DQB1*04:61, DQB1*04:62, DQB1*05:01:01:01, DQB1*05:01:01:02, DQB1*05:01:01:03, DQB1*05:01:01:04, DQB1*05:01:01:05, DQB1*05:01:02, DQB1*05:01:03, DQB1*05:01:04, DQB1*05:01:05, DQB1*05:01:06, DQB1*05:01:07, DQB1*05:01:08, DQB1*05:01:09, DQB1*05:01:10, DQB1*05:01:11, DQB1*05:01:12, DQB1*05:01:13, DQB1*05:01:14, DQB1*05:01:15, DQB1*05:01:16, DQB1*05:01:17, DQB1*05:01:18, DQB1*05:01:19, DQB1*05:01:20, DQB1*05:01:21, DQB1*05:01:22, DQB1*05:01:23, DQB1*05:01:24:01, DQB1*05:01:24:02, DQB1*05:01:25, DQB1*05:01:26, DQB1*05:01:27, DQB1*05:01:28, DQB1*05:01:29, DQB1*05:01:30, DQB1*05:01:31, DQB1*05:01:32, DQB1*05:01:33, DQB1*05:01:34, DQB1*05:02:01:01, DQB1*05:02:01:02, DQB1*05:02:01:03, DQB1*05:02:01:04, DQB1*05:02:01:05, DQB1*05:02:01:06, DQB1*05:02:02, DQB1*05:02:03, DQB1*05:02:04, DQB1*05:02:05, DQB1*05:02:06, DQB1*05:02:07, DQB1*05:02:08, DQB1*05:02:09, DQB1*05:02:10, DQB1*05:02:11, DQB1*05:02:12, DQB1*05:02:13, DQB1*05:02:14, DQB1*05:02:15, DQB1*05:02:16, DQB1*05:02:17, DQB1*05:02:18, DQB1*05:02:19, DQB1*05:03:01:01, DQB1*05:03:01:02, DQB1*05:03:01:03, DQB1*05:03:02, DQB1*05:03:03, DQB1*05:03:04, DQB1*05:03:05, DQB1*05:03:06, DQB1*05:03:07, DQB1*05:03:08, DQB1*05:03:09, DQB1*05:03:10, DQB1*05:03:11, DQB1*05:03:12, DQB1*05:03:13, DQB1*05:03:14, DQB1*05:03:15, DQB1*05:03:16, DQB1*05:03:17, DQB1*05:03:18, DQB1*05:03:19, DQB1*05:03:20, DQB1*05:04, DQB1*05:05:01, DQB1*05:05:02, DQB1*05:06:01, DQB1*05:06:02, DQB1*05:07, DQB1*05:08, DQB1*05:09,

DQB1*05:10, DQB1*05:100, DQB1*05:101, DQB1*05:102, DQB1*05:103, DQB1*05:104,
DQB1*05:105, DQB1*05:106, DQB1*05:107, DQB1*05:108, DQB1*05:109,
DQB1*05:110N, DQB1*05:111, DQB1*05:112, DQB1*05:113, DQB1*05:114,
DQB1*05:115, DQB1*05:116, DQB1*05:117, DQB1*05:118, DQB1*05:119,
DQB1*05:11:01, DQB1*05:11:02, DQB1*05:12, DQB1*05:120, DQB1*05:121,
DQB1*05:122, DQB1*05:123, DQB1*05:124, DQB1*05:125, DQB1*05:126,
DQB1*05:127, DQB1*05:128N, DQB1*05:129, DQB1*05:13, DQB1*05:130,
DQB1*05:131, DQB1*05:132Q, DQB1*05:133, DQB1*05:134, DQB1*05:135,
DQB1*05:136, DQB1*05:137, DQB1*05:138, DQB1*05:139, DQB1*05:14, DQB1*05:140,
DQB1*05:141, DQB1*05:142, DQB1*05:143, DQB1*05:144, DQB1*05:145,
DQB1*05:146, DQB1*05:147, DQB1*05:148, DQB1*05:149, DQB1*05:15, DQB1*05:150,
DQB1*05:151, DQB1*05:152, DQB1*05:153, DQB1*05:154, DQB1*05:155,
DQB1*05:156, DQB1*05:157, DQB1*05:158, DQB1*05:159, DQB1*05:16, DQB1*05:160,
DQB1*05:161, DQB1*05:162, DQB1*05:163, DQB1*05:164, DQB1*05:165,
DQB1*05:166, DQB1*05:167, DQB1*05:168, DQB1*05:169, DQB1*05:17, DQB1*05:170,
DQB1*05:171, DQB1*05:172, DQB1*05:173, DQB1*05:174, DQB1*05:175,
DQB1*05:176, DQB1*05:177, DQB1*05:178, DQB1*05:179, DQB1*05:18, DQB1*05:180,
DQB1*05:181, DQB1*05:182, DQB1*05:183, DQB1*05:184, DQB1*05:185N,
DQB1*05:186, DQB1*05:187, DQB1*05:188, DQB1*05:189, DQB1*05:19, DQB1*05:190,
DQB1*05:191, DQB1*05:192, DQB1*05:193, DQB1*05:194, DQB1*05:195,
DQB1*05:196, DQB1*05:197, DQB1*05:198, DQB1*05:199, DQB1*05:20, DQB1*05:200,
DQB1*05:201, DQB1*05:202, DQB1*05:203, DQB1*05:204, DQB1*05:205,
DQB1*05:206N, DQB1*05:207, DQB1*05:208N5bp, DQB1*05:209, DQB1*05:21,
DQB1*05:210, DQB1*05:211, DQB1*05:212, DQB1*05:213, DQB1*05:214,
DQB1*05:215N, DQB1*05:216, DQB1*05:217, DQB1*05:22, DQB1*05:23, DQB1*05:24,
DQB1*05:25, DQB1*05:26, DQB1*05:27, DQB1*05:28, DQB1*05:29, DQB1*05:30,
DQB1*05:31, DQB1*05:32, DQB1*05:33, DQB1*05:34, DQB1*05:35, DQB1*05:36,
DQB1*05:37, DQB1*05:38, DQB1*05:39, DQB1*05:40, DQB1*05:41N, DQB1*05:42,
DQB1*05:43:01, DQB1*05:43:02, DQB1*05:44, DQB1*05:45, DQB1*05:46,
DQB1*05:47, DQB1*05:48, DQB1*05:49, DQB1*05:50, DQB1*05:51, DQB1*05:52,
DQB1*05:53, DQB1*05:54, DQB1*05:55, DQB1*05:56, DQB1*05:57, DQB1*05:58,
DQB1*05:59, DQB1*05:60, DQB1*05:61, DQB1*05:62, DQB1*05:63, DQB1*05:64,

DQB1*05:65, DQB1*05:66:01, DQB1*05:66:02, DQB1*05:67, DQB1*05:68,
DQB1*05:69, DQB1*05:70, DQB1*05:71, DQB1*05:72, DQB1*05:73, DQB1*05:74,
DQB1*05:75, DQB1*05:76, DQB1*05:77, DQB1*05:78, DQB1*05:79, DQB1*05:80,
DQB1*05:81, DQB1*05:82, DQB1*05:83, DQB1*05:84, DQB1*05:85, DQB1*05:86,
DQB1*05:87Q, DQB1*05:88, DQB1*05:89:01, DQB1*05:89:02, DQB1*05:90N,
DQB1*05:91, DQB1*05:92, DQB1*05:93, DQB1*05:94, DQB1*05:95, DQB1*05:96,
DQB1*05:97, DQB1*05:98, DQB1*05:99, DQB1*06:01:01:01, DQB1*06:01:01:02,
DQB1*06:01:02, DQB1*06:01:03, DQB1*06:01:04, DQB1*06:01:05, DQB1*06:01:06,
DQB1*06:01:07, DQB1*06:01:08, DQB1*06:01:09, DQB1*06:01:10, DQB1*06:01:11,
DQB1*06:01:12, DQB1*06:01:13, DQB1*06:01:14, DQB1*06:01:15, DQB1*06:01:16,
DQB1*06:01:17, DQB1*06:01:18, DQB1*06:01:19, DQB1*06:01:20, DQB1*06:01:21,
DQB1*06:02:01:01, DQB1*06:02:01:02, DQB1*06:02:01:03, DQB1*06:02:01:04,
DQB1*06:02:02, DQB1*06:02:03, DQB1*06:02:04, DQB1*06:02:05, DQB1*06:02:06,
DQB1*06:02:07, DQB1*06:02:08, DQB1*06:02:09, DQB1*06:02:10, DQB1*06:02:11,
DQB1*06:02:12, DQB1*06:02:13, DQB1*06:02:14, DQB1*06:02:15, DQB1*06:02:16,
DQB1*06:02:17, DQB1*06:02:18, DQB1*06:02:19, DQB1*06:02:20, DQB1*06:02:21,
DQB1*06:02:22, DQB1*06:02:23, DQB1*06:02:24, DQB1*06:02:25, DQB1*06:02:26,
DQB1*06:02:27, DQB1*06:02:28, DQB1*06:02:29, DQB1*06:02:30, DQB1*06:02:31,
DQB1*06:02:32, DQB1*06:02:33, DQB1*06:02:34, DQB1*06:02:35, DQB1*06:02:36,
DQB1*06:02:37, DQB1*06:02:38, DQB1*06:03:01:01, DQB1*06:03:01:02,
DQB1*06:03:01:03, DQB1*06:03:02, DQB1*06:03:03, DQB1*06:03:04, DQB1*06:03:05,
DQB1*06:03:06, DQB1*06:03:07, DQB1*06:03:08, DQB1*06:03:09, DQB1*06:03:10,
DQB1*06:03:11, DQB1*06:03:12, DQB1*06:03:13, DQB1*06:03:14, DQB1*06:03:15,
DQB1*06:03:16, DQB1*06:03:17, DQB1*06:03:18, DQB1*06:03:19, DQB1*06:03:20,
DQB1*06:03:21, DQB1*06:03:22, DQB1*06:03:23, DQB1*06:03:24, DQB1*06:03:25,
DQB1*06:03:26, DQB1*06:03:27, DQB1*06:03:28, DQB1*06:03:29, DQB1*06:03:30,
DQB1*06:03:31, DQB1*06:03:32, DQB1*06:03:33, DQB1*06:03:34, DQB1*06:03:35,
DQB1*06:04:01, DQB1*06:04:02, DQB1*06:04:03, DQB1*06:04:04, DQB1*06:04:05,
DQB1*06:04:06, DQB1*06:04:07, DQB1*06:04:08, DQB1*06:04:09, DQB1*06:04:10,
DQB1*06:04:11, DQB1*06:04:12, DQB1*06:05:01, DQB1*06:05:02, DQB1*06:06,
DQB1*06:07:01, DQB1*06:07:02, DQB1*06:08:01, DQB1*06:08:02, DQB1*06:08:03,
DQB1*06:09:01:01, DQB1*06:09:01:02, DQB1*06:09:02, DQB1*06:09:03,

DQB1*06:09:04, DQB1*06:09:05, DQB1*06:09:06, DQB1*06:09:07, DQB1*06:09:08,
DQB1*06:09:09, DQB1*06:09:10, DQB1*06:10, DQB1*06:100, DQB1*06:101,
DQB1*06:102N, DQB1*06:103, DQB1*06:104, DQB1*06:105, DQB1*06:106,
DQB1*06:107, DQB1*06:108, DQB1*06:109, DQB1*06:110, DQB1*06:111,
DQB1*06:112N, DQB1*06:113, DQB1*06:114, DQB1*06:115, DQB1*06:116,
DQB1*06:117, DQB1*06:118:01, DQB1*06:118:02, DQB1*06:118:03, DQB1*06:119,
DQB1*06:11:01, DQB1*06:11:02, DQB1*06:11:03, DQB1*06:11:04, DQB1*06:12,
DQB1*06:120, DQB1*06:121, DQB1*06:122, DQB1*06:123, DQB1*06:124,
DQB1*06:125, DQB1*06:126, DQB1*06:127, DQB1*06:128, DQB1*06:129,
DQB1*06:130, DQB1*06:131, DQB1*06:132, DQB1*06:133, DQB1*06:134,
DQB1*06:135, DQB1*06:136, DQB1*06:137, DQB1*06:138, DQB1*06:139,
DQB1*06:13:01, DQB1*06:13:02, DQB1*06:13:03, DQB1*06:140, DQB1*06:141,
DQB1*06:142, DQB1*06:143, DQB1*06:144N, DQB1*06:145, DQB1*06:146:01,
DQB1*06:146:02, DQB1*06:147, DQB1*06:148, DQB1*06:149, DQB1*06:14:01,
DQB1*06:14:02, DQB1*06:14:03, DQB1*06:150, DQB1*06:151, DQB1*06:152,
DQB1*06:153:01, DQB1*06:153:02, DQB1*06:154, DQB1*06:155, DQB1*06:156,
DQB1*06:157, DQB1*06:158N, DQB1*06:159, DQB1*06:15:01, DQB1*06:15:02,
DQB1*06:16, DQB1*06:160, DQB1*06:161, DQB1*06:162, DQB1*06:163, DQB1*06:164,
DQB1*06:165, DQB1*06:166, DQB1*06:167, DQB1*06:168, DQB1*06:169, DQB1*06:17,
DQB1*06:170, DQB1*06:171, DQB1*06:172, DQB1*06:173, DQB1*06:174,
DQB1*06:175, DQB1*06:176, DQB1*06:177, DQB1*06:178, DQB1*06:179N,
DQB1*06:180, DQB1*06:181, DQB1*06:182, DQB1*06:183, DQB1*06:184,
DQB1*06:185, DQB1*06:186, DQB1*06:187, DQB1*06:188, DQB1*06:189,
DQB1*06:18:01, DQB1*06:18:02, DQB1*06:190:01, DQB1*06:190:02, DQB1*06:191,
DQB1*06:192, DQB1*06:193N, DQB1*06:194, DQB1*06:195, DQB1*06:196,
DQB1*06:197, DQB1*06:198, DQB1*06:199, DQB1*06:19:01, DQB1*06:19:02,
DQB1*06:20, DQB1*06:200, DQB1*06:201, DQB1*06:202, DQB1*06:203, DQB1*06:204,
DQB1*06:205, DQB1*06:206:01, DQB1*06:206:02, DQB1*06:207, DQB1*06:208,
DQB1*06:209, DQB1*06:21, DQB1*06:210, DQB1*06:211, DQB1*06:212, DQB1*06:213,
DQB1*06:214, DQB1*06:215, DQB1*06:216N, DQB1*06:217, DQB1*06:218,
DQB1*06:219, DQB1*06:221, DQB1*06:222, DQB1*06:223, DQB1*06:224,
DQB1*06:225, DQB1*06:226, DQB1*06:227, DQB1*06:228, DQB1*06:229,

DQB1*06:22:01, DQB1*06:22:02, DQB1*06:22:03, DQB1*06:23, DQB1*06:230,
DQB1*06:231, DQB1*06:232, DQB1*06:233, DQB1*06:234, DQB1*06:235,
DQB1*06:236, DQB1*06:237, DQB1*06:238, DQB1*06:239, DQB1*06:24, DQB1*06:240,
DQB1*06:241, DQB1*06:242, DQB1*06:243, DQB1*06:244, DQB1*06:245,
DQB1*06:246, DQB1*06:247, DQB1*06:248, DQB1*06:249, DQB1*06:25, DQB1*06:250,
DQB1*06:251, DQB1*06:252N, DQB1*06:253, DQB1*06:254, DQB1*06:255,
DQB1*06:256, DQB1*06:257, DQB1*06:258, DQB1*06:259, DQB1*06:260,
DQB1*06:261, DQB1*06:262, DQB1*06:263, DQB1*06:264, DQB1*06:265,
DQB1*06:266, DQB1*06:267, DQB1*06:268, DQB1*06:269, DQB1*06:26N,
DQB1*06:270:01, DQB1*06:270:02, DQB1*06:271, DQB1*06:272, DQB1*06:273,
DQB1*06:274, DQB1*06:275, DQB1*06:276, DQB1*06:277, DQB1*06:278,
DQB1*06:279, DQB1*06:27:01, DQB1*06:27:02, DQB1*06:28, DQB1*06:280,
DQB1*06:281, DQB1*06:282, DQB1*06:283, DQB1*06:284, DQB1*06:285,
DQB1*06:286, DQB1*06:287, DQB1*06:288, DQB1*06:289, DQB1*06:29, DQB1*06:290,
DQB1*06:291, DQB1*06:292, DQB1*06:293, DQB1*06:294, DQB1*06:295,
DQB1*06:296, DQB1*06:297, DQB1*06:298, DQB1*06:299, DQB1*06:30, DQB1*06:300,
DQB1*06:301, DQB1*06:302, DQB1*06:303N, DQB1*06:304N, DQB1*06:305,
DQB1*06:306N, DQB1*06:307, DQB1*06:308N, DQB1*06:309, DQB1*06:31,
DQB1*06:310, DQB1*06:311, DQB1*06:312, DQB1*06:313, DQB1*06:314,
DQB1*06:315, DQB1*06:316, DQB1*06:317N, DQB1*06:318, DQB1*06:319,
DQB1*06:320, DQB1*06:321, DQB1*06:322, DQB1*06:323, DQB1*06:324,
DQB1*06:325, DQB1*06:326, DQB1*06:32:01, DQB1*06:32:02, DQB1*06:33,
DQB1*06:34, DQB1*06:35, DQB1*06:36, DQB1*06:37, DQB1*06:38, DQB1*06:39,
DQB1*06:40, DQB1*06:41, DQB1*06:42, DQB1*06:43, DQB1*06:44, DQB1*06:45,
DQB1*06:46, DQB1*06:47, DQB1*06:48:01, DQB1*06:48:02, DQB1*06:49,
DQB1*06:50, DQB1*06:51:01, DQB1*06:51:02, DQB1*06:52, DQB1*06:53:01,
DQB1*06:53:02, DQB1*06:54N, DQB1*06:55, DQB1*06:56, DQB1*06:57, DQB1*06:58,
DQB1*06:59, DQB1*06:60, DQB1*06:61, DQB1*06:62, DQB1*06:63, DQB1*06:64,
DQB1*06:65, DQB1*06:66, DQB1*06:67, DQB1*06:68, DQB1*06:69:01,
DQB1*06:69:02, DQB1*06:70, DQB1*06:71, DQB1*06:72, DQB1*06:73, DQB1*06:74,
DQB1*06:75NX, DQB1*06:76, DQB1*06:77N, DQB1*06:78, DQB1*06:79:01,
DQB1*06:79:02, DQB1*06:80, DQB1*06:81, DQB1*06:82, DQB1*06:83, DQB1*06:84,

DQB1*06:85, DQB1*06:86, DQB1*06:87, DQB1*06:88, DQB1*06:89, DQB1*06:90, DQB1*06:91, DQB1*06:92:01, DQB1*06:92:02, DQB1*06:93, DQB1*06:94, DQB1*06:95, DQB1*06:96:01, DQB1*06:96:02, DQB1*06:97, DQB1*06:98, DQB1*06:99:01, DQB1*06:99:02, and any combination thereof.

II.D.3. HLA-DR Class II Molecules

[0179] In some aspects, the alpha chain is an HLA-DR alpha chain. Any HLA-DR alpha chain allele known in the art can be used in the compositions and methods disclosed herein. In some aspects, the alpha chain is an HLA-DRA*01 allele. In some aspects, the alpha chain is an HLA-DRA1 allele selected from *01:01:01:01, *01:01:01:02, *01:01:01:03, *01:01:02, *01:02:01, *01:02:02, *01:02:03, and any combination thereof.

[0180] In some aspects, the beta chain is an HLA-DR beta chain. Any HLA-DR beta chain allele known in the art can be used in the compositions and methods disclosed herein. In some aspects the beta chain is selected from an HLA-DRB1*01, HLA-DRB1*03, HLA-DRB1*04, HLA-DRB1*07, HLA-DRB1*08, HLA-DRB1*09, HLA-DRB1*10, HLA-DRB1*11, HLA-DRB1*12, HLA-DRB1*13, HLA-DRB1*14, HLA-DRB1*15, and HLA-DRB1*16 allele. In some aspects, the beta chain is a DRB3 allele. In some aspects, the beta chain is a DRB4 allele. In some aspects, the beta chain is a DRB5 allele.

[0181] In some aspects the beta chain is selected from DRB1*01:01:01, DRB1*01:01:02, DRB1*01:01:03, DRB1*01:01:04, DRB1*01:01:05, DRB1*01:01:06, DRB1*01:01:07, DRB1*01:01:08, DRB1*01:01:09, DRB1*01:01:10, DRB1*01:01:11, DRB1*01:01:12, DRB1*01:01:13, DRB1*01:01:14, DRB1*01:01:15, DRB1*01:01:16, DRB1*01:01:17, DRB1*01:01:18, DRB1*01:01:19, DRB1*01:01:20, DRB1*01:01:21, DRB1*01:01:22, DRB1*01:01:23, DRB1*01:01:24, DRB1*01:01:25, DRB1*01:01:26, DRB1*01:01:27, DRB1*01:01:28, DRB1*01:01:29, DRB1*01:01:30, DRB1*01:01:31, DRB1*01:01:32, DRB1*01:01:33, DRB1*01:02:01:01, DRB1*01:02:01:02, DRB1*01:02:02, DRB1*01:02:03, DRB1*01:02:04, DRB1*01:02:05, DRB1*01:02:06, DRB1*01:02:07, DRB1*01:02:08, DRB1*01:02:09, DRB1*01:02:10, DRB1*01:02:11, DRB1*01:02:12, DRB1*01:02:13, DRB1*01:03:01, DRB1*01:03:02, DRB1*01:03:03, DRB1*01:03:04, DRB1*01:04, DRB1*01:05, DRB1*01:06, DRB1*01:07, DRB1*01:08, DRB1*01:09, DRB1*01:10, DRB1*01:100, DRB1*01:11:01, DRB1*01:11:02, DRB1*01:12, DRB1*01:13, DRB1*01:14, DRB1*01:15, DRB1*01:16, DRB1*01:17, DRB1*01:18:01,

DRB1*01:18:02, DRB1*01:19, DRB1*01:20:01, DRB1*01:20:02, DRB1*01:21,
DRB1*01:22, DRB1*01:23, DRB1*01:24:01, DRB1*01:24:02, DRB1*01:25, DRB1*01:26,
DRB1*01:27, DRB1*01:28, DRB1*01:29:01, DRB1*01:29:02, DRB1*01:30, DRB1*01:31,
DRB1*01:32, DRB1*01:33N, DRB1*01:34, DRB1*01:35, DRB1*01:36, DRB1*01:37,
DRB1*01:38, DRB1*01:39N, DRB1*01:40N, DRB1*01:41, DRB1*01:42, DRB1*01:43,
DRB1*01:44:01, DRB1*01:44:02, DRB1*01:45, DRB1*01:46, DRB1*01:47, DRB1*01:48,
DRB1*01:49, DRB1*01:50, DRB1*01:51, DRB1*01:52N, DRB1*01:53, DRB1*01:54,
DRB1*01:55, DRB1*01:56, DRB1*01:57, DRB1*01:58, DRB1*01:59, DRB1*01:60,
DRB1*01:61, DRB1*01:62N, DRB1*01:63, DRB1*01:64, DRB1*01:65:01,
DRB1*01:65:02, DRB1*01:66, DRB1*01:67, DRB1*01:68N, DRB1*01:69, DRB1*01:70,
DRB1*01:71, DRB1*01:72, DRB1*01:73, DRB1*01:74, DRB1*01:75, DRB1*01:76,
DRB1*01:77, DRB1*01:78, DRB1*01:79, DRB1*01:80, DRB1*01:81, DRB1*01:82,
DRB1*01:83, DRB1*01:84, DRB1*01:85, DRB1*01:86, DRB1*01:87, DRB1*01:88,
DRB1*01:89, DRB1*01:90, DRB1*01:91Q, DRB1*01:92, DRB1*01:93, DRB1*01:94,
DRB1*01:95, DRB1*01:96, DRB1*01:97, DRB1*01:98, DRB1*01:99, DRB1*03:01:01:01,
DRB1*03:01:01:02, DRB1*03:01:01:03, DRB1*03:01:02, DRB1*03:01:03,
DRB1*03:01:04, DRB1*03:01:05, DRB1*03:01:06, DRB1*03:01:07, DRB1*03:01:08,
DRB1*03:01:09, DRB1*03:01:10, DRB1*03:01:11, DRB1*03:01:12, DRB1*03:01:13,
DRB1*03:01:14, DRB1*03:01:15, DRB1*03:01:16, DRB1*03:01:17, DRB1*03:01:18,
DRB1*03:01:19, DRB1*03:01:20, DRB1*03:01:21, DRB1*03:01:22, DRB1*03:01:23,
DRB1*03:01:24, DRB1*03:01:25, DRB1*03:01:26, DRB1*03:01:27, DRB1*03:01:28,
DRB1*03:02:01, DRB1*03:02:02, DRB1*03:02:03, DRB1*03:03, DRB1*03:04:01,
DRB1*03:04:02, DRB1*03:05:01, DRB1*03:05:02, DRB1*03:05:03, DRB1*03:06,
DRB1*03:07:01, DRB1*03:07:02, DRB1*03:08, DRB1*03:09, DRB1*03:10,
DRB1*03:100:01, DRB1*03:100:02, DRB1*03:101, DRB1*03:102, DRB1*03:103,
DRB1*03:104, DRB1*03:105, DRB1*03:106, DRB1*03:107, DRB1*03:108,
DRB1*03:109, DRB1*03:110, DRB1*03:111, DRB1*03:112, DRB1*03:113,
DRB1*03:114, DRB1*03:115, DRB1*03:116, DRB1*03:117, DRB1*03:118,
DRB1*03:119, DRB1*03:11:01, DRB1*03:12, DRB1*03:120, DRB1*03:121,
DRB1*03:122, DRB1*03:123, DRB1*03:124, DRB1*03:125, DRB1*03:126,
DRB1*03:127, DRB1*03:128, DRB1*03:129, DRB1*03:130, DRB1*03:131,
DRB1*03:132, DRB1*03:133, DRB1*03:134, DRB1*03:135, DRB1*03:136,

DRB1*03:137, DRB1*03:138, DRB1*03:139, DRB1*03:13:01, DRB1*03:13:02,
DRB1*03:14, DRB1*03:140, DRB1*03:141, DRB1*03:142, DRB1*03:143, DRB1*03:144,
DRB1*03:145, DRB1*03:146, DRB1*03:147, DRB1*03:148, DRB1*03:149,
DRB1*03:150, DRB1*03:151, DRB1*03:152, DRB1*03:153, DRB1*03:154,
DRB1*03:155, DRB1*03:156N, DRB1*03:157, DRB1*03:158, DRB1*03:15:01,
DRB1*03:15:02, DRB1*03:16, DRB1*03:17, DRB1*03:18, DRB1*03:19, DRB1*03:20,
DRB1*03:21, DRB1*03:22, DRB1*03:23, DRB1*03:24, DRB1*03:25:01, DRB1*03:25:02,
DRB1*03:26, DRB1*03:27, DRB1*03:28, DRB1*03:29, DRB1*03:30, DRB1*03:31,
DRB1*03:32, DRB1*03:33, DRB1*03:34, DRB1*03:35, DRB1*03:36, DRB1*03:37,
DRB1*03:38, DRB1*03:39, DRB1*03:40, DRB1*03:41:01, DRB1*03:41:02, DRB1*03:42,
DRB1*03:43, DRB1*03:44, DRB1*03:45, DRB1*03:46, DRB1*03:47, DRB1*03:48,
DRB1*03:49, DRB1*03:50, DRB1*03:51, DRB1*03:52, DRB1*03:53, DRB1*03:54,
DRB1*03:55, DRB1*03:56, DRB1*03:57, DRB1*03:58, DRB1*03:59, DRB1*03:60,
DRB1*03:61, DRB1*03:62, DRB1*03:63, DRB1*03:64, DRB1*03:65, DRB1*03:66,
DRB1*03:67N, DRB1*03:68N, DRB1*03:69, DRB1*03:70, DRB1*03:71:01,
DRB1*03:71:02, DRB1*03:72, DRB1*03:73, DRB1*03:74, DRB1*03:75, DRB1*03:76,
DRB1*03:77, DRB1*03:78, DRB1*03:79, DRB1*03:80, DRB1*03:81, DRB1*03:82,
DRB1*03:83, DRB1*03:84, DRB1*03:85, DRB1*03:86, DRB1*03:87, DRB1*03:88,
DRB1*03:89, DRB1*03:90, DRB1*03:91, DRB1*03:92, DRB1*03:93, DRB1*03:94,
DRB1*03:95, DRB1*03:96, DRB1*03:97, DRB1*03:98, DRB1*03:99, DRB1*04:01:01:01,
DRB1*04:01:01:02, DRB1*04:01:01:03, DRB1*04:01:02, DRB1*04:01:03,
DRB1*04:01:04, DRB1*04:01:05, DRB1*04:01:06, DRB1*04:01:07, DRB1*04:01:08,
DRB1*04:01:09, DRB1*04:01:10, DRB1*04:01:11, DRB1*04:01:12, DRB1*04:01:13,
DRB1*04:01:14, DRB1*04:01:15, DRB1*04:01:16, DRB1*04:01:17, DRB1*04:01:18,
DRB1*04:01:19, DRB1*04:01:20, DRB1*04:01:21, DRB1*04:02:01, DRB1*04:02:02,
DRB1*04:02:03, DRB1*04:02:04, DRB1*04:02:05, DRB1*04:02:06, DRB1*04:03:01:01,
DRB1*04:03:01:02, DRB1*04:03:02, DRB1*04:03:03, DRB1*04:03:04, DRB1*04:03:05,
DRB1*04:03:06, DRB1*04:03:07, DRB1*04:03:08, DRB1*04:03:09, DRB1*04:03:10,
DRB1*04:03:11, DRB1*04:03:12, DRB1*04:03:13, DRB1*04:03:14, DRB1*04:03:15,
DRB1*04:04:01, DRB1*04:04:02, DRB1*04:04:03, DRB1*04:04:04, DRB1*04:04:05,
DRB1*04:04:06, DRB1*04:04:07, DRB1*04:04:08, DRB1*04:04:09, DRB1*04:04:10,
DRB1*04:04:11, DRB1*04:04:12, DRB1*04:04:13, DRB1*04:04:14, DRB1*04:04:15,

DRB1*04:05:01:01, DRB1*04:05:01:02, DRB1*04:05:01:03, DRB1*04:05:02,
DRB1*04:05:03, DRB1*04:05:04, DRB1*04:05:05, DRB1*04:05:06, DRB1*04:05:07,
DRB1*04:05:08, DRB1*04:05:09, DRB1*04:05:10, DRB1*04:05:11, DRB1*04:05:13,
DRB1*04:05:14, DRB1*04:05:15, DRB1*04:05:16, DRB1*04:05:17, DRB1*04:05:18,
DRB1*04:05:19, DRB1*04:05:20, DRB1*04:06:01, DRB1*04:06:02, DRB1*04:06:03,
DRB1*04:06:04, DRB1*04:06:05, DRB1*04:06:06, DRB1*04:06:07, DRB1*04:07:01:01,
DRB1*04:07:01:02, DRB1*04:07:02, DRB1*04:07:03, DRB1*04:07:04, DRB1*04:07:05,
DRB1*04:07:06, DRB1*04:08:01, DRB1*04:08:02, DRB1*04:08:03, DRB1*04:08:04,
DRB1*04:09, DRB1*04:100, DRB1*04:101, DRB1*04:102, DRB1*04:103, DRB1*04:104,
DRB1*04:105:01, DRB1*04:105:02, DRB1*04:106, DRB1*04:107, DRB1*04:108,
DRB1*04:109, DRB1*04:10:01, DRB1*04:10:02, DRB1*04:10:03, DRB1*04:110,
DRB1*04:111, DRB1*04:112, DRB1*04:113, DRB1*04:114, DRB1*04:115,
DRB1*04:116, DRB1*04:117, DRB1*04:118, DRB1*04:119N, DRB1*04:11:01,
DRB1*04:11:02, DRB1*04:11:03, DRB1*04:11:04, DRB1*04:11:05, DRB1*04:12,
DRB1*04:120N, DRB1*04:121, DRB1*04:122, DRB1*04:123, DRB1*04:124,
DRB1*04:125, DRB1*04:126, DRB1*04:127, DRB1*04:128, DRB1*04:129, DRB1*04:13,
DRB1*04:130, DRB1*04:131:01, DRB1*04:131:02, DRB1*04:132, DRB1*04:133,
DRB1*04:134, DRB1*04:135, DRB1*04:136, DRB1*04:137, DRB1*04:138,
DRB1*04:139, DRB1*04:14, DRB1*04:140, DRB1*04:141, DRB1*04:142N,
DRB1*04:143, DRB1*04:144, DRB1*04:145, DRB1*04:146, DRB1*04:147,
DRB1*04:148, DRB1*04:149, DRB1*04:15, DRB1*04:150, DRB1*04:151, DRB1*04:152,
DRB1*04:153, DRB1*04:154, DRB1*04:155, DRB1*04:156, DRB1*04:157N,
DRB1*04:158N, DRB1*04:159, DRB1*04:16, DRB1*04:160, DRB1*04:161,
DRB1*04:162, DRB1*04:163, DRB1*04:164, DRB1*04:165, DRB1*04:166,
DRB1*04:167, DRB1*04:168, DRB1*04:169, DRB1*04:170, DRB1*04:171,
DRB1*04:172, DRB1*04:173, DRB1*04:174, DRB1*04:175, DRB1*04:176,
DRB1*04:177, DRB1*04:178N, DRB1*04:179, DRB1*04:17:01, DRB1*04:17:02,
DRB1*04:18, DRB1*04:180, DRB1*04:181, DRB1*04:182, DRB1*04:183, DRB1*04:184,
DRB1*04:185, DRB1*04:186N, DRB1*04:187, DRB1*04:188, DRB1*04:189,
DRB1*04:19, DRB1*04:190, DRB1*04:191, DRB1*04:192, DRB1*04:193, DRB1*04:194,
DRB1*04:195, DRB1*04:196, DRB1*04:197, DRB1*04:198, DRB1*04:199, DRB1*04:20,
DRB1*04:200, DRB1*04:201, DRB1*04:202, DRB1*04:203, DRB1*04:204,

DRB1*04:205, DRB1*04:206, DRB1*04:207, DRB1*04:208, DRB1*04:209, DRB1*04:21,
DRB1*04:210, DRB1*04:211, DRB1*04:212N, DRB1*04:213, DRB1*04:214N,
DRB1*04:215, DRB1*04:216, DRB1*04:217, DRB1*04:218, DRB1*04:219, DRB1*04:22,
DRB1*04:220, DRB1*04:221, DRB1*04:222, DRB1*04:223, DRB1*04:224,
DRB1*04:225, DRB1*04:226:01, DRB1*04:226:02, DRB1*04:227, DRB1*04:228,
DRB1*04:229, DRB1*04:23, DRB1*04:230, DRB1*04:231, DRB1*04:232, DRB1*04:233,
DRB1*04:234, DRB1*04:235, DRB1*04:236, DRB1*04:237, DRB1*04:238,
DRB1*04:239, DRB1*04:24, DRB1*04:240, DRB1*04:241, DRB1*04:242, DRB1*04:243,
DRB1*04:244, DRB1*04:245, DRB1*04:246, DRB1*04:247N, DRB1*04:248,
DRB1*04:249, DRB1*04:25, DRB1*04:250, DRB1*04:251, DRB1*04:252, DRB1*04:253,
DRB1*04:254, DRB1*04:255, DRB1*04:256, DRB1*04:257, DRB1*04:258,
DRB1*04:259, DRB1*04:26, DRB1*04:260, DRB1*04:261, DRB1*04:262, DRB1*04:263,
DRB1*04:264N, DRB1*04:265, DRB1*04:266N, DRB1*04:267N, DRB1*04:268,
DRB1*04:269, DRB1*04:27, DRB1*04:270, DRB1*04:271, DRB1*04:272, DRB1*04:28,
DRB1*04:29, DRB1*04:30, DRB1*04:31, DRB1*04:32, DRB1*04:33, DRB1*04:34,
DRB1*04:35, DRB1*04:36, DRB1*04:37, DRB1*04:38, DRB1*04:39, DRB1*04:40,
DRB1*04:41, DRB1*04:42, DRB1*04:43, DRB1*04:44:01, DRB1*04:44:02, DRB1*04:45,
DRB1*04:46, DRB1*04:47, DRB1*04:48, DRB1*04:49, DRB1*04:50, DRB1*04:51,
DRB1*04:52, DRB1*04:53:01, DRB1*04:53:02, DRB1*04:54, DRB1*04:55,
DRB1*04:56:01, DRB1*04:56:02, DRB1*04:57, DRB1*04:58, DRB1*04:59, DRB1*04:60,
DRB1*04:61, DRB1*04:62, DRB1*04:63, DRB1*04:64, DRB1*04:65, DRB1*04:66,
DRB1*04:67, DRB1*04:68, DRB1*04:69, DRB1*04:70, DRB1*04:71, DRB1*04:72:01,
DRB1*04:72:02, DRB1*04:73:01, DRB1*04:73:02, DRB1*04:74, DRB1*04:75,
DRB1*04:76, DRB1*04:77, DRB1*04:78, DRB1*04:79, DRB1*04:80, DRB1*04:81N,
DRB1*04:82, DRB1*04:83, DRB1*04:84, DRB1*04:85, DRB1*04:86, DRB1*04:87,
DRB1*04:88, DRB1*04:89, DRB1*04:90, DRB1*04:91, DRB1*04:92, DRB1*04:93,
DRB1*04:94:01N, DRB1*04:95:01, DRB1*04:95:02, DRB1*04:96, DRB1*04:97,
DRB1*04:98:01, DRB1*04:98:02, DRB1*04:99, DRB1*07:01:01:01, DRB1*07:01:01:02,
DRB1*07:01:01:03, DRB1*07:01:01:04, DRB1*07:01:02, DRB1*07:01:03,
DRB1*07:01:04, DRB1*07:01:05, DRB1*07:01:06, DRB1*07:01:07, DRB1*07:01:08,
DRB1*07:01:09, DRB1*07:01:10, DRB1*07:01:11, DRB1*07:01:12, DRB1*07:01:13,
DRB1*07:01:14, DRB1*07:01:15, DRB1*07:01:16, DRB1*07:01:17, DRB1*07:01:18,

DRB1*07:01:19, DRB1*07:01:20, DRB1*07:01:21, DRB1*07:01:22, DRB1*07:03,
DRB1*07:04, DRB1*07:05, DRB1*07:06, DRB1*07:07, DRB1*07:08, DRB1*07:09,
DRB1*07:100, DRB1*07:101N, DRB1*07:10N, DRB1*07:11, DRB1*07:12, DRB1*07:13,
DRB1*07:14, DRB1*07:15, DRB1*07:16, DRB1*07:17, DRB1*07:18, DRB1*07:19,
DRB1*07:20, DRB1*07:21, DRB1*07:22, DRB1*07:23, DRB1*07:24, DRB1*07:25,
DRB1*07:26N, DRB1*07:27, DRB1*07:28, DRB1*07:29, DRB1*07:30, DRB1*07:31,
DRB1*07:32, DRB1*07:33, DRB1*07:34, DRB1*07:35, DRB1*07:36, DRB1*07:37,
DRB1*07:38, DRB1*07:39, DRB1*07:40, DRB1*07:41, DRB1*07:42, DRB1*07:43,
DRB1*07:44, DRB1*07:45, DRB1*07:46, DRB1*07:47, DRB1*07:48, DRB1*07:49,
DRB1*07:50, DRB1*07:51, DRB1*07:52, DRB1*07:53, DRB1*07:54, DRB1*07:55,
DRB1*07:56, DRB1*07:57, DRB1*07:58N, DRB1*07:59, DRB1*07:60, DRB1*07:61,
DRB1*07:62, DRB1*07:63, DRB1*07:64, DRB1*07:65, DRB1*07:66, DRB1*07:67,
DRB1*07:68N, DRB1*07:69, DRB1*07:70, DRB1*07:71, DRB1*07:72, DRB1*07:73,
DRB1*07:74, DRB1*07:75, DRB1*07:76, DRB1*07:77, DRB1*07:78, DRB1*07:79,
DRB1*07:80, DRB1*07:81, DRB1*07:82, DRB1*07:83, DRB1*07:84, DRB1*07:85,
DRB1*07:86, DRB1*07:87N, DRB1*07:88, DRB1*07:89, DRB1*07:90, DRB1*07:91,
DRB1*07:92, DRB1*07:93, DRB1*07:94, DRB1*07:95, DRB1*07:96, DRB1*07:97,
DRB1*07:98, DRB1*07:99, DRB1*08:01:01, DRB1*08:01:02, DRB1*08:01:04,
DRB1*08:01:05, DRB1*08:01:06, DRB1*08:01:07, DRB1*08:02:01:01,
DRB1*08:02:01:02, DRB1*08:02:02, DRB1*08:02:03, DRB1*08:02:04,
DRB1*08:03:02:01, DRB1*08:03:02:02, DRB1*08:03:03, DRB1*08:03:04,
DRB1*08:03:05, DRB1*08:03:06, DRB1*08:03:07, DRB1*08:03:08, DRB1*08:03:09,
DRB1*08:04:01, DRB1*08:04:02, DRB1*08:04:03, DRB1*08:04:04, DRB1*08:04:05,
DRB1*08:04:06, DRB1*08:04:07, DRB1*08:05, DRB1*08:06, DRB1*08:07, DRB1*08:08,
DRB1*08:09, DRB1*08:10, DRB1*08:11, DRB1*08:12, DRB1*08:13, DRB1*08:14,
DRB1*08:15, DRB1*08:16, DRB1*08:17, DRB1*08:18, DRB1*08:19, DRB1*08:20,
DRB1*08:21, DRB1*08:22, DRB1*08:23, DRB1*08:24:01, DRB1*08:24:02, DRB1*08:25,
DRB1*08:26, DRB1*08:27, DRB1*08:28, DRB1*08:29, DRB1*08:30:01, DRB1*08:30:02,
DRB1*08:30:03, DRB1*08:31, DRB1*08:32, DRB1*08:33, DRB1*08:34, DRB1*08:35,
DRB1*08:36:01, DRB1*08:36:02, DRB1*08:37, DRB1*08:38, DRB1*08:39, DRB1*08:40,
DRB1*08:41, DRB1*08:42, DRB1*08:43, DRB1*08:44, DRB1*08:45:01, DRB1*08:45:02,
DRB1*08:46, DRB1*08:47, DRB1*08:48, DRB1*08:49, DRB1*08:50, DRB1*08:51,

DRB1*08:52, DRB1*08:53, DRB1*08:54, DRB1*08:55, DRB1*08:56, DRB1*08:57, DRB1*08:58, DRB1*08:59, DRB1*08:60N, DRB1*08:61, DRB1*08:62, DRB1*08:63, DRB1*08:64, DRB1*08:65, DRB1*08:66, DRB1*08:67, DRB1*08:68:01, DRB1*08:68:02, DRB1*08:69, DRB1*08:70, DRB1*08:71, DRB1*08:72, DRB1*08:73, DRB1*08:74, DRB1*08:75, DRB1*08:76, DRB1*08:77, DRB1*08:78N, DRB1*08:79, DRB1*08:80, DRB1*08:81, DRB1*08:82, DRB1*08:83, DRB1*08:84, DRB1*08:85, DRB1*08:86, DRB1*08:87, DRB1*08:88, DRB1*08:89N, DRB1*08:90, DRB1*09:01:02:01, DRB1*09:01:02:02, DRB1*09:01:03, DRB1*09:01:04, DRB1*09:01:05, DRB1*09:01:06, DRB1*09:01:07, DRB1*09:01:08, DRB1*09:01:09, DRB1*09:01:10, DRB1*09:01:11, DRB1*09:02:01, DRB1*09:02:02, DRB1*09:03, DRB1*09:04, DRB1*09:05, DRB1*09:06, DRB1*09:07, DRB1*09:08, DRB1*09:09, DRB1*09:10, DRB1*09:11, DRB1*09:12, DRB1*09:13, DRB1*09:14, DRB1*09:15, DRB1*09:16, DRB1*09:17, DRB1*09:18, DRB1*09:19, DRB1*09:20, DRB1*09:21, DRB1*09:22, DRB1*09:23, DRB1*09:24, DRB1*09:25, DRB1*09:26, DRB1*09:27, DRB1*09:28, DRB1*09:29, DRB1*09:30, DRB1*09:31, DRB1*09:32, DRB1*09:33, DRB1*09:34, DRB1*09:35, DRB1*09:36, DRB1*09:37N, DRB1*09:38, DRB1*09:39, DRB1*09:40, DRB1*10:01:01:01, DRB1*10:01:01:02, DRB1*10:01:01:03, DRB1*10:01:02, DRB1*10:01:03, DRB1*10:01:04, DRB1*10:01:05, DRB1*10:01:06, DRB1*10:01:07, DRB1*10:01:08, DRB1*10:01:09, DRB1*10:01:10, DRB1*10:01:11, DRB1*10:01:12, DRB1*10:02, DRB1*10:03, DRB1*10:04, DRB1*10:05, DRB1*10:06, DRB1*10:07, DRB1*10:08, DRB1*10:09, DRB1*10:10, DRB1*10:11, DRB1*10:12, DRB1*10:13, DRB1*10:14, DRB1*10:15, DRB1*10:16, DRB1*10:17, DRB1*10:18, DRB1*10:19, DRB1*10:20, DRB1*10:21, DRB1*10:22, DRB1*10:23, DRB1*10:24, DRB1*10:25, DRB1*10:26, DRB1*10:27, DRB1*10:28, DRB1*10:29, DRB1*10:30, DRB1*10:31, DRB1*10:32, DRB1*10:33, DRB1*11:01:01:01, DRB1*11:01:01:02, DRB1*11:01:01:03, DRB1*11:01:01:04, DRB1*11:01:02, DRB1*11:01:03, DRB1*11:01:04, DRB1*11:01:05, DRB1*11:01:06, DRB1*11:01:07, DRB1*11:01:08, DRB1*11:01:09, DRB1*11:01:10, DRB1*11:01:11, DRB1*11:01:12, DRB1*11:01:13, DRB1*11:01:14, DRB1*11:01:15, DRB1*11:01:16, DRB1*11:01:17, DRB1*11:01:18, DRB1*11:01:19, DRB1*11:01:20, DRB1*11:01:21, DRB1*11:01:22, DRB1*11:01:23, DRB1*11:01:24, DRB1*11:01:25, DRB1*11:01:26, DRB1*11:01:27, DRB1*11:01:28, DRB1*11:01:29, DRB1*11:01:30, DRB1*11:01:31, DRB1*11:01:32, DRB1*11:01:33, DRB1*11:02:01, DRB1*11:02:02,

DRB1*11:02:03, DRB1*11:02:04, DRB1*11:02:05, DRB1*11:03:01, DRB1*11:03:02,
DRB1*11:03:03, DRB1*11:03:04, DRB1*11:04:01, DRB1*11:04:02, DRB1*11:04:03,
DRB1*11:04:04, DRB1*11:04:05, DRB1*11:04:06, DRB1*11:04:07, DRB1*11:04:08,
DRB1*11:04:09, DRB1*11:04:10, DRB1*11:04:11, DRB1*11:04:12, DRB1*11:04:13,
DRB1*11:04:14, DRB1*11:04:15, DRB1*11:04:16, DRB1*11:04:17, DRB1*11:04:18,
DRB1*11:05, DRB1*11:06:01, DRB1*11:06:02, DRB1*11:06:03, DRB1*11:07:01,
DRB1*11:07:02, DRB1*11:08:01, DRB1*11:08:02, DRB1*11:08:03, DRB1*11:09,
DRB1*11:100, DRB1*11:101:01, DRB1*11:101:02, DRB1*11:102:01, DRB1*11:102:02,
DRB1*11:103:01, DRB1*11:103:02, DRB1*11:104, DRB1*11:105, DRB1*11:106,
DRB1*11:107, DRB1*11:108, DRB1*11:109, DRB1*11:10:01, DRB1*11:10:02,
DRB1*11:110, DRB1*11:111, DRB1*11:112, DRB1*11:113, DRB1*11:114,
DRB1*11:115, DRB1*11:116, DRB1*11:117:01, DRB1*11:117:02, DRB1*11:118,
DRB1*11:119, DRB1*11:11:01, DRB1*11:11:03, DRB1*11:120, DRB1*11:121,
DRB1*11:122, DRB1*11:123, DRB1*11:124:01, DRB1*11:124:02, DRB1*11:125,
DRB1*11:126, DRB1*11:127, DRB1*11:128, DRB1*11:129, DRB1*11:12:01,
DRB1*11:12:02, DRB1*11:12:03, DRB1*11:130, DRB1*11:131, DRB1*11:132,
DRB1*11:133, DRB1*11:134, DRB1*11:135, DRB1*11:136, DRB1*11:137,
DRB1*11:138, DRB1*11:139, DRB1*11:13:01, DRB1*11:13:02, DRB1*11:140,
DRB1*11:141, DRB1*11:142, DRB1*11:143, DRB1*11:144, DRB1*11:145,
DRB1*11:146, DRB1*11:147:01, DRB1*11:147:02, DRB1*11:148, DRB1*11:149,
DRB1*11:14:01, DRB1*11:14:02, DRB1*11:15, DRB1*11:150, DRB1*11:151,
DRB1*11:152, DRB1*11:153, DRB1*11:154, DRB1*11:155, DRB1*11:156,
DRB1*11:157, DRB1*11:158, DRB1*11:159, DRB1*11:16, DRB1*11:160, DRB1*11:161,
DRB1*11:162, DRB1*11:163, DRB1*11:164, DRB1*11:165:01, DRB1*11:165:02,
DRB1*11:166, DRB1*11:167, DRB1*11:168, DRB1*11:169N, DRB1*11:17,
DRB1*11:170, DRB1*11:171, DRB1*11:172, DRB1*11:173, DRB1*11:174,
DRB1*11:175, DRB1*11:176, DRB1*11:177, DRB1*11:178, DRB1*11:179, DRB1*11:18,
DRB1*11:180, DRB1*11:181, DRB1*11:182, DRB1*11:183, DRB1*11:184,
DRB1*11:185, DRB1*11:186, DRB1*11:187, DRB1*11:188, DRB1*11:189,
DRB1*11:190, DRB1*11:191, DRB1*11:192, DRB1*11:193:01, DRB1*11:193:02,
DRB1*11:194, DRB1*11:195, DRB1*11:196, DRB1*11:197, DRB1*11:198,
DRB1*11:199, DRB1*11:19:01, DRB1*11:19:02, DRB1*11:19:03, DRB1*11:20,

DRB1*11:200, DRB1*11:201, DRB1*11:202, DRB1*11:203, DRB1*11:204,
DRB1*11:205, DRB1*11:206, DRB1*11:207, DRB1*11:208, DRB1*11:209, DRB1*11:21,
DRB1*11:210, DRB1*11:211, DRB1*11:212, DRB1*11:213, DRB1*11:214,
DRB1*11:215, DRB1*11:216, DRB1*11:217N, DRB1*11:218, DRB1*11:219,
DRB1*11:22, DRB1*11:220, DRB1*11:221, DRB1*11:222, DRB1*11:223, DRB1*11:224,
DRB1*11:225, DRB1*11:226, DRB1*11:227, DRB1*11:228, DRB1*11:229,
DRB1*11:230, DRB1*11:231, DRB1*11:232, DRB1*11:233, DRB1*11:234,
DRB1*11:235, DRB1*11:236, DRB1*11:237, DRB1*11:238, DRB1*11:239,
DRB1*11:23:01, DRB1*11:23:02, DRB1*11:240, DRB1*11:241, DRB1*11:242,
DRB1*11:243, DRB1*11:244, DRB1*11:245, DRB1*11:246N, DRB1*11:247,
DRB1*11:248Q, DRB1*11:249, DRB1*11:24:01, DRB1*11:24:02, DRB1*11:25,
DRB1*11:250N, DRB1*11:251, DRB1*11:252, DRB1*11:253, DRB1*11:254,
DRB1*11:26, DRB1*11:27:01, DRB1*11:27:02, DRB1*11:27:03, DRB1*11:28:01,
DRB1*11:28:02, DRB1*11:29:01, DRB1*11:29:02, DRB1*11:30, DRB1*11:31,
DRB1*11:32, DRB1*11:33, DRB1*11:34, DRB1*11:35, DRB1*11:36, DRB1*11:37:01,
DRB1*11:37:02, DRB1*11:38, DRB1*11:39, DRB1*11:40, DRB1*11:41, DRB1*11:42:01,
DRB1*11:42:02, DRB1*11:43, DRB1*11:44, DRB1*11:45, DRB1*11:46:01,
DRB1*11:46:02, DRB1*11:47, DRB1*11:48, DRB1*11:49:01, DRB1*11:49:02,
DRB1*11:50, DRB1*11:51, DRB1*11:52, DRB1*11:53, DRB1*11:54:01, DRB1*11:54:02,
DRB1*11:55, DRB1*11:56, DRB1*11:57, DRB1*11:58:01, DRB1*11:58:02, DRB1*11:59,
DRB1*11:60, DRB1*11:61, DRB1*11:62:01, DRB1*11:62:02, DRB1*11:63:01,
DRB1*11:63:02, DRB1*11:64, DRB1*11:65:01, DRB1*11:65:02, DRB1*11:66:01,
DRB1*11:66:02, DRB1*11:67, DRB1*11:68, DRB1*11:69, DRB1*11:70, DRB1*11:72,
DRB1*11:73, DRB1*11:74:01, DRB1*11:74:02, DRB1*11:75, DRB1*11:76, DRB1*11:77,
DRB1*11:78, DRB1*11:79, DRB1*11:80, DRB1*11:81, DRB1*11:82, DRB1*11:83,
DRB1*11:84:01, DRB1*11:84:02, DRB1*11:84:03, DRB1*11:85, DRB1*11:86,
DRB1*11:87, DRB1*11:88, DRB1*11:89, DRB1*11:90, DRB1*11:91, DRB1*11:92,
DRB1*11:93, DRB1*11:94, DRB1*11:95, DRB1*11:96, DRB1*11:97, DRB1*11:98,
DRB1*11:99, DRB1*12:01:01:01, DRB1*12:01:01:02, DRB1*12:01:01:03,
DRB1*12:01:01:04, DRB1*12:01:01:05, DRB1*12:01:01:06, DRB1*12:01:02,
DRB1*12:01:03, DRB1*12:01:04, DRB1*12:01:05, DRB1*12:01:06, DRB1*12:01:07,
DRB1*12:01:08, DRB1*12:01:09, DRB1*12:02:01:01, DRB1*12:02:01:02,

DRB1*12:02:01:03, DRB1*12:02:01:04, DRB1*12:02:02, DRB1*12:02:03,
DRB1*12:02:04, DRB1*12:02:05, DRB1*12:02:06, DRB1*12:02:07, DRB1*12:02:08,
DRB1*12:02:09, DRB1*12:03:02, DRB1*12:03:03, DRB1*12:04, DRB1*12:05,
DRB1*12:06, DRB1*12:07, DRB1*12:08, DRB1*12:09, DRB1*12:10, DRB1*12:11,
DRB1*12:12, DRB1*12:13, DRB1*12:14, DRB1*12:15, DRB1*12:16:01, DRB1*12:16:02,
DRB1*12:16:03, DRB1*12:17, DRB1*12:18, DRB1*12:19, DRB1*12:20, DRB1*12:21,
DRB1*12:22, DRB1*12:23, DRB1*12:24N, DRB1*12:25, DRB1*12:26, DRB1*12:27,
DRB1*12:28, DRB1*12:29, DRB1*12:30, DRB1*12:31N, DRB1*12:32, DRB1*12:33,
DRB1*12:34, DRB1*12:35, DRB1*12:36, DRB1*12:37, DRB1*12:38, DRB1*12:39,
DRB1*12:40, DRB1*12:41, DRB1*12:42, DRB1*12:43, DRB1*12:44, DRB1*12:45,
DRB1*12:46, DRB1*12:47, DRB1*12:48, DRB1*12:49, DRB1*12:50, DRB1*12:51,
DRB1*12:52, DRB1*12:53, DRB1*12:54, DRB1*12:55, DRB1*12:56, DRB1*12:57,
DRB1*12:58, DRB1*12:59, DRB1*12:60N, DRB1*12:61, DRB1*12:62, DRB1*12:63,
DRB1*12:64, DRB1*12:65, DRB1*12:66, DRB1*12:67, DRB1*12:68, DRB1*12:69,
DRB1*12:70, DRB1*12:71, DRB1*12:72N, DRB1*12:73, DRB1*12:74N, DRB1*12:75,
DRB1*13:01:01:01, DRB1*13:01:01:02, DRB1*13:01:02, DRB1*13:01:03,
DRB1*13:01:04, DRB1*13:01:05, DRB1*13:01:06, DRB1*13:01:07, DRB1*13:01:08,
DRB1*13:01:09, DRB1*13:01:10, DRB1*13:01:11, DRB1*13:01:12, DRB1*13:01:13,
DRB1*13:01:14, DRB1*13:01:15, DRB1*13:01:16, DRB1*13:01:17, DRB1*13:01:18,
DRB1*13:01:19, DRB1*13:01:20, DRB1*13:01:21, DRB1*13:01:22, DRB1*13:01:23,
DRB1*13:01:24, DRB1*13:01:25, DRB1*13:01:26, DRB1*13:02:01:01,
DRB1*13:02:01:02, DRB1*13:02:01:03, DRB1*13:02:02, DRB1*13:02:03,
DRB1*13:02:04, DRB1*13:02:05, DRB1*13:02:06, DRB1*13:02:07, DRB1*13:02:08,
DRB1*13:02:09, DRB1*13:02:10, DRB1*13:02:11, DRB1*13:02:12, DRB1*13:02:13,
DRB1*13:02:14, DRB1*13:02:15, DRB1*13:02:16, DRB1*13:02:17, DRB1*13:03:01,
DRB1*13:03:02, DRB1*13:03:03, DRB1*13:03:04, DRB1*13:03:05, DRB1*13:03:06,
DRB1*13:03:07, DRB1*13:03:08, DRB1*13:03:09, DRB1*13:04, DRB1*13:05:01,
DRB1*13:05:02, DRB1*13:05:03, DRB1*13:06, DRB1*13:07:01, DRB1*13:07:02,
DRB1*13:08, DRB1*13:09, DRB1*13:10, DRB1*13:100, DRB1*13:101, DRB1*13:102,
DRB1*13:103, DRB1*13:104, DRB1*13:105, DRB1*13:106, DRB1*13:107,
DRB1*13:108, DRB1*13:109, DRB1*13:110, DRB1*13:111, DRB1*13:112,
DRB1*13:113N, DRB1*13:114, DRB1*13:115, DRB1*13:116, DRB1*13:117,

DRB1*13:118, DRB1*13:119, DRB1*13:11:01, DRB1*13:11:02, DRB1*13:120,
DRB1*13:121, DRB1*13:122, DRB1*13:123, DRB1*13:124, DRB1*13:125,
DRB1*13:126, DRB1*13:127, DRB1*13:128, DRB1*13:129, DRB1*13:12:01,
DRB1*13:12:02, DRB1*13:12:03, DRB1*13:12:04, DRB1*13:13, DRB1*13:130,
DRB1*13:131, DRB1*13:132, DRB1*13:133, DRB1*13:134, DRB1*13:135,
DRB1*13:136, DRB1*13:137N, DRB1*13:138, DRB1*13:139, DRB1*13:140,
DRB1*13:141, DRB1*13:142N, DRB1*13:143, DRB1*13:144, DRB1*13:145,
DRB1*13:146, DRB1*13:147, DRB1*13:148, DRB1*13:149, DRB1*13:14:01,
DRB1*13:14:02, DRB1*13:14:03, DRB1*13:15, DRB1*13:150, DRB1*13:151,
DRB1*13:152, DRB1*13:153, DRB1*13:154, DRB1*13:155, DRB1*13:156,
DRB1*13:157, DRB1*13:158, DRB1*13:159, DRB1*13:16, DRB1*13:160, DRB1*13:161,
DRB1*13:162, DRB1*13:163, DRB1*13:164, DRB1*13:165, DRB1*13:166,
DRB1*13:167, DRB1*13:168, DRB1*13:169, DRB1*13:17, DRB1*13:170,
DRB1*13:171:01, DRB1*13:171:02, DRB1*13:172, DRB1*13:173, DRB1*13:174,
DRB1*13:175, DRB1*13:176, DRB1*13:177, DRB1*13:178, DRB1*13:179, DRB1*13:18,
DRB1*13:180, DRB1*13:181, DRB1*13:182, DRB1*13:183, DRB1*13:184,
DRB1*13:185N, DRB1*13:186, DRB1*13:187, DRB1*13:188, DRB1*13:189,
DRB1*13:19, DRB1*13:190, DRB1*13:191, DRB1*13:192, DRB1*13:193, DRB1*13:194,
DRB1*13:195, DRB1*13:196, DRB1*13:197, DRB1*13:198, DRB1*13:199, DRB1*13:20,
DRB1*13:200N, DRB1*13:201, DRB1*13:202, DRB1*13:203, DRB1*13:204,
DRB1*13:205, DRB1*13:206, DRB1*13:207, DRB1*13:208, DRB1*13:209,
DRB1*13:210, DRB1*13:211, DRB1*13:212, DRB1*13:213, DRB1*13:214,
DRB1*13:215, DRB1*13:216, DRB1*13:217, DRB1*13:218, DRB1*13:219,
DRB1*13:21:01, DRB1*13:21:02, DRB1*13:220, DRB1*13:221, DRB1*13:222,
DRB1*13:223, DRB1*13:224, DRB1*13:225, DRB1*13:226, DRB1*13:227,
DRB1*13:228, DRB1*13:229, DRB1*13:22:01, DRB1*13:22:02, DRB1*13:230,
DRB1*13:231, DRB1*13:232, DRB1*13:233, DRB1*13:234, DRB1*13:235,
DRB1*13:236, DRB1*13:237, DRB1*13:238, DRB1*13:239, DRB1*13:23:01,
DRB1*13:23:02, DRB1*13:24, DRB1*13:240, DRB1*13:241, DRB1*13:242:01,
DRB1*13:242:02, DRB1*13:243, DRB1*13:244, DRB1*13:245, DRB1*13:246,
DRB1*13:247, DRB1*13:248, DRB1*13:249N, DRB1*13:25, DRB1*13:250,
DRB1*13:251, DRB1*13:252N, DRB1*13:253, DRB1*13:254, DRB1*13:255N,

DRB1*13:256, DRB1*13:257, DRB1*13:258, DRB1*13:259, DRB1*13:260,
DRB1*13:261, DRB1*13:262, DRB1*13:263, DRB1*13:264, DRB1*13:265,
DRB1*13:266, DRB1*13:267, DRB1*13:268N, DRB1*13:269, DRB1*13:26:01,
DRB1*13:26:02, DRB1*13:27, DRB1*13:270, DRB1*13:271, DRB1*13:272,
DRB1*13:273, DRB1*13:274, DRB1*13:275, DRB1*13:276, DRB1*13:277,
DRB1*13:278Q, DRB1*13:279, DRB1*13:28:01, DRB1*13:28:02, DRB1*13:29,
DRB1*13:30, DRB1*13:31, DRB1*13:32, DRB1*13:33:01, DRB1*13:33:02,
DRB1*13:33:03, DRB1*13:34, DRB1*13:35, DRB1*13:36, DRB1*13:37, DRB1*13:38,
DRB1*13:39, DRB1*13:40, DRB1*13:41, DRB1*13:42, DRB1*13:43, DRB1*13:44,
DRB1*13:45, DRB1*13:46, DRB1*13:47, DRB1*13:48, DRB1*13:49, DRB1*13:50:01,
DRB1*13:50:02, DRB1*13:50:03, DRB1*13:51, DRB1*13:52, DRB1*13:53, DRB1*13:54,
DRB1*13:55, DRB1*13:56, DRB1*13:57, DRB1*13:58, DRB1*13:59, DRB1*13:60,
DRB1*13:61:01, DRB1*13:61:02, DRB1*13:62, DRB1*13:63, DRB1*13:64, DRB1*13:65,
DRB1*13:66:01, DRB1*13:66:02, DRB1*13:67, DRB1*13:68, DRB1*13:69, DRB1*13:70,
DRB1*13:71, DRB1*13:72, DRB1*13:73, DRB1*13:74, DRB1*13:75, DRB1*13:76,
DRB1*13:77, DRB1*13:78, DRB1*13:79, DRB1*13:80, DRB1*13:81, DRB1*13:82,
DRB1*13:83, DRB1*13:84, DRB1*13:85, DRB1*13:86, DRB1*13:87, DRB1*13:88,
DRB1*13:89:01, DRB1*13:89:02, DRB1*13:90, DRB1*13:91, DRB1*13:92, DRB1*13:93,
DRB1*13:94:01, DRB1*13:94:02, DRB1*13:95, DRB1*13:96:01, DRB1*13:96:02,
DRB1*13:97:01, DRB1*13:97:02, DRB1*13:98, DRB1*13:99, DRB1*14:01:01,
DRB1*14:01:02, DRB1*14:01:03, DRB1*14:01:04, DRB1*14:02:01:01,
DRB1*14:02:01:02, DRB1*14:02:02, DRB1*14:02:03, DRB1*14:02:04, DRB1*14:02:05,
DRB1*14:02:06, DRB1*14:02:07, DRB1*14:03:01, DRB1*14:03:02, DRB1*14:04:01,
DRB1*14:04:02, DRB1*14:04:03, DRB1*14:04:04, DRB1*14:04:05, DRB1*14:04:06,
DRB1*14:05:01:01, DRB1*14:05:01:02, DRB1*14:05:02, DRB1*14:05:03,
DRB1*14:05:04, DRB1*14:06:01, DRB1*14:06:02, DRB1*14:06:03, DRB1*14:06:04,
DRB1*14:07:01, DRB1*14:07:02, DRB1*14:08, DRB1*14:09, DRB1*14:10,
DRB1*14:100, DRB1*14:101, DRB1*14:102, DRB1*14:103, DRB1*14:104,
DRB1*14:105, DRB1*14:106, DRB1*14:107, DRB1*14:108, DRB1*14:109, DRB1*14:11,
DRB1*14:110, DRB1*14:111, DRB1*14:112, DRB1*14:113, DRB1*14:114,
DRB1*14:115, DRB1*14:116, DRB1*14:117, DRB1*14:118, DRB1*14:119,
DRB1*14:120, DRB1*14:121, DRB1*14:122, DRB1*14:123, DRB1*14:124,

DRB1*14:125, DRB1*14:126:01, DRB1*14:126:02, DRB1*14:127:01, DRB1*14:127:02, DRB1*14:128, DRB1*14:129, DRB1*14:12:01, DRB1*14:12:02, DRB1*14:13, DRB1*14:130, DRB1*14:131, DRB1*14:132, DRB1*14:133, DRB1*14:134, DRB1*14:135, DRB1*14:136, DRB1*14:137N, DRB1*14:138, DRB1*14:139, DRB1*14:14, DRB1*14:140, DRB1*14:141, DRB1*14:142, DRB1*14:143, DRB1*14:144, DRB1*14:145, DRB1*14:146, DRB1*14:147, DRB1*14:148, DRB1*14:149, DRB1*14:15, DRB1*14:150, DRB1*14:151, DRB1*14:152N, DRB1*14:153, DRB1*14:154, DRB1*14:155, DRB1*14:156, DRB1*14:157, DRB1*14:158, DRB1*14:159, DRB1*14:16, DRB1*14:160, DRB1*14:161, DRB1*14:162, DRB1*14:163, DRB1*14:164, DRB1*14:165, DRB1*14:166N, DRB1*14:167, DRB1*14:168, DRB1*14:169, DRB1*14:17, DRB1*14:170, DRB1*14:171, DRB1*14:172, DRB1*14:173, DRB1*14:174, DRB1*14:175, DRB1*14:176, DRB1*14:177, DRB1*14:178, DRB1*14:179, DRB1*14:18, DRB1*14:180, DRB1*14:181, DRB1*14:182, DRB1*14:183, DRB1*14:184, DRB1*14:185, DRB1*14:186, DRB1*14:187, DRB1*14:188N, DRB1*14:189, DRB1*14:19, DRB1*14:190, DRB1*14:191, DRB1*14:192, DRB1*14:193, DRB1*14:194, DRB1*14:195N, DRB1*14:196, DRB1*14:197N, DRB1*14:198, DRB1*14:199, DRB1*14:20, DRB1*14:200, DRB1*14:201, DRB1*14:202, DRB1*14:203, DRB1*14:204, DRB1*14:205, DRB1*14:206, DRB1*14:207, DRB1*14:208, DRB1*14:209, DRB1*14:21, DRB1*14:210Q, DRB1*14:211, DRB1*14:22, DRB1*14:23:01, DRB1*14:23:02, DRB1*14:23:03, DRB1*14:23:04, DRB1*14:24, DRB1*14:25:01, DRB1*14:25:02, DRB1*14:26, DRB1*14:27:01, DRB1*14:27:02, DRB1*14:28, DRB1*14:29, DRB1*14:30, DRB1*14:31, DRB1*14:32:01, DRB1*14:32:02, DRB1*14:32:03, DRB1*14:33, DRB1*14:34, DRB1*14:35, DRB1*14:36, DRB1*14:37, DRB1*14:38:01, DRB1*14:38:02, DRB1*14:39, DRB1*14:40, DRB1*14:41, DRB1*14:42, DRB1*14:43, DRB1*14:44:01, DRB1*14:44:02, DRB1*14:44:03, DRB1*14:45, DRB1*14:46, DRB1*14:47, DRB1*14:48, DRB1*14:49, DRB1*14:50, DRB1*14:51, DRB1*14:52, DRB1*14:53, DRB1*14:54:01:01, DRB1*14:54:01:02, DRB1*14:54:01:03, DRB1*14:54:01:04, DRB1*14:54:02, DRB1*14:54:03, DRB1*14:54:04, DRB1*14:54:05, DRB1*14:54:06, DRB1*14:54:07, DRB1*14:55, DRB1*14:56, DRB1*14:57, DRB1*14:58, DRB1*14:59, DRB1*14:60, DRB1*14:61, DRB1*14:62, DRB1*14:63, DRB1*14:64, DRB1*14:65, DRB1*14:67, DRB1*14:68:01, DRB1*14:68:02, DRB1*14:69, DRB1*14:70, DRB1*14:71, DRB1*14:72, DRB1*14:73, DRB1*14:74, DRB1*14:75, DRB1*14:76, DRB1*14:77, DRB1*14:78,

DRB1*14:79, DRB1*14:80, DRB1*14:81, DRB1*14:82, DRB1*14:83, DRB1*14:84, DRB1*14:85, DRB1*14:86, DRB1*14:87, DRB1*14:88, DRB1*14:89, DRB1*14:90, DRB1*14:91, DRB1*14:92N, DRB1*14:93, DRB1*14:94, DRB1*14:95, DRB1*14:96, DRB1*14:97, DRB1*14:98, DRB1*14:99, DRB1*15:01:01:01, DRB1*15:01:01:02, DRB1*15:01:01:03, DRB1*15:01:01:04, DRB1*15:01:01:05, DRB1*15:01:02, DRB1*15:01:03, DRB1*15:01:04, DRB1*15:01:05, DRB1*15:01:06, DRB1*15:01:07, DRB1*15:01:08, DRB1*15:01:09, DRB1*15:01:10, DRB1*15:01:11, DRB1*15:01:12, DRB1*15:01:13, DRB1*15:01:14, DRB1*15:01:15, DRB1*15:01:16, DRB1*15:01:17, DRB1*15:01:18, DRB1*15:01:19, DRB1*15:01:20, DRB1*15:01:21, DRB1*15:01:22, DRB1*15:01:23, DRB1*15:01:24, DRB1*15:01:25, DRB1*15:01:26, DRB1*15:01:27, DRB1*15:01:28, DRB1*15:01:29, DRB1*15:01:30, DRB1*15:01:31, DRB1*15:01:32, DRB1*15:01:33, DRB1*15:01:34, DRB1*15:01:35, DRB1*15:01:36, DRB1*15:01:37, DRB1*15:01:38, DRB1*15:01:39, DRB1*15:01:40, DRB1*15:01:41, DRB1*15:02:01:01, DRB1*15:02:01:02, DRB1*15:02:01:03, DRB1*15:02:02, DRB1*15:02:03, DRB1*15:02:04, DRB1*15:02:05, DRB1*15:02:06, DRB1*15:02:07, DRB1*15:02:08, DRB1*15:02:09, DRB1*15:02:10, DRB1*15:02:11, DRB1*15:02:12, DRB1*15:02:13, DRB1*15:02:14, DRB1*15:02:15, DRB1*15:02:16, DRB1*15:02:17, DRB1*15:02:18, DRB1*15:02:19, DRB1*15:03:01:01, DRB1*15:03:01:02, DRB1*15:03:01:03, DRB1*15:03:02, DRB1*15:03:03, DRB1*15:03:04, DRB1*15:04, DRB1*15:05, DRB1*15:06:01, DRB1*15:06:02, DRB1*15:06:03, DRB1*15:06:04, DRB1*15:07:01, DRB1*15:07:02, DRB1*15:07:03, DRB1*15:08, DRB1*15:09, DRB1*15:10, DRB1*15:100, DRB1*15:101, DRB1*15:102, DRB1*15:103, DRB1*15:104:01, DRB1*15:104:02, DRB1*15:104:03, DRB1*15:105:01, DRB1*15:105:02, DRB1*15:106, DRB1*15:107, DRB1*15:108, DRB1*15:109, DRB1*15:110, DRB1*15:111, DRB1*15:112, DRB1*15:113N, DRB1*15:114, DRB1*15:115N, DRB1*15:116, DRB1*15:117, DRB1*15:118, DRB1*15:119, DRB1*15:11:01, DRB1*15:11:02, DRB1*15:12, DRB1*15:120, DRB1*15:121, DRB1*15:122, DRB1*15:123, DRB1*15:124, DRB1*15:125, DRB1*15:126, DRB1*15:127, DRB1*15:128, DRB1*15:129N, DRB1*15:13, DRB1*15:130, DRB1*15:131, DRB1*15:132, DRB1*15:133, DRB1*15:134N, DRB1*15:135, DRB1*15:136, DRB1*15:137N, DRB1*15:138N, DRB1*15:139, DRB1*15:14, DRB1*15:140, DRB1*15:141, DRB1*15:142, DRB1*15:143, DRB1*15:144, DRB1*15:145, DRB1*15:146, DRB1*15:147, DRB1*15:148N,

DRB1*15:149, DRB1*15:150, DRB1*15:151, DRB1*15:152, DRB1*15:153,
DRB1*15:154N, DRB1*15:155, DRB1*15:156, DRB1*15:157, DRB1*15:158,
DRB1*15:159N, DRB1*15:15:01, DRB1*15:15:02, DRB1*15:15:03, DRB1*15:16,
DRB1*15:160, DRB1*15:161, DRB1*15:162, DRB1*15:163N, DRB1*15:164Q,
DRB1*15:165, DRB1*15:166, DRB1*15:167, DRB1*15:168, DRB1*15:169,
DRB1*15:170, DRB1*15:17N, DRB1*15:18, DRB1*15:19, DRB1*15:20, DRB1*15:21,
DRB1*15:22, DRB1*15:23, DRB1*15:24, DRB1*15:25, DRB1*15:26, DRB1*15:27,
DRB1*15:28, DRB1*15:29, DRB1*15:30, DRB1*15:31:01, DRB1*15:31:02, DRB1*15:32,
DRB1*15:33, DRB1*15:34, DRB1*15:35, DRB1*15:36, DRB1*15:37:01, DRB1*15:37:02,
DRB1*15:38, DRB1*15:39, DRB1*15:40, DRB1*15:41, DRB1*15:42, DRB1*15:43,
DRB1*15:44, DRB1*15:45, DRB1*15:46, DRB1*15:47, DRB1*15:48, DRB1*15:49,
DRB1*15:50N, DRB1*15:51, DRB1*15:52, DRB1*15:53, DRB1*15:54, DRB1*15:55,
DRB1*15:56, DRB1*15:57, DRB1*15:58, DRB1*15:59, DRB1*15:60, DRB1*15:61,
DRB1*15:62, DRB1*15:63, DRB1*15:64, DRB1*15:65, DRB1*15:66:01, DRB1*15:66:02,
DRB1*15:67, DRB1*15:68, DRB1*15:69, DRB1*15:70, DRB1*15:71, DRB1*15:72,
DRB1*15:73, DRB1*15:74, DRB1*15:75, DRB1*15:76, DRB1*15:77, DRB1*15:78,
DRB1*15:79, DRB1*15:80N, DRB1*15:81, DRB1*15:82, DRB1*15:83, DRB1*15:84,
DRB1*15:85, DRB1*15:86, DRB1*15:87, DRB1*15:88, DRB1*15:89, DRB1*15:90,
DRB1*15:91, DRB1*15:92, DRB1*15:93, DRB1*15:94, DRB1*15:95, DRB1*15:96,
DRB1*15:97, DRB1*15:98, DRB1*15:99, DRB1*16:01:01, DRB1*16:01:02,
DRB1*16:01:03, DRB1*16:01:04, DRB1*16:01:05, DRB1*16:01:06, DRB1*16:01:07,
DRB1*16:01:08, DRB1*16:01:09, DRB1*16:01:10, DRB1*16:01:11, DRB1*16:01:12,
DRB1*16:01:13, DRB1*16:01:14, DRB1*16:01:15, DRB1*16:01:16, DRB1*16:02:01:01,
DRB1*16:02:01:02, DRB1*16:02:01:03, DRB1*16:02:02, DRB1*16:02:03,
DRB1*16:02:04, DRB1*16:02:05, DRB1*16:02:06, DRB1*16:02:07, DRB1*16:02:08,
DRB1*16:03, DRB1*16:04:01, DRB1*16:04:02, DRB1*16:05:01, DRB1*16:05:02,
DRB1*16:07, DRB1*16:08, DRB1*16:09:01, DRB1*16:09:02, DRB1*16:10:01,
DRB1*16:10:02, DRB1*16:11, DRB1*16:12, DRB1*16:13N, DRB1*16:14, DRB1*16:15,
DRB1*16:16, DRB1*16:17, DRB1*16:18, DRB1*16:19, DRB1*16:20, DRB1*16:21N,
DRB1*16:22, DRB1*16:23, DRB1*16:24, DRB1*16:25, DRB1*16:26, DRB1*16:27,
DRB1*16:28, DRB1*16:29, DRB1*16:30, DRB1*16:31, DRB1*16:32, DRB1*16:33,
DRB1*16:34, DRB1*16:35, DRB1*16:36, DRB1*16:37, DRB1*16:38:01, DRB1*16:38:02,

DRB1*16:39, DRB1*16:40, DRB1*16:41N, DRB1*16:42, DRB1*16:43, DRB1*16:44, DRB1*16:45, DRB1*16:46, DRB1*16:47, DRB1*16:48, DRB1*16:49, DRB1*16:50, DRB1*16:51, DRB1*16:52, DRB1*16:53, DRB1*16:54, DRB1*16:55N, DRB1*16:56, DRB3*01:01:02:01, DRB3*01:01:02:02, DRB3*01:01:02:03, DRB3*01:01:03, DRB3*01:01:04, DRB3*01:01:05, DRB3*01:01:06, DRB3*01:01:07, DRB3*01:01:08, DRB3*01:01:09, DRB3*01:01:10, DRB3*01:02, DRB3*01:03, DRB3*01:04, DRB3*01:05, DRB3*01:06, DRB3*01:07, DRB3*01:08, DRB3*01:09, DRB3*01:10, DRB3*01:11, DRB3*01:12, DRB3*01:13, DRB3*01:14, DRB3*01:15, DRB3*01:16, DRB3*01:17, DRB3*01:18, DRB3*01:19, DRB3*01:20, DRB3*01:21, DRB3*01:22, DRB3*01:23, DRB3*01:24, DRB3*01:25, DRB3*01:26N, DRB3*01:27, DRB3*01:28, DRB3*01:29, DRB3*01:30, DRB3*01:31, DRB3*01:32, DRB3*01:33, DRB3*01:34, DRB3*01:35, DRB3*01:36, DRB3*01:37, DRB3*01:38, DRB3*01:39, DRB3*01:40:01N, DRB3*01:40:02N, DRB3*01:41, DRB3*01:42, DRB3*01:43, DRB3*01:44, DRB3*01:45, DRB3*01:46, DRB3*01:47, DRB3*01:48, DRB3*01:49, DRB3*01:50, DRB3*01:51, DRB3*01:52, DRB3*01:53, DRB3*01:54, DRB3*01:55, DRB3*01:56, DRB3*01:57, DRB3*01:58, DRB3*01:59, DRB3*01:60, DRB3*01:61, DRB3*01:62, DRB3*02:01, DRB3*02:02:01:01, DRB3*02:02:01:02, DRB3*02:02:01:03, DRB3*02:02:01:04, DRB3*02:02:02, DRB3*02:02:03, DRB3*02:02:04, DRB3*02:02:05, DRB3*02:02:06, DRB3*02:02:07, DRB3*02:02:08, DRB3*02:02:09, DRB3*02:02:10, DRB3*02:02:11, DRB3*02:02:12, DRB3*02:02:13, DRB3*02:02:14, DRB3*02:02:15, DRB3*02:02:16, DRB3*02:02:17, DRB3*02:02:18, DRB3*02:02:19, DRB3*02:02:20, DRB3*02:02:21, DRB3*02:03, DRB3*02:04, DRB3*02:05, DRB3*02:06, DRB3*02:07, DRB3*02:08, DRB3*02:09, DRB3*02:10, DRB3*02:11, DRB3*02:12, DRB3*02:13, DRB3*02:14, DRB3*02:15, DRB3*02:16, DRB3*02:17, DRB3*02:18, DRB3*02:19, DRB3*02:20, DRB3*02:21, DRB3*02:22:01, DRB3*02:22:02, DRB3*02:23, DRB3*02:24, DRB3*02:25, DRB3*02:26, DRB3*02:27, DRB3*02:28, DRB3*02:29N, DRB3*02:30, DRB3*02:31:01, DRB3*02:31:02, DRB3*02:32, DRB3*02:33, DRB3*02:34, DRB3*02:35, DRB3*02:36, DRB3*02:37, DRB3*02:38, DRB3*02:39, DRB3*02:40, DRB3*02:41, DRB3*02:42, DRB3*02:43, DRB3*02:44, DRB3*02:45, DRB3*02:46, DRB3*02:47, DRB3*02:48, DRB3*02:49, DRB3*02:50, DRB3*02:51, DRB3*02:52, DRB3*02:53, DRB3*02:54, DRB3*02:55N, DRB3*02:56, DRB3*02:57, DRB3*02:58, DRB3*02:59, DRB3*02:60, DRB3*02:61Q, DRB3*02:62, DRB3*02:63, DRB3*02:64, DRB3*02:65, DRB3*02:66,

DRB3*02:67N, DRB3*02:68, DRB3*02:69, DRB3*02:70, DRB3*02:71, DRB3*02:72, DRB3*02:73, DRB3*02:74, DRB3*02:75, DRB3*02:76, DRB3*02:77, DRB3*02:78, DRB3*02:79, DRB3*02:80N, DRB3*02:81, DRB3*02:82, DRB3*02:83, DRB3*02:84, DRB3*02:85, DRB3*02:86, DRB3*02:87, DRB3*02:88, DRB3*02:89, DRB3*02:90, DRB3*02:91, DRB3*02:92, DRB3*02:93, DRB3*02:94, DRB3*02:95N, DRB3*03:01:01:01, DRB3*03:01:01:02, DRB3*03:01:02, DRB3*03:01:03, DRB3*03:01:04, DRB3*03:01:05, DRB3*03:01:06, DRB3*03:01:07, DRB3*03:02, DRB3*03:03, DRB3*03:04, DRB3*03:05, DRB3*03:06, DRB3*03:07, DRB3*03:08, DRB3*03:09, DRB3*03:10, DRB3*03:11, DRB3*03:12, DRB3*03:13, DRB3*03:14, DRB3*03:15, DRB3*03:16, DRB3*03:17, DRB3*03:18, DRB3*03:19, DRB3*03:20, DRB3*03:21, DRB3*03:22, DRB3*03:23, DRB3*03:24, DRB3*03:25, DRB4*01:01:01:01, DRB4*01:01:02, DRB4*01:01:03, DRB4*01:01:04, DRB4*01:01:05, DRB4*01:01:06, DRB4*01:02, DRB4*01:03:01:01, DRB4*01:03:01:02N, DRB4*01:03:01:03, DRB4*01:03:01:04, DRB4*01:03:01:05, DRB4*01:03:01:06, DRB4*01:03:01:07, DRB4*01:03:01:08, DRB4*01:03:01:09, DRB4*01:03:01:10, DRB4*01:03:01:11, DRB4*01:03:02, DRB4*01:03:03, DRB4*01:03:04, DRB4*01:03:05, DRB4*01:03:06, DRB4*01:03:07, DRB4*01:03:08, DRB4*01:03:09, DRB4*01:03:10, DRB4*01:03:11, DRB4*01:04, DRB4*01:05, DRB4*01:06, DRB4*01:07:01, DRB4*01:07:02, DRB4*01:08, DRB4*01:09, DRB4*01:10, DRB4*01:11, DRB4*01:12, DRB4*01:13, DRB4*01:14, DRB4*01:15, DRB4*01:16N, DRB4*01:17, DRB4*01:18, DRB4*01:19, DRB4*01:20, DRB4*01:21, DRB4*01:22, DRB4*01:23, DRB4*01:24, DRB4*01:25, DRB4*01:26, DRB4*01:27, DRB4*01:28, DRB4*01:29, DRB4*01:30, DRB4*01:31, DRB4*01:32, DRB4*01:33, DRB4*01:34, DRB4*01:35, DRB4*01:36, DRB4*01:37, DRB4*01:38N, DRB4*01:39, DRB4*01:40, DRB4*01:41, DRB4*01:42, DRB4*01:43, DRB4*01:44, DRB4*01:45, DRB4*01:46, DRB4*01:47, DRB4*01:48, DRB4*01:49, DRB4*01:50, DRB4*01:51, DRB4*01:52, DRB4*01:53, DRB4*01:54N, DRB4*01:55, DRB4*01:56N, DRB4*01:57N, DRB4*01:58, DRB4*01:59, DRB4*01:60, DRB4*01:61N, DRB4*01:62, DRB4*01:63, DRB4*01:64, DRB4*01:65N, DRB4*01:66, DRB4*01:67, DRB4*01:68, DRB4*01:69, DRB4*01:70, DRB4*01:71N, DRB4*01:72, DRB4*01:73, DRB4*01:74, DRB4*01:75, DRB4*01:76, DRB4*01:77, DRB4*01:78, DRB4*01:79, DRB4*01:80N, DRB4*01:81, DRB4*01:82, DRB4*01:83, DRB4*01:84N, DRB4*01:85, DRB4*01:86, DRB4*01:87, DRB4*01:88, DRB4*01:89, DRB4*01:90, DRB4*01:91, DRB4*01:92,

DRB4*01:93, DRB4*02:01N, DRB5*01:01:01:01, DRB5*01:01:01:02, DRB5*01:01:02, DRB5*01:01:03, DRB5*01:01:04, DRB5*01:02, DRB5*01:03, DRB5*01:04, DRB5*01:05, DRB5*01:06, DRB5*01:07, DRB5*01:08N, DRB5*01:09, DRB5*01:10N, DRB5*01:11, DRB5*01:12, DRB5*01:13, DRB5*01:14, DRB5*01:15, DRB5*01:16, DRB5*01:17, DRB5*01:18, DRB5*01:19, DRB5*01:20, DRB5*01:21, DRB5*01:22:01, DRB5*01:22:02, DRB5*01:23, DRB5*01:24, DRB5*01:25, DRB5*01:26, DRB5*01:27N, DRB5*01:28, DRB5*01:29, DRB5*01:30, DRB5*01:31, DRB5*01:32, DRB5*01:33, DRB5*01:34, DRB5*01:35, DRB5*01:36, DRB5*01:37, DRB5*01:38, DRB5*01:39, DRB5*01:40, DRB5*01:41, DRB5*01:42, DRB5*01:43, DRB5*01:44, DRB5*01:45, DRB5*01:46, DRB5*01:47, DRB5*01:48N, DRB5*01:49N, DRB5*01:50, DRB5*01:51, DRB5*01:52N, DRB5*01:53N, DRB5*01:54, DRB5*01:55, DRB5*02:02:01, DRB5*02:02:02, DRB5*02:02:03, DRB5*02:03, DRB5*02:04, DRB5*02:05, DRB5*02:06, DRB5*02:07, DRB5*02:08, DRB5*02:09, DRB5*02:10, DRB5*02:11, DRB5*02:12, DRB5*02:13, DRB5*02:14, DRB5*02:15, DRB5*02:16, DRB5*02:17, DRB5*02:18, DRB5*02:19N, DRB5*02:20, DRB5*02:21, DRB5*02:22, DRB5*02:23, DRB5*02:24 and any combination thereof.

[0182] In some aspects, the HLA class II molecule is a monomer. In some aspects, the HLA class II molecule is a dimer. In some aspects, the HLA class II molecule is a multimer. In some aspects, the HLA class II molecule is a trimer. In some aspects, the HLA class II molecule is a tetramer. In some aspects, the HLA class II molecule is a pentamer.

[0183] Certain aspects of the present disclosure are directed to antigen presenting cells (APCs) comprising any HLA class II molecule disclosed herein. In certain aspects, the APC expressed the HLA class II molecule on the surface of the APC. In certain aspects, the APC comprises more than one HLA class II molecule disclosed herein.

II.E. Vaccines

[0184] Certain aspects of the present disclosure a cancer vaccine comprising a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 13. In some aspects, the cancer vaccine comprises a peptide that consists of the amino acid sequence set forth in SEQ ID NO: 13. In some aspects, the vaccine further comprises one or more excipient. In some aspects, the vaccine further comprises one or more additional peptides. In some aspects, the one or more additional peptides comprise one or more additional epitopes.

III. Methods of the Disclosure

[0185] Certain aspects of the present disclosure are directed to methods of treating a cancer in a subject in need thereof. Other aspects of the present disclosure are directed to methods of engineering an antigen-targeting cell. Other aspects of the present disclosure are directed to methods of enriching a target population of T cells obtained from a human subject.

III.A. Methods of Treating Cancer

[0186] Certain aspects of the present disclosure are directed to methods of treating a cancer in a subject in need thereof, comprising administering to the subject a nucleic acid molecule disclosed herein, a recombinant TCR disclosed herein, a bispecific TCR disclosed herein, an epitope disclosed herein, or an HLA class II molecule disclosed herein, or a vector or cell comprising any of the above.

[0187] In some aspects, the cancer is selected from melanoma, bone cancer, renal cancer, prostate cancer, breast cancer, colon cancer, lung cancer, cutaneous or intraocular malignant melanoma, pancreatic cancer, skin cancer, cancer of the head or neck, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL) (including non T cell ALL), chronic lymphocytic leukemia (CLL), solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell

lymphoma, environmentally induced cancers including those induced by asbestos, other B cell malignancies, and combinations of said cancers. In some aspects, the cancer melanoma.

[0188] In some aspects, the cancer is relapsed. In some aspects, the cancer is refractory. In some aspects, the cancer is advanced. In some aspects, the cancer is metastatic.

[0189] In some aspects, the methods disclosed herein treat a cancer in a subject. In some aspects, the methods disclosed herein reduce the severity of one or more symptom of the cancer. In some aspects, the methods disclosed herein reduce the size or number of a tumor derived from the cancer. In some aspects, the methods disclosed herein increase the overall survival of the subject, relative to a subject not provided the methods disclosed herein. In some aspects, the methods disclosed herein increase the progressive-free survival of the subject, relative to a subject not provided the methods disclosed herein. In some aspects, the methods disclosed herein lead to a partial response in the subject. In some aspects, the methods disclosed herein lead to a complete response in the subject.

[0190] In some aspects, the methods disclosed herein comprise treating a cancer in a subject in need thereof, comprising administering to the subject a cell described herein, wherein the cell comprises a nucleic acid molecule disclosed herein, a vector disclosed herein, a recombinant TCR disclosed herein, and/or a bispecific antibody disclosed herein. In some aspects, the cell is a T cell. In some aspects, the cell is a cell that is modified to express CD4.

[0191] In some aspects, the cell, *e.g.*, a T cell, is obtained from the subject. In some aspects, the cell, *e.g.*, a T cell, is obtained from a donor other than the subject.

[0192] In some aspects, the subject is preconditioned prior to administering the cells. The preconditioning can comprise any substance that promotes T cell function and/or survival. In some aspects, the preconditioning comprises administering to the subject a chemotherapy, a cytokine, a protein, a small molecule, or any combination thereof. In some aspects, the preconditioning comprises administering an interleukin. In some aspects, the preconditioning comprises administering IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, or any combination thereof. In some aspects, the preconditioning comprises administering cyclophosphamide, fludarabine, or both. In some aspects, the preconditioning comprises administering vitamin C, an AKT inhibitor, ATRA (vesanoid, tretinoin), rapamycin, or any combination thereof.

III.B. Methods of Engineering an Antigen-Targeting Cell

[0193] Certain aspects of the present disclosure are directed to methods of engineering an antigen-targeting cell. In some aspects, the antigen is a MAGE-A2 antigen. In some aspects, the method comprises transducing a cell with a nucleic acid molecule disclosed herein or a vector disclosed herein. The cell can be any cell described herein. In some aspects, the cell is a T cell described herein. In some aspects, the cell is a cell that is modified to express CD4, as described herein. In some aspects, the cell, *e.g.*, the T cell, is obtained from a subject in need of a T cell therapy. In some aspects, the cell is obtained from a donor other than the subject in need of the T cell therapy. In some aspects, the cell is a T cell or a natural killer cell.

III.C. Methods of Enriching a Target Population of T Cells

[0194] Certain aspects of the present disclosure are directed to methods of enriching a target population of T cells obtained from a human subject. In some aspects, the method comprises contacting the T cells with an HLA class II molecule disclosed herein. In some aspects, the method comprises contacting the T cells with an APC disclosed herein. In some aspects, following the contacting, the enriched population of T cells comprises a higher number of T cells capable of binding the HLA class II molecule relative to the number of T cells capable of binding the HLA class II molecule prior to the contacting.

[0195] In some aspects, the method comprises contacting the T cells *in vitro* with a peptide, wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 13. In some aspects, the method comprises contacting the T cells *in vitro* with a peptide, wherein the peptide consists of the amino acid sequence set forth in SEQ ID NO: 13. In some aspects, following the contacting, the enriched population of T cells comprises a higher number of T cells capable of binding the HLA class II molecule relative to the number of T cells capable of binding the HLA class II molecule prior to the contacting.

[0196] Some aspects of the present disclosure are directed to a method of selecting a T cell capable of targeting a tumor cell. In some aspects, the method comprises contacting a population of isolated T cells *in vitro* with a peptide, wherein the peptide consists of an amino acid sequence as set forth in SEQ ID NO: 13. In some aspects, the T cells are obtained from a human subject.

- [0197] The T cells obtained from the human subject can be any T cells disclosed herein. In some aspects, the T cells obtained from the human subject are tumor infiltrating lymphocytes (TIL).
- [0198] In some aspects, the method further comprises administering to the human subject the enriched T cells. In some aspects, the subject is preconditioned prior to receiving the T cells, as described herein.
- [0199] All of the various aspects, aspects, and options described herein can be combined in any and all variations.
- [0200] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
- [0201] Having generally described this disclosure, a further understanding can be obtained by reference to the examples provided herein. These examples are for purposes of illustration only and are not intended to be limiting.

EXAMPLES

Example 1 – Methods

- [0202] *Cells*
- [0203] Peripheral mononuclear cells were obtained via density gradient centrifugation (Ficoll-Paque PLUS, GE Healthcare Life Sciences, Marlborough, MA). The K562 cell line is an erythroleukemic cell line with defective HLA class I/II expression. K562-based artificial APCs (aAPCs) individually expressing various HLA class II genes as a single HLA allele in conjunction with CD80 and CD83 have been reported previously (Butler et al., *PloS One* 7, e30229 (2012)). The Jurkat 76 cell line is a T cell leukemic cell line lacking endogenous TCR, CD4, and CD8 expression. Jurkat 76/CD4 cells were generated by retrovirally transducing the human CD4 gene. HEK293T cells and melanoma cell lines were grown in DMEM supplemented with 10% FBS and 50 µg/ml gentamicin (Thermo Fisher Scientific, Waltham, MA). The K562 and Jurkat 76 cell lines were cultured in RPMI 1640 supplemented with 10% FBS and 50 µg/ml gentamicin.
- [0204] *Peptides*

[0205] The MAGE-A2₁₀₈₋₁₂₇ synthetic peptide was purchased from Genscript (Piscataway, NJ) and dissolved at 50 µg/ml in DMSO.

[0206] ***Genes***

[0207] Novel TCR genes were cloned via 5'-rapid amplification of cDNA ends (RACE) PCR using SMARTer RACE 5'/3' Kit (Takara Bio, Shiga, Japan) and sequenced as previously described. All genes were cloned into the pMX retroviral vector and transduced into cell lines using the 293GPG and PG13 cell-based retrovirus system.

[0208] ***Antibodies***

[0209] The following antibodies were used for flow cytometry analysis: APC-Cy7-conjugated anti-CD4 (RPA-T4, Biolegend, San Diego, CA)⁴⁴, and PE-conjugated anti-His tag (AD1.1.10, Abcam, Cambridge, MA). Dead cells were distinguished with the LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit 465 (Thermo Fisher Scientific, Waltham, MA). Stained cells were analyzed with Canto II or LSRFortessa X-20 (BD Biosciences, Franklin Lakes, NJ). Cell sorting was conducted using a FACS Aria II (BD Biosciences, Franklin Lakes, NJ). Data analysis was performed using FlowJo software (Tree Star, Ashland, OR).

[0210] The following antibodies were used for immunoblot analysis: anti-β-actin (C4, Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal anti-MAGE-A2 (Abcam, Cambridge, MA), HRP-conjugated goat anti-mouse IgG (H+L) secondary antibody (Promega, Fitchburg, WI), and HRP-conjugated anti-rabbit IgG (H+L) secondary antibody (Promega, Fitchburg, WI).

[0211] ***TCR transduction into primary T cells***

[0212] CD3⁺ and CD4⁺ T cells were purified using the Pan T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and CD4⁺ T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany), respectively. Purified T cells were stimulated with aAPC/mOKT3 irradiated with 200 Gy at an E:T ratio of 20:1. Starting the following day, activated T cells were retrovirally transduced with the cloned TCR genes via centrifugation for 1 hour at 1,000 × g at 32°C for 3 consecutive days or using a Retronectin-coated plate (Takara Bio, Shiga, Japan). On the following day, 100 IU/ml IL-2 and 10 ng/ml IL-15 were added to the TCR-transduced T cells. The culture medium was replenished every 2-3 days.

[0213] ***Generation of the HLA class II monomer and dimer***

[0214] The extracellular domain of the wild-type class II α gene was fused with an acidic leucine zipper via a GGGS (SEQ ID NO: 29) linker followed by a 6xHis tag via a GS linker

(see SEQ ID NO: 15; Table 5). The ectodomain of the class II β gene carrying mutations (see SEQ ID NO: 14) was similarly linked with a basic leucine zipper via a GGS (SEQ ID NO: 29) linker (see SEQ ID NO: 14). HEK293T cells and A375 cells were transfected with the α and β genes using the 293GPG cell-based retrovirus system and cultured in DMEM supplemented with 10% FBS and 50 μ g/ml gentamicin. For DP4 dimer staining, HEK293T cells stably secreting soluble DP4^{L112W/V141M} protein were grown until confluent, and the medium was changed to serum-free 293 SFM II medium (Thermo Fisher Scientific, Waltham, MA). After forty-eight hours, the conditioned medium was harvested and concentrated using Amicon Ultra filters (molecular weight cut-off (MWCO) 10 kDa) (MilliporeSigma, Burlington, MA). The soluble HLA class II-containing supernatant was then mixed with 100 μ g/ml peptide of interest for 20-24 hours at 37°C for *in vitro* peptide exchange. Monomer that was not subjected to peptide exchange was used as a control. The concentration of the monomer was measured by specific ELISA using a nickel-coated plate (XPressBio, Frederick, MD) and an anti-His tag biotinylated mAb (AD1.1.10, R&D Systems, Minneapolis, MN). Soluble HLA class II monomer was dimerized using PE-conjugated anti-His mAb (AD1.1.10, Abcam, Cambridge, MA) at a 2:1 molar ratio for 1.5 hours at 4°C for staining.

Table 5: HLA-DP Class II Molecules

Signal Peptide; DPB1*04:01 L112W/V141M Extracellular Domain; Gly/Ser Linker; Zip Sequences and His tag sequences) (SEQ ID NO: 14) MMRPVIVLVLLFATSALARATPENYLFQGRQECYAFNGTQRFLERYIYNREEFARFDSVDVGEFRAVTELGRPAAYWNSQKDILEEKRAVPDRMCRHNYELGGPMTLQRRVQPRVNVSPSKKGPLQHHNWLVCVHTDFYPGSIQVRWFLNGQEETAGVMSTNLIRNGDWTQILVMLEMTQQGDVYTQVEHTSLDSPVTVEWKAQSDSARSKGGGGSLEIEAAFLERENTALETRVAELRQVRQRLNRVSOYRTRYGPLGGGK
Signal Peptide; DPA1*01:03 Extracellular Domain; Gly/Ser Linker, Zip Sequences and His tag sequences) (SEQ ID NO: 15) MMRPVIVLVLLFATSALAIKADHVSTYAAAFVQTHRPTGEFMFEFDEDEMFYVDLDKKETVWHLEEFQAFSFEAQGGLANIAILNNNLNTLIQRSNHTQATNDPPEVTVPKEPVELGQPNTLICHIDKFFPPVLNVTWLCNGELVTEGVAESLFLPRTDYSFHKFHYLTFVPSAEDFYDCRVEHWGLDQPLLKHWEAQEPIQMPETTETGGGGSLEIRAAFLRQNTALRTEVAELEQEVORLENEVSQYETRYGPLGGGKGSHHHHHH

[0215] Stimulation of DP4-restricted antigen-specific CD4⁺ T cells

[0216] CD4⁺ T cells were purified using a CD4⁺ T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Purified T cells were stimulated with DP4-expressing aAPCs pulsed with DP4-restricted peptides at 10 μ g/ml and irradiated at 200 Gy at an E:T ratio of 20:1. After forty-eight hours, 10 IU/ml IL-2 and 10 ng/ml IL-15 were added to the CD4⁺ T cells. The culture medium supplemented with IL-2 (10 IU/ml) and IL-15 (10 ng/ml) was

replenished every 2-3 days. After 2 weeks of stimulation, the T cells were subjected to DP4^{L112W/V141M} dimer staining.

[0217] *HLA class II dimer staining*

[0218] Primary T cells and Jurkat 76/CD4 T cells transduced with exogenous TCR gene were pretreated with 50 nM dasatinib (LC Laboratories, Woburn, MA) for 30 min at 37°C⁴⁶ and stained with 5-15 µg/ml class II dimer for 4-5 hours at room temperature. After washing, cell surface molecules were counterstained with an APC-Cy7-conjugated anti-CD4 mAb.

[0219] *ELISPOT assay*

[0220] Cytokine ELISPOT assays were performed as previously reported (*see, e.g.,* Yamashita et al., *Nat. Commun.* 8:15244 (2017); and Anczurowski et al., *Sci. Rep.* 8:4804 (2018)).

[0221] *Statistical analysis*

[0222] Statistical analysis was performed using GraphPad Prism 6.0 software (GraphPad Software, San Diego, CA). Unpaired two-tailed Student's t-tests were used for two-sample comparisons. No statistical method was used to predetermine sample size. The investigators were not blinded to allocation during the experiments or outcome assessment. The experiments were not randomized.

Example 2 – Characterization of MAGE-A2₁₀₈₋₁₂₇TCR

[0223] Primary CD4⁺ T cells isolated from six DP4⁺ melanoma patients were stimulated only once with DP4-aAPCs individually pulsed with a peptide fragment of MAGE-A2 (108-127) and stained with cognate DP4^{L112W/V141M} dimers. To avoid potential *in vitro* priming, weak stimulatory conditions were utilized. The MAGE-A2₁₀₈₋₁₂₇ was found to be immunogenic by dimer staining (data not shown).

[0224] To validate the dimer staining results, we cloned a DP4-restricted TCR gene specific for MAGE-A2₁₀₈₋₁₂₇ (FIGs. 1A-1B and Table 6) from the dimer-positive T cells. When clonotypically reconstituted in human CD4⁺ TCR-deficient T cells, the MAGE-A2₁₀₈₋₁₂₇ TCR was successfully stained by the cognate DP4^{L112W/V141M} dimers (FIGs. 2A-2D) and were functional in a DP4-restricted and antigen-specific manner (FIG. 3).

[0225] The TCR 03-MAGE-A2₁₀₈₋₁₂₇ was able to recognize a cognate peptide that was endogenously processed and presented by DP4 (FIGs. 4A-4E and 5). Importantly, 06-

MAGE-A2108-127-transduced primary T cells were able to recognize melanoma cell lines in a DP4- and MAGE-A2-dependent manner (FIGs. 6A-6E).

Table 6: DP4-Restricted TCR

No.	Peptide	TRAV	TRAJ	TCR-alpha CDR 3	TRBV	TRBJ	TCR-beta CDR 3
06	MAGE-A2 ₁₀₈₋₁₂₇	19*01	40*01	CALSVGTYKYIF (SEQ ID NO: 7)	7- 9*01	2-5*01	CASSPGTGGRETQYF (SEQ ID NO: 10)

Claims

1. A nucleic acid molecule comprising (i) a first nucleotide sequence encoding a recombinant T cell receptor (TCR) or an antigen binding portion thereof that specifically binds human melanoma-associated antigen 2 (MAGE-A2) ("anti-MAGE-A2 TCR"); and (ii) a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR,

wherein the anti-MAGE-A2 TCR cross competes for binding to human MAGE-A2 with a reference TCR, which comprises an alpha chain and a beta chain, and wherein the alpha chain comprises an amino acid sequence as set forth in SEQ ID NO: 1 and the beta chain comprises an amino acid sequence as set forth in SEQ ID NO: 2.
2. A nucleic acid molecule comprising (i) a first nucleotide sequence encoding a recombinant T cell receptor (TCR) or an antigen binding portion thereof that specifically binds human MAGE-A2 ("anti-MAGE-A2 TCR"); and (ii) a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR,

wherein the anti-MAGE-A2 TCR binds the same epitope or an overlapping epitope of human MAGE-A2 as a reference TCR, which comprises an alpha chain and a beta chain, wherein the alpha chain comprises an amino acid sequence as set forth in SEQ ID NO: 1 and the beta chain comprises an amino acid sequence as set forth in SEQ ID NO: 2.
3. The nucleic acid molecule of claim 1 or 2, wherein the anti-MAGE-A2 TCR binds to an epitope of MAGE-A2 consisting of an amino acid sequence as set forth in SEQ ID NO: 13.
4. The nucleic acid molecule of claim 2 or 3, wherein the epitope is complexed with an HLA class II molecule.
5. The nucleic acid molecule of claim 4, wherein the HLA class II molecule is an HLA-DP, HLA-DQ, or HLA-DR allele, or any combination thereof.

6. The nucleic acid molecule of claim 4, wherein the HLA class II molecule is an HLA-DP allele.
7. The nucleic acid molecule of any one of claims 4 to 6, wherein the HLA class II molecule is an HLA-DP4 allele.
8. The nucleic acid molecule of any one of claims 1 to 7, wherein the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain,

wherein the alpha chain comprises a variable region comprising an alpha chain CDR1, an alpha chain CDR2, and an alpha chain CDR3; and

wherein the beta chain comprises variable domain comprising a beta chain CDR1, a beta chain CDR2, and a beta chain CDR3;

wherein the alpha chain CDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 7.
9. The nucleic acid molecule of claim 8, wherein the beta chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 10.
10. The nucleic acid molecule of any one of claims 1 to 7, wherein the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises a variable region comprising an alpha chain CDR1, an alpha chain CDR2, and an alpha chain CDR3; and

wherein the beta chain comprises variable domain comprising a beta chain CDR1, a beta chain CDR2, and a beta chain CDR3;

wherein the beta chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 10.
11. The nucleic acid molecule of claim 10, wherein the alpha chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 7.

12. The nucleic acid molecule of any one of claims 8 to 11, wherein the alpha chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 5.
13. The nucleic acid molecule of any one of claims 8 to 12, wherein the beta chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 8.
14. The nucleic acid molecule of any one of claims 8 to 13, wherein the alpha chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 6.
15. The nucleic acid molecule of any one of claims 8 to 14, wherein the beta chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 9.
16. The nucleic acid molecule of any one of claims 8 to 15, wherein the alpha chain variable domain of the anti-MAGE-A2 TCR comprises an amino acid sequence of a variable domain present in the amino acid sequence set forth SEQ ID NO: 1.
17. The nucleic acid molecule of any one of claims 8 to 16, wherein the beta chain variable domain of the anti-MAGE-A2 TCR comprises an amino acid sequence of a variable domain present in the amino acid sequence set forth SEQ ID NO: 2.
18. The nucleic acid molecule of any one of claims 8 to 17, wherein the alpha chain of the anti-MAGE-A2 TCR further comprises a constant region, wherein the constant region is different from endogenous constant region of the alpha chain.
19. The nucleic acid molecule of any one of claims 8 to 18, wherein the alpha chain of the anti-MAGE-A2 TCR further comprises a constant region, wherein the alpha chain constant region comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to a constant region present in the amino acid sequence set forth SEQ ID NO: 1.

20. The nucleic acid molecule of claim 18 or 19, wherein the alpha chain constant region comprises an amino acid sequence comprising at least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence set forth SEQ ID NO: 1.
21. The nucleic acid molecule of any one of claims 8 to 20, wherein the beta chain of the anti-MAGE-A2 TCR further comprises a constant region, wherein the constant region is different from endogenous constant regions of the beta chain.
22. The nucleic acid molecule of any one of claims 8 to 21, wherein the beta chain of the anti-MAGE-A2 TCR further comprises a constant region, wherein the beta chain constant region comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to a constant region present in the amino acid sequence set forth SEQ ID NO: 2.
23. The nucleic acid molecule of claim 21 or 22, wherein the beta chain constant region comprises an amino acid sequence comprising at least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence set forth SEQ ID NO: 2.
24. The nucleic acid molecule of any one of claims 8 to 23, wherein the alpha chain of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 1.
25. The nucleic acid molecule of any one of claims 8 to 24, wherein the beta chain of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 2.
26. The nucleic acid molecule of any one of claims 1 to 25, wherein the second nucleotide sequence is one or more siRNAs that reduce the expression of endogenous TCRs.
27. The nucleic acid molecule of claim 26, wherein the one or more siRNAs are complementary to a target sequence within a nucleotide sequence encoding a constant region of the endogenous TCRs.

28. The nucleic acid molecule of claim 26 or 27, wherein the one or more siRNAs comprise one or more nucleotide sequences selected from the group consisting of SEQ ID NOs: 25-28.
29. The nucleic acid molecule of any one of claims 1 to 28, wherein the anti-MAGE-A2 TCR comprises an alpha chain constant region, a beta chain constant region, or both; and wherein the alpha chain constant region, the beta chain constant region, or both comprises an amino acid sequence having at least 1, at least 2, at least 3, at least 4, or at least 5 substitutions within the target sequence relative to the corresponding amino acid sequence of an endogenous TCR.
30. The nucleic acid molecule of any one of claims 1 to 29, wherein the alpha chain comprises a signal peptide, the beta chain comprises a signal peptide, or both the alpha chain and the beta chain comprise a single peptide.
31. The nucleic acid molecule of claim 30, wherein the signal peptide comprises an amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs: 20-22 and any combination thereof.
32. A vector comprising the nucleic acid molecule of any one of claims 1 to 31.
33. The vector of claim 32, which is a viral vector, a mammalian vector, or bacterial vector.
34. The vector of claim 32 or 33, which is a retroviral vector.
35. The vector of any one of claims 31 to 33, which is selected from the group consisting of an adenoviral vector, a lentivirus, a Sendai virus vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, a hybrid vector, and an adeno associated virus (AAV) vector.
36. The vector of any one of claims 32 to 35, which is a lentivirus.
37. A T cell receptor (TCR) or an antigen binding portion thereof comprising the alpha chain variable domain of the anti-MAGE-A2 TCR of any one of claims 8 to 31 and the beta chain variable domain of the anti-MAGE-A2 TCR of any one of claims 8 to 31.

38. A recombinant T cell receptor (TCR) or an antigen binding portion thereof that specifically binds human MAGE-A2 ("an anti-MAGE-A2 TCR"), which cross competes for binding to human MAGE-A2 with a reference TCR;

wherein the reference TCR comprises an alpha chain and a beta chain, and wherein the alpha chain comprises an amino acid sequence as set forth in SEQ ID NO: 1 and the beta chain comprises an amino acid sequence as set forth in SEQ ID NO: 2; and

wherein the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises a constant region, and wherein the beta chain comprises a constant region; wherein

- (i) the alpha chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence set forth in SEQ ID NO: 1 or
- (ii) the beta chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence of SEQ ID NO: 2.

39. A recombinant T cell receptor (TCR) or an antigen binding portion thereof that specifically binds human MAGE-A2 ("an anti-MAGE-A2 TCR"), which binds the same epitope or an overlapping epitope of human MAGE-A2 as a reference TCR;

wherein the reference TCR comprises an alpha chain and a beta chain, and wherein the alpha chain comprises an amino acid sequence as set forth in SEQ ID NO: 1 and the beta chain comprises an amino acid sequence as set forth in SEQ ID NO: 2; and

wherein the anti-MAGE-A2 TCR comprises an alpha chain and a beta chain, wherein the alpha chain comprises a constant region, and wherein the beta chain comprises a constant region; wherein

- (i) the alpha chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence set forth in SEQ ID NO: 1 or
 - (ii) the beta chain constant region comprises an amino acid sequence having a least 1, at least 2, at least 3, at least 4, or at least 5 amino acid substitutions relative to a constant region present in the amino acid sequence set forth in SEQ ID NO: 2.
40. The anti-MAGE-A2 TCR of claim 38 or 39, which binds to an epitope of MAGE-A2 consisting of an amino acid sequence as set forth in SEQ ID NO: 13.
41. The anti-MAGE-A2 TCR of claim 39 or 40, wherein the epitope is complexed with an HLA class II molecule.
42. The anti-MAGE-A2 TCR of claim 42, wherein the HLA class II molecule is an HLA-DP, HLA-DQ, or HLA-DR allele, or any combination thereof.
43. The anti-MAGE-A2 TCR of claim 42 or 43, wherein the HLA class II molecule is an HLA-DP allele.
44. The anti-MAGE-A2 TCR of any one of claims 42 to 44, wherein the HLA class II molecule is selected from an HLA-DP4 allele.
45. The anti-MAGE-A2 TCR of any one of claims 38 to 44, wherein the alpha chain of the anti-MAGE-A2 TCR comprises a variable domain comprising an alpha chain CDR1, an alpha chain CDR2, and an alpha chain CDR3; and
- wherein the beta chain of the anti-MAGE-A2 TCR comprises variable domain comprising a beta chain CDR1, a beta chain CDR2, and a beta chain CDR3;
- wherein the alpha chain CDR3 of the anti-MAGE-A2 comprises an amino acid sequence as set forth in SEQ ID NO: 7.
46. The anti-MAGE-A2 TCR of claim 45, wherein the beta chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 10.

47. The anti-MAGE-A2 TCR of any one of claims 38 to 44, wherein the alpha chain of the anti-MAGE-A2 TCR comprises a variable domain comprising an alpha chain CDR1, an alpha chain CDR2, and an alpha chain CDR3;
- wherein the beta chain of the anti-MAGE-A2 TCR comprises a variable domain comprising a beta chain CDR1, a beta chain CDR2, and a beta chain CDR3; and
- wherein the beta chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 10.
48. The anti-MAGE-A2 TCR of claim 47, wherein the alpha chain CDR3 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 7.
49. The anti-MAGE-A2 TCR of claim 48, wherein the alpha chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 5.
50. The anti-MAGE-A2 TCR of any one of claims 45 to 49, wherein the beta chain CDR1 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 8.
51. The anti-MAGE-A2 TCR of any one of claims 45 to 50, wherein the alpha chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 6.
52. The anti-MAGE-A2 TCR of any one of claims 45 to 51, wherein the beta chain CDR2 of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 9.
53. The anti-MAGE-A2 TCR of any one of claims 45 to 52, wherein the alpha chain variable domain of the anti-MAGE-A2 TCR comprises an amino acid sequence of a variable domain present in the amino acid sequence set forth in SEQ ID NO: 1.
54. The anti-MAGE-A2 TCR of any one of claims 45 to 53, wherein the beta chain variable domain of the anti-MAGE-A2 TCR comprises an amino acid sequence of a variable domain present in the amino acid sequence set forth in SEQ ID NO: 2.

55. The anti-MAGE-A2 TCR of any one of claims 38 to 54, wherein the alpha chain constant region comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence of a constant region present in the amino acid sequence set forth in SEQ ID NO: 1.
56. The anti-MAGE-A2 TCR of any one of claims 38 to 55, wherein the beta chain constant region comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the amino acid sequence of a constant region present in the amino acid sequence set forth in SEQ ID NO: 2.
57. The anti-MAGE-A2 TCR of any one of claims 38 to 56, wherein the alpha chain of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 1.
58. The anti-MAGE-A2 TCR of any one of claims 38 to 57, wherein the beta chain of the anti-MAGE-A2 TCR comprises an amino acid sequence as set forth in SEQ ID NO: 2.
59. The anti-MAGE-A2 TCR of any one of claims 38 to 58, wherein the alpha chain comprises a signal peptide, the beta chain comprises a signal peptide, or both the alpha chain and the beta chain comprise a single peptide.
60. The anti-MAGE-A2 TCR of claim 59, wherein the signal peptide comprises an amino acid sequence selected from the amino acid sequences set forth in SEQ ID NOs: 20-22 and any combination thereof.
61. A bispecific TCR comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain comprises the TCR or an antigen-binding portion thereof of claim 37 or the TCR or an antigen-binding portion thereof of any one of claims 38 to 60.
62. The bispecific TCR of claim 61, wherein the first antigen-binding domain comprises a single chain variable fragment ("scFv").
63. The bispecific TCR of claim 61 or 62, wherein the second antigen-binding domain binds specifically to a protein expressed on the surface of a T cell.

64. The bispecific TCR of any one of claims 61 to 63, wherein the second antigen-binding domain binds specifically to CD3.
65. The bispecific TCR of any one of claims 61 to 64, wherein the second antigen-binding domain comprises an scFv.
66. The bispecific TCR of any one of claims 61 to 65, wherein the first antigen-binding domain and the second antigen-binding domain are linked or associated by a covalent bond.
67. The bispecific TCR of any one of claims 61 to 66, wherein the first antigen-binding domain and the second antigen-binding domain are linked by a peptide bond.
68. A cell comprising the nucleic acid molecule of any one of claims 1 to 31, the vector of any one of claims 32 to 36, the TCR of claim 37, the recombinant TCR of any one of claims 38 to 60, or the bispecific TCR of any one of claims 61 to 67.
69. The cell of claim 68, which further expresses CD3.
70. The cell of claim 68 or 69, which is selected from the group consisting of a T cell, a natural killer (NK) cell, an natural killer T (NKT) cell, or an ILC cell.
71. A method of treating a cancer in a subject in need thereof, comprising administering to the subject the cell of any one of claims 68 to 70.
72. The method of claim 71, wherein the cancer is selected from the group consisting of melanoma, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic

or acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia (ALL) (including non T cell ALL), chronic lymphocytic leukemia (CLL), solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, other B cell malignancies, and combinations of said cancers.

73. The method of claim 71 or 72, wherein the cancer is relapsed or refractory.
74. The method of any one of claims 71 to 73, wherein the cancer is locally advanced.
75. The method of any one of claims 71 to 74, wherein the cancer is advanced.
76. The method of any one of claims 71 to 75, wherein the cancer is metastatic.
77. The method of any one of claims 71 to 76, wherein the cells are obtained from the subject.
78. The method of any one of claims 71 to 77, wherein the cells are obtained from a donor other than the subject.
79. The method of any one of claims 71 to 78, wherein the subject is preconditioned prior to the administering of the cells.
80. The method of claim 79, wherein the preconditioning comprises administering to the subject a chemotherapy, a cytokine, a protein, a small molecule, or any combination thereof.
81. The method of claim 79 or 80, wherein the preconditioning comprises administering an interleukin.
82. The method of any one of claims 79 to 81, wherein the preconditioning comprises administering IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, or any combination thereof.

83. The method of any one of claims 79 to 82, wherein the preconditioning comprises administering a preconditioning agent selected from the group consisting of cyclophosphamide, fludarabine, vitamin C, an AKT inhibitor, ATRA, Rapamycin, or any combination thereof.
84. The method of any one of claims 79 to 83, wherein the preconditioning comprises administering cyclophosphamide, fludarabine, or both.
85. A method of engineering an antigen-targeting cell, comprising transducing a cell collected from a subject in need of a T cell therapy with the nucleic acid molecule of any one of claims 1 to 31 or the vector of any one of claims 32 to 36.
86. The method of claim 85, wherein the antigen-targeting cell further expresses CD4.
87. The method of claim 85 or 86, wherein the cell is a T cell or a natural killer (NK) cell.
88. An HLA class II molecule complexed to a peptide, wherein the HLA class II molecule comprises an alpha chain and a beta chain; and wherein the peptide consists of an amino acid sequence as set forth in SEQ ID NO: 13.
89. The HLA class II molecule of claim 88, which is an HLA-DP, HLA-DQ, or HLA-DR allele, or any combination thereof.
90. The HLA class II molecule of claim 88 or 89, which is an HLA-DP allele.
91. The HLA class II molecule of claim 85 or 86, which is an HLA-DQ allele.
92. The HLA class II molecule of claim 85 or 86, which is an HLA-DR allele.
93. The HLA class II molecule of any one of claims 88 to 92, which is a monomer.
94. The HLA class II molecule of any one of claims 88 to 92, which is a dimer.
95. The HLA class II molecule of any one of claims 88 to 92, which is a trimer.
96. The HLA class II molecule of any one of claims 88 to 92, which is a tetramer.
97. The HLA class II molecule of any one of claims 88 to 92, which is a pentamer.

98. An antigen presenting cell (APC), comprising the HLA class II molecule of any one of claims 88 to 97.
99. The APC of claims 98, wherein the HLA class II molecule is expressed on the surface of the APC.
100. A method of enriching a target population of T cells obtained from a human subject, comprising contacting the T cells with the HLA class II molecule of any one of claims 88 to 97 or the APC of claim 98 or 99, wherein following the contacting, the enriched population of T cells comprises a higher number of T cells capable of binding the HLA class II molecule relative to the number of T cells capable of binding the HLA class II molecule prior to the contacting.
101. A method of enriching a target population of T cells obtained from a human subject, comprising contacting the T cells *in vitro* with a peptide, wherein the peptide consists of an amino acid sequence as set forth in SEQ ID NO: 13, wherein following the contacting, the enriched population of T cells comprises a higher number of T cells capable of targeting a tumor cell relative to the number of T cells capable of targeting a tumor cell prior to the contacting.
102. The method of claim 100 or 101, wherein the T cells obtained from the human subject are tumor infiltrating lymphocytes (TIL).
103. A method of treating a tumor in a subject in need thereof, comprising administering to the subject the enriched T cells of any one of claims 100 to 102.
104. A method of enhancing cytotoxic T cell-mediated targeting of cancer cells in a subject afflicted with a cancer, comprising administering to the subject a peptide having an amino acid sequence as set forth in SEQ ID NO: 13.
105. A cancer vaccine comprising a peptide having an amino acid sequence as set forth in SEQ ID NO: 13.
106. A method of selecting a T cell capable of targeting a tumor cell, comprising contacting a population of isolated T cells *in vitro* with a peptide, wherein the peptide consists of an amino acid sequence as set forth in SEQ ID NO: 13.

107. The method of claim 106, wherein the T cell is a tumor infiltrating lymphocytes (TIL).